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Abstract 
Bioinfonnatics, the discipline concerned with biological infonnation management 
is essential in the post-genome era, where the complexity of data processing allows 
for contemporaneous multi level research including that at the genome level, 
transcriptome level, proteome level, the metabolome level, and the integration of 
these -omic studies towards gaining an understanding of biology at the systems 
level. This research is also having a major impact on disease research and drug 
discovery, particularly through phannacogenomics studies. 
In this study innovative resources have been generated via the use of two case 
studies. One was of the Research & Development Genetics (RDG) department at 
AstraZeneca, Alderley Park and the other was of the Phannacogenomics Group at 
the Sanger Institute in Cambridge UK. In the AstraZeneca case study senior 
scientists were interviewed using semi-structured interviews to detennine 
infonnation behaviour through the study scientific workflows. Document analysis 
was used to generate an understanding of the underpinning concepts and fonned 
one of the sources of context-dependent infonnation on which the interview 
questions were based. The objectives of the Sanger Institute case study were 
slightly different as interviews were carried out with eight scientists together with 
the use of participation observation, to collect data to develop a database standard 
for one process oftheir Phannacogenomics workflow. 
The results indicated that AstraZeneca would benefit through upgrading their data 
management solutions in the laboratory and by development of resources for the 
storage of data from larger scale projects such as whole genome scans. These 
studies will also generate very large amounts of data and the analysis of these will 
require more sophisticated statistical methods. At the Sanger Institute a minimum 
infonnation standard was reported for the manual design of primers and included in 
a decision making tree developed for Polymerase Chain Reactions (PCRs). This 
tree also illustrates problems that can be encountered when designing primers along 
with procedures that can be taken to address such issues. 
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Chapter One Introduction 
Chapter One: Introduction 
1.1 Context and Background 
Bioinfonnatics is a discipline that has its roots in molecular biology, computer 
science, information science and technologies. It is a young discipline that, as yet, 
does not have a single definition. However, some sort of definition would be useful, 
so for this study bioinformatics will be defined as: 
"the research, development or application of computational tools and 
approaches for the management of biological data" (The Nlli Biomedical 
fufonnation Science and Technology fuitiative Consortium 2000). 
The management referred to in this definition encompasses the processes used to 
acquire, store, organise, archive, analyse, retrieve and visualise biological data. The 
study considers mainly computational bioinformatics which is made up of two 
active areas: first, finding and understanding computationally, answers to biological 
queries and second, the development of software and databases (Ramanathan & 
Davison 2002, pp.l06-107). Computational bioinfonnatics is often used 
interchangeably with computational biology and it is true that there is much overlap 
at their interface. However, they are still distinct disciplines and so it would be 
useful to differentiate between the two. Computational biology will be defined here 
as the development and application of data analysis, theoretical methods, 
mathematical modelling and computational simulations to study biological, 
behavioural and social systems (The Nlli Biomedical fufonnation Science and 
Technology fuitiative Consortium 2000). 
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1.2 The era of '-omics' 
Modem biology has become a high throughput industrialised operation, made up of 
a number of steps that are in turn composed of a number of processes. Studies of 
this kind are known as -omics. Bioinformatics is central to studying information 
flows through these high throughput experiments (see Figure 1.2 on p.4). Genomics 
is a simple omic, and includes activities such as gene sequencing, gene mapping, 
annotation of genomes, and comparisons of multiple genomes. The primary aim of 
genomics is the determination of the complete DNA sequence of an organism's 
genome (Lockhart & Winzeler 2000). This area of molecular biology is perhaps the 
most advanced at present with the complete human genome being decoded from 
both private and public perspectives (Venter et aI., 2001; The International Human 
Genome Sequencing Consortium 2001). 
Despite the numerous genomes that have been fully sequenced, the raw information 
derived do not provide any evidence as to the functions or interactions of genes 
(Buchanan 2003). This is where transcriptomics is extremely useful. In essence, the 
aim of transcriptomics is to act as a complement to the genomic sequence and add 
biological information that is useful to each gene (Bayat 2002; Fu & Y oun 2003). 
To take advantage of the huge amounts of sequenced genome data, new 
information-based innovations are required. These technologies include high-
density arrays of oligonucleotides or cDNAs. 
One of the most important applications of arrays is to monitor gene expression. The 
resulting gene expression profile is an important determinant of phenotype and 
function. Studies on global gene expression enable the collection of data from 
thousands of genes. Knowledge bases are needed not only· to store and organise 
these data, but also to store and organise facts, observations and relationships that 
are the basis for our current understanding. This is not easy because the scientific 
2 
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literature is disorganised and unstructured, without the use of a restricted and 
controlled vocabulary and well defined semantics (Lockhart & Winzeler 2000). 
The large-scale study of proteins usually by high throughput methods is known as 
proteomics (Pandey & Mann 2000). Initially proteomics applied methods, such as 
two-dimensional gel electrophoresis to carry out the identification and 
quantification of protein expression profiles among various samples. The field now 
also covers protein localisation, modifications, and interactions. In effect, 
proteomics makes use of any procedure that ultimately will enable the 
characterisation of protein function. Protein arrays recently bring hope of 
interrogating protein activity on a proteomic scale (Tyers & Mann 2003). Mass 
spectrometry is currently the most popular method used in proteomics (Aebersold 
& Goodlett 2001). Increasingly studies in genomics, gene expression, and 
proteomics can further be integrated to study biology more holistic ally through 
systems biology (Kitano 2002). Genomics, transcriptomics and proteomics have 
extremely important consequences for clinical studies and drug discovery. 
3 
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Pharmacogenomics 
Introduction 
UD 
Clinical 
Pharmacokinetics, 
Pharmacodynamics, 
Side effects 
Figure 1.2 Studies increase in complexity as they transition through genomics-
transciptomics-proteomics-systems biology. The integration of data from these 
studies with clinical data facilitates pharmacogenomics experiments. These 
different data sets are stored in heterogeneous databases, which are associated 
with computer based analysis tools. 
The impact of the completion of the mapping of the human genome and high 
throughput genomic technologies on the pharmaceutical industry is huge. All stages 
of the drug discovery and development cycle are feeling this impact (see Section 
6.1 on p.140). For instance, the 30,000 human genes so far identified will increase 
dramatically the number of drug targets that may be found during the discovery 
stage of drug design (Dracopoli 2003). Vital facilitators of these activities will be 
the fields of pharmacogenetics and pharmacogenomics as they enable studies to be 
carried out which can test for association between disease processes and genetic 
variation during discovery or studying the influence of genetic variation on drug 
4 
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response (e.g. adverse drug reactions, drug toxicity and drug efficacy) during 
development. 
The tenns phannacogenetics and phannacogenomics are often used 
interchangeably. Furthennore scientists around the world also define these two 
tenns differently which can lead to confusion. In general phannacogenomics is 
considered to be the broader field out of the two, encompassing those studies 
associated with phannacogenetics. For example Lesko & Woodcock (2004) in their 
definition include the study of inter-individual variations in whole genome or 
candidate gene SNPs, haplotypes (blocks of SNPs) and differences in gene 
expression that could be correlated with therapeutic response. These same authors 
define phannacogenetics in more narrow tenns referring to it as the study of inter-
individual differences in DNA sequence and association with drug absorption and 
disposition (phannacokinetics) and action of a drug (phannacodynamics) (Lesko & 
Woodcock 2004). Lindpainter (2002) comments on the distinctions in intended use 
of the two fields. According to this author phannacogenetics will help in finding 
the best medicine for a patient while phannacogenomics aids the selection of the 
best drug candidate from a series of compounds under investigation. 
1.3 Information management issues 
Currently bioinfonnatics is overwhelmed by the amount of data being generated 
through the different types of studies discussed in the section above (Critchlow, 
Musick & Slezak 2001). The genomic database GenBank illustrates this mass 
infonnation (see Figure 1.3 on p.6). GenBank started up with 680,338 base pairs in 
1982. In Release 143 in August 2004 the repository was reported to have contained 
a staggering 41.8 billion base pairs from 37.3 million sequences (Benson et aI., 
2005) (see Section 2.9.2.1 on p.68). 
5 
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Figure 1.3 The exponential growth of Genbank in billions of base pairs from 
Release 3 in 1994 to Release 142 in the spring of 2004. 
Source: NCBI News (2004) 
Infonnation overload is a state in which infonnation that should be of use is in fact 
rendered useless (see Chapter Four on p.103). Humans can experience infonnation 
overload through a feeling of loss of control of infonnation, a failure to use the 
available infonnation in an effective manner, and carrying out work inefficiently 
(Bawden 2001). Infonnation overload is a phenomenon that has had an immense 
impact on numerous science fields, including biology. Biological infonnation 
overload has highlighted difficulties faced by scientific researchers and several key 
issues still need to be addressed to ensure that research scientists have effective and 
efficient access to all infonnation that may be relevant to them. We are in a 
generation where use of high throughput experimentation is rapidly becoming the 
nonn and the magnitude of data they produce is increasing in the post-genome era. 
Experiments produce more infonnation than that in a single study and more 
knowledge can be created when different researchers make analyses on the same 
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data or from comparing the analysis of patterns in one system with that of another 
(Brazma 2001). The value added though integration of different data is obvious and 
yet it is non-trivial. A large number of data sources exist and each one has its own 
format (Critchlow, Musick & Slezak 2001). This syntactic heterogeneity means 
researchers end up having to make translations between two sources because one, 
say for example, represents a protein sequence in three-character code, whereas the 
same protein sequence in another source is represented in one-character code 
(Sklyar 2001). As a consequence researchers are spending more time doing 
fundamental information management tasks rather than their required research. 
There is also a semantic heterogeneity problem that is resulting in making database 
searching and retrieval more difficult (Barnes et aI., 2002). For example, there is a 
synonym problem in that the same entity, say a gene for example, may have a 
different name in different databases. Likewise a homonym problem exists in that 
different entities can also have the same name (Barnes et aI., 2002). This means 
that researchers have to inspect and work with data in a number of different ways, 
trailing through a number of resources and having to rely on their own biological 
knowledge to be watchful of these terminology differences. The result of this is a 
time increase in query execution and more complex interfaces (Critchlow, Musick 
& Slezak 2001). To address these such issues requires the adoption of common 
metadata standards. 
Metadata is data or information that is used to annotate other data or information, 
and is a fundamental component of the semantic web (see Section 1.4 on p.8). 
Scientific data and metadata can be described using languages such as Extensible 
Markup Language (XML) (Extensible Markup Language (XML) 2005) and 
Resource Description Framework (RDF) (Resource Description Framework (RDF) 
2005). XML technology is increasingly being used to create data exchange formats 
for the representation and exchange of biological objects while RDF is an XML-
based language used to encode information in semantic web resources. In addition, 
ontologies are increasingly being used to facilitate the management of biomedical 
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infonnation. An ontology is a philosophical concept used in the knowledge 
representation community, and hence it would be useful to give such a definition 
first: 
"an ontology IS a fonnal, explicit specification of a shared 
conceptualisation. 'Conceptualisation' refers to an abstract model of 
phenomena in the world by having identified the relevant concepts of 
those phenomena. 'Explicit' means the type of concepts used, and the 
constraints on their use are explicitly defined. 'Fonnal' refers to the fact that 
the ontology should be machine-readable. 'Shared' reflects that ontology 
should capture consensual knowledge accepted by the communities". 
Gruber (1993). 
The use of ontologies in bioinfonnatics can be explained further with a simple 
example. We may for instance, want to capture knowledge about an entity or 
concept Enzyme. It could be said that this enzyme is a kind of Protein. A property 
of this protein is to catalyse a Reaction. Substrates and Products make up this 
reaction. This and additional infonnation is what is understood about the concept 
Enzyme found in the domain of molecular biology (Stevens et aI., 2003a). 
Ontologies can be used to provide controlled tenns to describe concepts and their 
relationships used within semantic web applications such as web services and 
GRIDs (see Section 2.4.3 on p.28). 
1.4 The semantic web 
The semantic web transfonns current web technologies into a machine-
understandable fonn that allows automated polling of infonnation requested via 
intelligent software agents (Bemers-Lee, Hendler & Lassila 2001) (see Appendix A 
on p.267). This advance is suggested as an opportunity to address issues of 
integration and interoperability associated with the management of disparate 
bioinfonnatics infonnation resources. The groundbreaking semantic web system 
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for phannacogenomics (and only one to date) IS the 
PhannacogeneticslPhannacogenomics Knowledge Base (PhannGKB) (Hewett et 
aI., 2002). PhannGKB is a storage and retrieval system implemented in Protege 
which is a frame based knowledge management system (see Section 2.6.1 on p.38). 
PhannGKB contains genetic sequences, cellular and molecular phenotype and 
clinical phenotype data. The diverse concepts that represent these data and the 
numerous relationships between them are modelled using the PhannGKB ontology, 
giving rise to the PharmGKB data model. 
XML Schema (Daconta et aI., 2003, p.29) enables the contents of XML-based 
documents to be constrained according to a structure and a particular vocabulary 
and is used in PhannGKB as a mediator to map the structure and content of data 
coming into the knowledge base to the PharmGKB ontology. The XML schema is 
designed such that users submitting their data can map their internal data schemas 
into an XML document (Rubin et aI., 2002). This is the main method for 
infonnation integration with other external submitting centres. PhannGKB is also 
interoperable with the dbSNP database (Sherry, Ward & Sirotkin., 1999). Users can 
submit SNP data to PhannGKB and if a particular SNP is not contained in db SNP , 
PharmGKB can automatically submit a SNP to it (Klein et aI., 2001). PhannGKB 
also has associated with it a SNP surveillance system, as it is vital that researchers 
have knowledge of new SNPs as and when they are discovered so that duplicated 
work can be avoided. 
PharmGKB has proved to be an important initial resource designed specifically for 
phannacogenetics/pharmacogenomics science. However as these fields mature it 
will be equally vital to develop more standards based storage and analysis tools to 
keep up with infonnation overload. The current study will use case studies (see 
Section 3.2.1 on p.81) to explore the need for more pharmacogenomics resources 
both in industry and academia, along with their development and utilisation. The 
possibility of reuse of objects used for the development of standards developed for 
PharmGKB and those being designed under other public initiatives such as the 
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Microarray Gene Expression Data Society (MGED) (MGED Society 2005) and 
HUPO-PSI for the proteomics community (HUPO Proteomics Standards Initiative 
2005) will be explored (see Section 5.1.1 on p.121). 
This work will benefit researchers involved in pharmacogenomics and related 
areas. In broad terms research into a standards based framework would facilitate 
information integration, sharing, seeking and ultimately discovery of knowledge in 
pharmacogenomics and other related disciplines such as functional genomics and 
proteomics. More specifically, guidelines for information to be captured for 
different parameters, will ensure interpretability of experimental results, and allow 
them to be verified independently (Brazma et aI., 2001). This will also facilitate the 
creation of public repositories for pharmacogenomics, as researchers will have a 
reference as to what information to input into these. 
1.5 Aims and objectives of the study 
Three aims and five objectives describe the research landscape to be 
investigated. 
1.5.1 Aims 
1. To critically review the different ways in which the principles and concepts 
of information management are applied to Bioinformatics. 
2. To reVIew causes of information overload experienced by scientific 
researchers and to propose a theoretical/technological solution. 
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3. To evaluate the use of the semantic web and e-science technologies, to 
improve knowledge repositories, manipulation and dissemination. 
1.5.2 Objectives 
1. To carry out two case studies to explore the information environments in 
biomedical departments in academia and industry. (Aims 1,2 and 3). 
2. To study scientific workflows associated with pharmacogenomics. (Aims 1 
and 3). 
3. To study the different datasets generated and used in pharmacogenomics 
workflows. (Aim 1). 
4. To determine resources used for data storage and processing. (Aim 1 and 
3). 
5. To develop a prototype for pharmacogenomics metadata. (Aims 1, 2 and 
3). 
1.6 Plan of thesis 
In Chapter Two the major focus will be the bioinformatics field; firstly a historical 
perspective will be given followed by an in depth review of the current 
bioinformatics literature. 
11 
Chapter One Introduction 
Chapter Three will discuss the research methods used in the current study. This 
chapter will mainly argue for the use of a qualitative research design and case study 
methodology, describing the particular methods used to collect and analyse data. 
Chapter Four will be an in depth discussion of the information overload topic, in 
which the current information overload literature will be highlighted. The next two 
chapters will talk about the case studies carried out as a part of the research in the 
current study. Chapter Five will focus upon the happenings in the Sanger Institute 
case study and the requirement for standards will be explored further. Chapter Six 
will describe in detail the AstraZeneca case study, how it was carried out and 
discusses its findings regarding data management activities within the RDG 
department. Logically, the discussion will follow in Chapter Seven in which the 
implications of the findings of both of the case studies will be reviewed along with 
other aspects such as how these findings fit into the wider field. The final chapter 
(Chapter Eight), will include conclusions, reviewing the aims and objectives and 
descriptions of whether they were satisfied or not, along with recommendations for 
the two organisation sites, limitations ofthe study and plans for future research. 
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Chapter Two: A review of the bioinformatics field 
2.1 A historical perspective 
Bioinfonnatics is an interdisciplinary field used to collect, store, retrieve and 
analyse large amounts of biological infonnation. Indeed, it can be thought of as the 
point where biological science, computer science, infonnation science and 
mathematics intersect. People always associate bioinfonnatics with modem cutting 
edge research and they would be correct in doing so. However, it is by no means a 
new discipline (Chen 2001). There is some debate however, as to the exact period 
when the tenn 'bioinfonnatics' first came into use. According to Boguski (1998), 
the tenn first appeared in the literature in 1991, but some believe the tenn was 
introduced in the mid-1980s (Attwood & Parry-Smith 1999, p.3). 
Other researchers believe bioinfonnatics to have its origins in molecular biology 
from the 19th century, a time when ideas about the hereditary function of DNA 
were evolving. These days, bioinfonnatics deals with most types of biological 
infonnation but there is no denying that the field was initially concerned with the 
manipulation of molecular biological data. So firstly, this short historical review 
will concentrate on the important theoretical and experimental developments of 
molecular biology relevant to bioinfonnatics, such as biological sequencing during 
the 1960s until the end of the 1970s. The second part will discuss the development 
of bioinfonnatics further, with the introduction of biological databases during the 
period 1980 to 1986. The third part will concentrate on the expansion of 
bioinfonnatics during the period 1988-1994, with particular relevance given to 
computational tools. 
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The final part ofthe review (1995-2005) will discuss entire genome sequencing and 
annotation. 
2.1.1 Biological Sequencing (1960s till the end of the 1970s) 
The period between the 1960s till the end ofthe 1970s was when the sequencing of 
nucleic acids began. As more sequences emerged scientists created information by 
analysing these sequences and creating models of macromolecular structures 
through the use of computers (Trifonov 2000). The primary aim was to find 
relationships between the molecular structure of molecules and function. Indeed it 
was during this time when Stahl & Goheen (1963) made the first reference to 
bioinformatics or its other common name computational biology in their paper. 
This work showed that operations carried out by cells on macromolecules were 
computable (Chen 2001). 
Important evidence was observed almost as soon as computational techniques 
began, for example, the similarity of related proteins (Trifonov 2000). Emphasis, 
during this time was placed on looking at evolutionary relationships of organisms 
and Zuckerkandl & Pauling (1962) made an important discovery about the 
variability of sequences and their connections with their evolutionary relations. 
Ultimately, this created the molecular evolution field (Bioinformatics milestones 
2003). The divergence of sequences during evolution meant that it was not an easy 
task to establish in a quantitative way, the relatedness among them. This called for 
the development of computational tools. 
What was needed, were better sequence comparison methods. A technique using 
computers to describe protein evolutionary studies by Margaret Dayhoff (1969) 
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called Point Accepted Mutations (P AM) matrices, improved sequence comparisons 
drastically (Trifonov 2000). Another influential development to the sequence 
comparison problem was Needleman & Wunschs' work on sequence alignment. 
This was the first reported similarity search algorithm between two proteins 
(Needleman & Wunsch 1970). 
Era of mass sequencing 
Preliminary efforts into the sequencing of DNA (and RNA) were tedious and 
inefficient. This can be exemplified by the different combinations of chemical, 
enzymatic and spectral analysis techniques that were applied to every single base 
step, to ensure that it was identified correctly. Such techniques could only be 
extended minimally to the genome level (Trifonov 2000). The time of huge 
massive DNA sequencing began in 1975-1977. Two rapid 'read-the-gel' techniques 
were introduced; the most important one will be discussed here. 
When carrying out experiments to uncover the amino acids present in insulin, 
Sanger developed the fundamentals of modem day sequencing techniques. 
Specifically, his method of sequencing was based on template DNA synthesis that 
was disrupted at random locations at one of four letters (A, C, T, G) by a restricted 
supply of the respective dNTPs (deoxyribonucleic acid triphosphates) (Genome 
Network News 2000-2004). This process is slow and tiresome, as the sequencing of 
a few million letters in a relatively small amount of DNA would take several man-
years and present in this DNA would be hundreds of millions, and even billions of 
letters (Trifinov 2000). 
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Use of read-the-gel techniques like the Sanger method meant very soon, the 
completion of the first viral genome, the RNA bateriophage MS, made up of 3569 
bases (Fiers et aI., 1976). The sequencing of more viral genomes followed and in 
1977, Staden in his paper described the need for computer programs to manage the 
ever, increasing data produced from the speedy new DNA sequencing techniques 
(Staden 1977). 
2.1.2 Introduction of sequence databases (1980-1986) 
The field ofbioinformatics expanded greatly during the period 1980-1986, and this 
was due to the onset of large scale sequencing in 1980-1981. This sequencing 
technology established the need for public databases, so that these could be used to 
house the enormous amounts of sequence information. Parallel to this, simple 
computational algorithms and programs were implemented, in order to search and 
analyse the sequences contained in these databases (Chen 2001). 
In 1981, The European Molecular Biology Laboratory (EMBL) made the first 
public release of the Genome Database (GDB). The same year saw the 
development of the Smith-Waterman algorithm (Smith & Waterman 1981). Other 
key developments saw the Phage lambda genome being sequenced in 1982 
(Bioinformatics milestones 2003). In the same year, the Genetics Computer Group 
was founded who would later create the comprehensive GCG Wisconsin Package 
of computational biology tools. This package has gone on to become a huge 
success and is still a fundamental standard today (Accelrys GCG 2001-2005). 
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With the development of huge public data banks consisting of nucleic acids and 
protein sequences such as GenBank in 1982 and the Protein Infonnation Resource 
(PIR) in 1984, more efficient search methods were introduced. In 1983 Wilbur and 
Lipman presented their sequence database searching algorithm (Wilbur & Lipman 
1983). Due to the labour intensive and costly sequence techniques, in 1986 Leroy 
Hood modified the Sanger method using fluorescent dyes instead of radio labels 
and by integrating laser and computer technology created the first automated 
sequencer (Genome Network News 2000-2004). 
2.1.3 The growth of computational tools (1988-1994) 
The initiation ofthe Human Genome Project in 1988 and the exponential growth of 
sequences in the public databases meant that bioinfonnatics from a computational 
tools point of view enjoyed the greatest productivity between 1988 and 1994. 
Computational technologies grew in sophistication, and were able to cover not only 
analysis and comparisons of sequences, but also other aspects of bioinfonnatics 
including gene-finding, motif-finding, clustering, multiple sequence analysis and 
protein secondary/tertiary structure predictions. Heuristic algorithms were 
introduced, using machine learning techniques including the F ASTA algorithm 
(Pearson & Lipman 1988) for fast sequence comparison in 1988 and statistical 
methods like hidden Markov Models (HMM) and Bayesian networks (Baldi & 
Brunsak 2001 p.189). 
Other developments during this period include in 1989, when for the first time 
HMMs were applied to sequence analysis of DNA, and the creation of an approach 
for rapid sequence comparison called basic local alignment search tool or BLAST 
(Altschul et aI., 1990) (see Section 7.5.3 on p.206). Importantly in 1991, ESTs, or 
expressed 
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sequence tag sequencmg was introduced when Adams' team described the 
generation of expressed sequence tags (ESTs). The importance of ESTs lie in their 
applications to discovering new genes, mapping of the human genome and 
identifying coding regions in genomic sequences (Adams et aI., 1991). The period 
between 1988 and 1994 also saw the opening of large bioinformatics research 
institutes such as the EMBL European Bioinformatics Institute in Hinxton, UK 
(Bioinformatics milestones 2003) and the integration of analysis tools into 
sophisticated software packages and systems, allowing data access from multiple 
sources over the Internet. Distinguished examples include multi-database data 
retrieval systems like the SRS (Sequence Retrieval System) (Etzold, Ulyanov & 
Argos 1996) and Entrez in 1994 (Wheeler et aI., 2005). 
2.1.4 Accelerated sequencing and annotation of entire genomes 
(1996-2005) 
The final period to be discussed in this historical review is from 1996 until 2005. 
During this period not only did bioinformatics grow in terms of scale, but also in 
terms of scope. Accelerated sequencing of complete genomes and data generation 
through the use of high throughput technologies like microarrays and mass 
spectroscopy involved with the new range of -omics, including functional 
genomics, proteomics, and pharmacogenomics etc, has created an information 
overload (see Chapter Four on p.l 03) problem for biologists. 
Important whole genome annotation developments included the worldwide 
sequencing collaboration in 1996 of the baker's yeast S. cerevisae (12,068 
kilobases) (Goffeau et aI., 1996) and in 1998, the completion of the sequencing of 
the 130 Mb multicellular worm (c. elegans) genome (The C. elegans Sequencing 
Consortium 1998) and in 2000, that of the D. melanogaster genome (Adams et aI., 
2000) or as its more commonly known, the fruit fly (180Mb). In 2001, the biggest 
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challenge of them all was the focus of attention and the completion of the 
sequencing of the human genome (The International Human Genome Consortium 
2001; Venter et aI., 2001). Having the knowledge that almost any gene in the 
human is present in the mouse saw in December 2002, the Mouse Sequencing 
Consortium complete a draft of the mouse genome (International Mouse 
Sequencing Consortium 2002). Another recent mammalian genome to be 
sequenced is that of the chimpanzee, which showed that, both chimpanzees and 
humans are almost the same in terms of identity, sharing 96% of DNA sequence 
(Chimpanzee Sequencing and Analysis Consortium 2005). 
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2.2 Bioinformatics: a critical literature review 
The following literature reVIew will illlustrate vanous ways III which 
bioinformatics uses different information management principles for the effective 
management of data, information, and knowledge generated through modem day 
biological studies. 
2.2.1 A definition of information 
It is difficult to offer a precise definition of information as members of various 
disciplines have developed practical definitions for their own respective fields. As 
this literature review will concentrate on information in bioinformatics, by its 
nature an interdisciplinary domain, a general definition of information is 
appropriate. An example of such a definition by Losee (1997) is that 'Information 
is produced by all processes and it is the value of characteristics in the processes 
output that are information'. This definition can be expanded for further 
clarification. Processes can be thought to produce data which after having context 
added to them becomes information. Knowledge can subsequently be derived from 
the information through human understanding and mental thoughts. For example a 
string of letters could be considered as data. This string of sequences could 
represent a particular protein sequence which is information. A human user may 
have knowledge that this protein sequence is involved in causing mutation. 
21 sI century biology is beginning to use the traditional concepts of information 
science. Bates (1999) gives some useful descriptions of information science, one of 
which describes it as being an interdisciplinary field that cuts boundaries between 
several disciplines. Bioinformatics, the field of biological information management 
comprises studies from the biological sciences, and other fields like computer 
science, mathematics, and physics. For this reason there is often confusion as to 
what 
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bioinfonnatics actually refers to, and many definitions of it exist. Another 
description of infonnation science used by Bates (1999) calls it the study of 
infonnation gathering, its organisation, its subsequent storing and retrieval, and 
finally its dissemination. This description can be directly applied within the context 
of bioinformatics. Here, this definition will be elaborated upon in order to define 
bioinfonnatics as the application of information science to obtain, store, organise, 
collect, visualise and analyse information of a biomedical nature. The literature 
review that will follow illustrates how bioinfonnatics is applied in seven key 
infonnation management areas which are creation of infonnation, distribution of 
infonnation, organisation of information, control of infonnation by content, 
infonnation retreival, analysis and presentation of infonnation, and storage of 
infonnation (Middleton 2002, p.89-299). 
2.3 Creation of bioinformatics information 
Biological data are highly diverse which can range from laboratory records to 
pUblications in the literature. A major source of raw biological data in the post-
genome era are high throughput technologies which include for example, 
. sequencing machines, microarrays, genotyping machines, mass. spectrometers, 
nuclear magnetic resonance (NMR) etc. These generate in an automated fashion 
different types of data ranging from nucleic acid and protein sequence data, to 
expression data, to proteomics data to metabolomics data. High throughput 
instruments output raw data mainly in electronic binary fonnat, which alone are 
meaningless. Data in order to become meaningful need to be transfonned into 
infonnation on web resources. Annotation is an important process that is able to do 
this. 
By adding additional descriptive infonnation to experimental data, data objects can 
be developed that can be linked in an intelligent manner to similar data in other 
resources. 
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Increasingly in bioinformatics, annotation is being carried using the self-describing 
model through attachment of metadata (data about data) to data fields (Berman & 
Henson 2003). XML is a popular language that is being used for annotation in the 
bioinformatics field, and recently there has been a surge in many XML-based 
markup languages that have been developed as data exchange formats such as the 
Microarray Gene Expression Markup Language (Spellman et aI., 2002) and the 
Systems Biology Markup Language (Hucka et aI., 2003). There are disadvantages 
to such open standards. For example, data described using annotation standards are 
often incomparable and processing overheads are inherent in the markup process 
(Hancock et aI., 2002). In addition the actual expressiveness of the XML data 
model is limited as is its scalability (Archard, Vaysseix & Barillot 2001). XML is 
only able to capture limited relationships, and is unable to capture relationships at 
the semantic level. Wang, Gorlitsky & Almeida (2005) in their recent paper, using 
two-dimensional gel electrophoresis explained how additional relationships that are 
often needed to invoke certain applications can be explicitly captured using the 
RDF model, a foundation for the semantic web (see Appendix A on p.267). 
2.4 Distribution of bioinformatics information 
Bioinformatics data are placed in distributed databases around the world and can be 
found in mUltiple data formats such as flat files, XML documents and relational 
databases. These formats are often incompatible and different programming 
languages are used to implement database and analysis resources. Such resources 
often need to be integrated as workflows in which output from one program will be 
needed as input in another program (Lu et aI., 2005). A number of integration 
architectures have been used for the development of interoperable bioinformatics 
resources. 
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2.4.1 Effective integration 
Good database integration that enables efficient exchange and storage of data is 
essential so that scientists all over the world have access to the data sets they 
require for their experiments. Many challenges exist such as the existence of 
independent, heterogeneous repositories with limited interoperability, proprietary 
user interfaces, and different data formats storing data that are inherent with 
terminology and semantic problems (Hammer & Schneider 2003). For example, 
there is a synonym problem in that the same entity, (say a gene for example), may 
have a different name in different databases. Likewise a homonym problem exists 
in that different entities can also have the same name. In addition, there is often 
confusion as to the definition of the most fundamental biological objects, such as 
gene and protein (Attwood 2000). For example, a term that has mUltiple meanings 
is 'protein function'. In terms of biochemical function, 'protein function' could 
mean 'enzyme catalysis', or in terms of genetic function it could also mean 
'transcription repressor' (Schulze-Kremer 2002). Some of the main methods used 
for integration of biological data will now be discussed. 
Link Integration 
Traditional methods for integration have been through federation, one type of 
which is link integration. With this method, the user extracts information from one 
database and moves to other databases through hyperlinks (Davidson et aI., 2001). 
This type of navigation integration is commonly used to connect web databases and 
is easy to use. However, maintaining and updating links can prove to be difficult. 
For example it is a common scenario for a web user to click a link only to find that 
it is no longer valid. An example of such integration can be found in the powerful 
and efficient keyword 
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indexing and search application: sequence retrieval system (SRS) (Wong 2002). 
SRS is associated with a simple graphical user interface that provides access to 
over 400 databases, including repositories for DNA and protein sequences, 
mapping data, protein domains, molecular structures, metabolic pathways, and 
literature abstracts etc. Integration in SRS is achieved by parsing 'flat files' (sets of 
data in text file format) or databanks that contain structured text with field names. 
Users can then access these data using the SRS Query Language by providing the 
system with keywords. An advantage of flat file indexing is that it enables easy 
addition of new data sources and the hundreds of resources that can be accessed 
through SRS is proof of this. In addition, the easy to use interface means queries 
can be formulated simply. However the emphasis of SRS on flat file indexing is 
also one of its drawbacks. For example other remote sources such as relational 
databases cannot be catered for as no advanced querying or transformation 
mechanism is available (Zdobnov et aI., 2002, p.278). 
View Integration 
Another type of integration is view integration or federation. A key feature of this 
approac? is that all the information is kept in source databases but an environment 
is created, where the databases seem as if they are part of one central system to 
form a global schema. This central system is a common data model, which can be 
object-oriented, relational or complex value. Such an approach removes the high 
costs of physically integrating many databases, but the onus of integration is now 
left to the application accessing the data and often multiple applications are made to 
carry out the same integration tasks (Arenson 2003). Federated systems can be 
further classified into tightly coupled or loosely coupled. In a tightly coupled 
federated system a global 
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schema is created and queries are expressed on this schema. An example of a 
system based on such an approach is the TAMBIS system (Goble et aI., 2001). In 
the T AMBIS system, source dependent CPL queries are mapped onto ontology 
concepts in a global schema. 
An example of a loosely coupled federation integration system is K2lKleisli 
(Davidson et aI., 2001). In such a system no global schema exists and it is up to the 
user to specify using a multi-database query language the component databases in 
the query (Ben-Miled et aI., [n.d.]b). For example the mediator in K2lKleisli relies 
on the high-level query language OQL that provides the ability to query several 
resources. The language processor then analyses the query to determine what part 
of the query can be answered by a data source and generates a set of sub queries. 
The processor then submits to the sub queries, drivers that extract information from 
particular databases. K2lK1eisli is limited however. For example, the slowest data 
source governs the processing of a query. Because of this, KIeisli1K2 does not have 
the performance that one associates with directly accessing source databases. The 
difficulty associated with writing and maintenance of database drivers is also 
another problem (Stein 2003). 
Warehouses 
In data warehousing all the information is dumped into storage as a global schema 
and any querying is dealt with by the information in the warehouse, instead of 
individual data sources (Stein 2003). A major advantage ofthe warehouse approach 
is the increase in system performance as all queries are made against the warehouse 
locally rather than over a network. Warehouse systems are usually based upon 
relational data models and a recent example is the Atlas system for bioinformatics 
research. Integration in this system is carried out at two levels. The first level 
involves the development of common relational models for source data (to enable 
the reuse of each 
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data model to store data of similar type), which includes sequence data, protein 
interaction data, gene ontology data and genetic data etc. The second level utilises 
tools such as ontologies to enable cross-referencing of disparate types of data (Shah 
et aI., 2005). 
In general the warehouse approach has not been utilised in the bioinformatics domain, 
as it is not often possible to scale to numerous databases. For example the non-static 
nature of database architectures means that the addition of new databases could require 
the contents of the warehouse to be repopulated and redesigned. In the Atlas system for 
example, a change to the structure of the source data would require changes in software 
code to ensure that the new data can be appropriately parsed (Shah et aI., 2005). The 
warehouse approach is also infamous for maintenance problems. For instance, new 
information that is continuously added to the source databases would also have to be 
re-imported into the warehouse in a timely fashion to keep it up to date (Stein 2003). 
Current technology in general is inadequate for effective integration and 
interoperability in an interdisciplinary discipline such as bioinformatics. An 
opportunity to remove problems such as those discussed above is provided by semantic 
web applications such as web services and GRIDs. 
2.4.2 Web Services 
A recent type of integration technology is known as web services, which provide a 
framework for the systematic and flexible interaction of applications. They simplify 
the communication between incompatible applications online (and therefore are 
well suited to the bioinformatics discipline), by defining a standardised means for 
their description, location and communication. An example of a bioinformatics web 
services scenario could be the EBI, NCBI and University of California Santa Cruz 
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providing a sequence similarity service. A script written for the use of one service 
would work for all three organisations even though they may use different sequence 
similarity tools (Stein 2002). 
Web services are standard-based software components that by using other software 
components can be accessed over the Internet. These components can include 
accepted data formats and access methods, and directory services that enable scripts 
to find them. Despite the advantages of web services such as interoperability and 
reuse, the downside to their widespread use is that it will take a number of years 
before web services are stable enough to replace existing sites (Blank 2003). 
Having said this, the technology exists, and this is the most promising and 
reinforcing aspect. The XML-based language Web Services Flow Language 
(WSFL) is used for making descriptions of web services compositions. UDDI 
(Universal Description, Discovery and Integration) is an XML-based registry, 
which web services can use to register themselves automatically as being available 
for use on the Internet. The Web Services Description Language (WSDL) is used to 
describe web services and communication among web services is carried out using 
the Simple Object Access Protocol (SOAP) (Bernardi et aI., 2004). 
An example of an early web service is the Distributed Annotation System (DAS) 
(Dowell et aI., 2001). DAS provides a web service for the exchanging of genomic 
annotations. In DAS the user asks for a genomic region of interest and does this by 
naming the genome, a landmark on the genome (for instance a clone accession 
number or a genetic marker), and a region of the genome related to that landmark 
(Stein 2003). Specialised annotation servers then return a structured document 
listing annotations across defined areas of the genome. It also provides integration 
where users can make use of DAS to provide additional annotations to data in 
resources such as Ensembl (Birney et aI., 2004a) but this is limited and does not 
solve semantic discrepancies 
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between resources (Dowell et aI., 2001). DAS has other disadvantages like the fact 
that it is not easily extendable. For instance if groups wish to create a DAS that 
functions for protein motifs, genetic and physical maps then this would not be a 
simple thing to do (Dowell et aI., 2001). 
The information about annotations transmitted by DAS is minimal so that 
compatibility with applications expecting only fundamental information is not lost. 
Other weaknesses include a difficulty to locate DAS servers with no existence of a 
method to register a new server. However, it is its semantic weakness that is the 
main problem and can be addressed through the use of ontologies (Stein 2003). The 
term ontology is often used to refer to the semantic understanding or capturing the 
knowledge shared by communities belonging to specific domains (Jacob 2003). 
Ontologies by themselves do not integrate bioinformatics resources, but they are 
excellent facilitators (see Section 2.6.1 on p.38). For example a shared ontology 
between two resources gives added confidence to researchers that both the 
resources are using the same terms (Stein 2003). BioMOBY is another example of a 
web services project for bioinformatics (Wilkinson & Links 2002). It provides a 
simple common format that is able to describe in a machine-readable way, a broad 
range of host interfaces. Each hosf (or service provider) is able to register their 
service types into a central registry database known as 'MOBY Central'. 
Application programs then search this registry to find web services that could be of 
use. However a limitation of BioMOBY is that it is unable to describe all 
components ofthe web services it supports (Stein 2003). 
2.4.3 GRID Computing 
GRID computing is the name given to advanced computing environments in which 
resources over the Internet are connected seamlessly, autonomously and 
transparently. 
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Most e-Science GRID projects for the biomedical sciences execute in silico 
experiments as workflows through network connecting software i.e. middleware 
platforms (using XML). It is possible to place web services into GRIDs to develop 
GRID-enabled web services (Daconta et aI., 2003, pp.82-83). 
The Globus Toolkit is a community-wide open source set of tools and services for 
the development of GRID applications. Some of the issues addressed by the toolkit 
are security, information discovery and management and communication. The 
Open Grid Services Architecture (OGSA) is an evolution of the Globus Toolkit. 
OGSA provides an environment where previously inflexible functions such as the 
invoking of remote web services can be re-implemented in other application 
programs. This functionality allows the integration and interoperability of GRID 
services that parallel similar functions in the provision of web services. Further, 
OGSA extends a service-oriented approach where a Grid service makes use of 
existing web service standards such as WSDL to develop standard interfaces. The 
application of appropriate standards can address issues that include among others, 
the creating, naming and discovery of GRID services, and their lifetime 
management (Foster et aI., 2002). 
GeneGRID has been developed as a GRID solution for the management and mining 
of the wealth of genomic data to facilitate target identification for protein and 
antibody discovery. GeneGRID extends OGSA through three main components 
which themselves are made up of further web services (Kelly et aI., 2004). The 
three components are the GeneGRID Data Manager (GDM) that is responsible for 
access and integration of datasets, the GeneGRID Application Manager (GAM) 
that integrates bioinformatics applications and the GeneGRID Workflow and 
Process Manager (GWPM) for the creation and manipUlation of workflows. The 
scheduling and allocation of resources needed to complete these workflows also 
takes place via the 
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GWPM (Kelly et aI., 2004). However, GeneGRID lacks an active tool for the 
graphical construction and submission of work flows. 
The e-Protein project aims to deliver a GRID infrastructure of distributed resources 
and specialised analysis software for protein structure annotation; such analyses 
require enormous computing power (O'Brien et aI., 2004). The three main sites 
involved in the project are the European Bioinformatics Institute at Cambridge, 
UK., Imperial College, and University College, both based in London, UK. At each 
of these sites a local DAS interface to the database provides access allowing each 
organisation to contribute towards proteome annotation (O'Brien et aI., 2004). The 
GRID middleware used to enable sharing of high-performance computing 
resources is the Imperial College e-Science Networked Infrastructure (lCENI) 
(Furmento et aI., 2003). ICENI enables scientists to compose workflows through 
drag-and-drop components in a graphical environment. These are then mapped onto 
the available resources through scheduling functionality. Within ICENI, XML 
Schema is used to provide rich metadata about resource capability, availability of 
GRID services and behaviour of applications. XML Schema enables the contents of 
XML-based documents to be constrained according to a structure and a particular 
vocabulary (Daconta et aI., 2003, p.29). 
The implementation of ICENI in the e-Protein project made use of version 1.4 and 
has since been migrated to ICENI 11 due to problems such as software decay and 
complexity in installation with a full installation required for each component. 
ICENI 11 bypasses this difficulty as it is being created into a number of individual 
toolkits and each of these can be used separately to perfonn GRID functions (Das 
et aI., 2005). The e-Protein project (and GeneGRID) it seems are more focused on 
the computationally intensive problems inherent in bioinformatics rather than 
semantically related issues that have driven the design of myGRID (discussed 
below) (Goble et aI., 2004). 
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Indeed, The e-Protein project lacks an ontology that can be used to describe 
services and their capabilities involved in complex workflows. 
Interestingly, when examined more closely, the relationship between the GRID and 
the semantic web is complementary. Both require the need for machine-
understandable metadata to support information discovery, integration and 
aggregation. In addition, both function in an environment that is distributed, global 
and susceptible to frequent change (Goble & De Roure 2002). So the incorporation 
of met ad at a and ontologies in the GRID will transform them into semantic GRIDs. 
myGRID is such as example, and its emphasis is not only on database integration 
and optimising workflow, but also on the inclusion of provenance data which is a 
type of metadata that can be used to audit various tasks (Stevens et aI., 2003b). In 
myGRID its uses include allowing scientists to record information about their 
experiments in an electronic lab book, and also for keeping track of workflow 
execution such as start and end times to ensure traceability of in silica experiments. 
Also available in myGRID are personalisation functions in which users can have 
their own personal views over data and services offered depending on the tasks they 
are performing. Semantic web technologies utilized in myGRID include RDF to 
describe resources; Life Science Identifiers (LSIDs) (Clark et aI., 2004) which are a 
type of Universal Resource Name (URN) to identify the bioinformatics resources 
and ontologies expressed in DAML+OIL to provide a common semantic view of 
the data. The myGRID ontology is also used for the annotation of data and their 
interpretation produced via in silica experiments (Stevens et aI., 2003b). myGRID 
could be improved through increased security of networks; an area that seems to be 
preceded by providing functionality in terms of priority by the developers of 
myGRID. 
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2.5 Organisation of bioinformatics information 
The experiments carried out in high throughput laboratories produce different types 
of data in complex workflows. It is commonplace for scientists in biological 
laboratories to make use of high throughput technologies such as genotyping 
machines and microarrays to be integrated with sophisticated software such as 
databases and Laboratory Information Management Systems (LIMS). Answers are 
needed to questions, such as what different kinds of data are created by each 
experimental technique or what information is derived from the primary data? 
(Bomberg-Bauer & Paton 2002). Therefore it is important to develop clear and 
understandable data models for the development of databases (see Section 2.5.1 
below) in which different biological data are captured effectively. It is important 
that structures used not only represent biological data that reflect the physical 
models used to understand biological systems, but also cater for the ways in which 
experimental data are collected and archived. The literature shows examples of 
implementation-independent conceptual modelling in bioinformatics. More 
specifically entity-relationship modelling and object-oriented modelling has been 
used. 
2.5.1 Conceptual modelling 
An entity-relationship (ER) model is usually illustrated as an entity-relationship 
diagram in which boxes are used to represent entities and lines are used to represent 
relationships between the entities (see Figure 2.S.1a on p.33). Entities themselves 
have attributes that correspond to columns in a relational database. The primary 
advantage of using entity-relationship modelling as an implementation-independent 
platform is that it can be easily mapped onto relational database systems (Nelson et 
aI., 2003). An 
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example of a bioinfonnatics ER model that has actually, been implemented as a 
relational model is the PRINTS database of fingerprints (Attwood 2000). The first 
implementation of PRINTS was in ASCII files, but migration to relational 
technology occurred due to a need for better perfonnance and functionality 
(Attwood 2000) (see Section 2.9.2.2 on p.70). 
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Figure 2.S.la A partial entity-relationship diagram for an experimental 
proteomics database. 
After: MacMullen (2003) 
An example of another database whose relational schema has been reported is the 
RNA Abundance Database (RAD) for capturing gene expression data generated 
through different high throughput methods. RAD is unique in that it enables cross-
platfonn comparisons of array-based methods and others such as EST-based Serial 
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Analysis of Gene Expression (SAGE) (Stoeckert et aI., 2001). A logical 
representation of a gene experiment is carried out through the use of three main sets 
of tables. These are Platfonn, Experiment and Data. The Platfonn tables hold 
information about platfonn types and the genes being investigated etc. The 
Experiment tables hold particulars about how each experiment was carried out and 
any associated parameters, sources of RNA and software used for scanning and 
image analysis. In addition quantitative infonnation about the experiment is also 
captured such as raw data points, as well as processed data points. This database 
since its conception is compatible with Microarray Gene Expression Data Society 
(MGED) MAGE standards (MGED Society 2005), as it is Minimum Infonnation 
About a Microarray Experiment (MIAME) compliant (Brazma et aI., 2001), 
making use of ontologies and enabling data export to databases that accept the 
MAGE-ML fonnat (Spellman et aI., 2002). MIAME is an experimental and 
protocol annotation standard that provides researchers in functional genomics with 
a methodology by which to submit their micro array experiments. Researchers when 
following the MIAME guidelines must provide descriptions for experimental 
design, array design, samples, hybridisations, and measurement data and 
specifications of data processing. The MAGE-ML fonnat is an Extensible Markup 
Language (XML) exchange protocol based upon an object model called MAGE-
OM. This object model provides a solid platfonn upon which other microarray 
repositories can be built. 
With ER modelling, database designers have to make decisions early on as to what 
entities to include and which attributes will belong to the entities. Biological data 
due to their non-static nature means that entity-relationship models once 
implemented are extremely difficult to change (Keet 2003). Data become 
increasingly complex through the introduction of more challenging data sets such 
as interaction and pathway data for instance, which would be difficult to capture 
with the ER model. These reasons have driven the development of object-oriented 
databases and particularly the use of the 
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industry standard object-oriented modelling language UML (Unified Modelling 
Language) (Paton et aI., 2000). Not many reviews can be found in the 
bioinformatics literature that critically compares the use of entity relationship 
modelling, with object-oriented modelling, although an exception is the work by 
Bomberg-Bauer & Paton (2002). This research provides a decent review of 
biological data modelling in a conceptual manner but has also come under scrutiny 
for discussing only what is possible in data modelling rather than what should be in 
terms of satisfying the requirements of biologists (Keet 2003). 
UML class diagrams are a part of the wider set of tools for the object-oriented 
approach to system design. The classes in a class diagram are depicted as boxes, 
which incorporate attributes and operations. The class diagram can be used to show 
relationships between classes (Wiseth 2005). UML has been used to model 
genomic data, protein-interaction data, transcriptome data etc (paton et aI., 2000). 
MacMullen (2003) used a class model to express a metadata framework for 
proteomics. As entity-relationship models can be implemented as relational 
systems, similarly, UML models can be mapped onto object-oriented 
implementations. The Proteomics Experiment Data Repository a standard for the 
capturing of proteomics experimental data and metadata is based upon a UML class 
diagram (Taylor et aI., 2003). PEDRo is created according to the MGED guidelines 
and has a similar focus to the microarray model, capturing data (and associated 
metadata) produced in the steps of a proteomics experiment from hypothesis 
generation to peak identification. The UML class diagram upon which PEDRo is 
based can be considered to be complex as it contains many classes, however it 
forms the basis upon which proteomics repositories can be developed and a data 
entry tool known as PEDRoDC is able to generate a Protein Expression Markup 
Language (PEML) file (see Figure 2.5.lb on p.36). 
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In general, whether conceptual modelling is to be a success or failure does not 
depend on whether ER modelling is used in preference to UML, or vice versa. The 
choice of method usually depends on past experience in the use of techniques, 
modelling tools and the implementation platform most likely to be used (Bornberg-
Bauer & Paton 2002). 
Other work in this area has, been carried out by Silverstein et aI., (2001). Their 
work concentrates on the classification of protein sequence data and they developed 
a protein family resource called Metafam. Metafam puts related families into 
'supersets' using an algorithm that is automated. Recognising the importance of 
integrating data sets and the difficulty of such activities, Metafam is based upon a 
data warehouse approach to result in an integrated database (Shoop et aI., 2001) 
(see Warehouses on p.25). These authors developed a conceptual schema using the 
ER model and converted this conceptual schema into a relational schema using an 
Oracle database management system. Metafam however suffers from problems 
associated with data warehouse architectures such as the development of a parser 
for a new database to be included into the system. Berrar et aI., (2001) developed a 
database to allow searching and analysis of comparative genomic hybridisation data 
(CGH). CGH is a cytogenetic analysis method that can be used to study imbalances 
in chromosomes in genomes. After determining what aspects of the real world is to 
be modelled through conceptual data modelling, the resulting conceptual model 
was mapped to the relational model creating the database at the logical level, 
through the use of ER modelling. The subsequent physical database design step 
included the use of SQL (Structured Query Language), and an Oracle database 
management system. A limitation of this work was the lack of integration with 
other resources (Berrar et aI., 2001). 
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2.6 Control of recorded bioinformatics information by 
content 
This area involves tools for the representation of knowledge which encompasses 
aspects such as the classification of information using controlled vocabularies and 
ontologies, and the annotation of collections (Denn & MacMullen 2002). 
2.6.1 Controlled vocabularies and ontologies 
The evaluation of meaning of terms used in data and metadata can be done through 
ontologies, where terms are organised according to their semantic relationship and 
mapping fragments of heterogeneous data into a common framework (Buttler et aI., 
2002). In fact ontologies are a fundamental component ofthe semantic web which aims 
to transform the current web into one which is, machine understandable (Bemers-Lee, 
Hendler & Lassila 2001). The most well known ontology in the bioinformatics domain 
is the Gene Ontology (GO) whose main purpose is database annotation (The Gene 
Ontology Consortium 2000). GO is used to annotate gene products according to three 
separate hierarchies known as molecular function, biological process and cellular 
location. The terms in GO are represented in Resource Description Framework (RDF) 
and are arranged as nodes in a directed acyclic graph. RDF is an XML-based language 
used to encode information in semantic web resources (Resource Description 
Framework (RDF) 2005). 
A natural language term, its definition and a seven digit numeric identifier are used to 
represent each node in the GO structure, while edges are is-a or part-of relationships 
(Bada et aI., 2004). Despite its name, GO is not considered a fully-fledged ontology. 
For example, it lacks both additional ontological characteristics such as relationships 
between the molecular function, biological process and cellular location controlled 
vocabularies; 
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and aXIOms that can be used to constrain values of concepts and instances. The 
existence of such components would enable the capturing of further biological facts in 
the ontology. The handcrafted nature of natural language ontologies also means that 
they are difficult to maintain and are prone to errors (Stevens et aI., 2002). 
The TAMBIS system provides maXImum transparency when accessing 
bioinformatics resources, relieving researchers of the difficulties of knowing what 
applications to use, their locations etc (Gob le et aI., 2001). Within the system, the 
TAMBIS ontology (TaO) is used for querying resources. TaO is based upon the 
more expressive Description Logic (DL) formalism. Such a conceptualisation is 
complex and is based upon an object-oriented approach where the structure of the 
domain being modelled is described in terms of classes and properties. Class 
definitions and descriptions are provided through the use of assertions or axioms. In 
addition, DL supports logical reasoning that can be used to automatically create 
classification schemes. The objectives of TaO are different to that of GO. While 
GO provides a controlled vocabulary for databases annotation, TaO on the other 
hand provides an ontology-based search. Another difference between the two 
ontologies is that TaO is dynamic and can grow without the requirement for new 
knowledge to be conceptualised or encoded. GO on the other hand is static and 
needs developers to work on encoding novel conceptualisations to form new 
concepts (Stevens et aI., 2002). 
PharmGKB is a knowledge base for pharmacogenetics that contains an ontology 
(the PharmGKB ontology) made up of clinical, pharmacological and biological 
knowledge that is interconnected by relationships and organised by different levels 
of abstraction. Experimental data and results are represented as instances in the 
knowledge base allowing for more complex data and information processing than is 
possible with generic databases (Hewett et aI., 2002). The PharmGKB ontology is 
based upon a frame-based conceptualisation that is also similar to taking an object 
view of the world. 
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However frame-based ontologies are essentially handcrafted and inconsistencies in 
classification schemes can be a problem (Stevens et aI., 2002). 
2.6.2 Automatic annotation tools 
For raw data to be of any use to researchers it must be annotated giving the data 
meaning so that it can be understood. However, there is a problem in that a gap 
exists between the amount of new protein data being generated and consistent 
functional annotation, with this gap continually growing in size. Traditional manual 
annotation is usually carried out by literature curation and sequence analysis where 
firstly protein information is usually found in text format in databases like SWISS-
PROT, (Boeckmann et aI., 2003) and each record contains the sequence and 
additional related information. This can include its name, accession number, 
bibliographic information, a descriptor and keywords etc. When a protein sequence 
is discovered, normally its function is not known. The use of other databases such 
as protein sequence resources including PRINTS (Attwood et aI., 2003) and 
PROSITE can help (Falquet et aI., 2002). Relationships exist in these databases 
between annotation and protein data. However these are very often many-to-many, 
where one annotation may be stored for many proteins and one protein sequence 
may match to various proteins. This whole process of compiling, carrying out 
analysis, evaluation and obtaining information across various databases is awkward 
and takes up too much time. Inefficiencies then occur, because these traditional 
methods are unable to keep up with the ever, increasing quantity of data. What are 
required are automated annotation systems (Kretschmann et aI., 2001). 
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Fleischmann et aI., (1999) developed an automatic annotation method to aid in the 
annotation of uncharacterised sequences in TrEMBL known as the RuleBase system. 
RuleBase automatically annotates TrEMBL entries, and also makes use of manual 
intervention where scientists check annotations that are automatically suggested. 
Another similar method known as Spearmint makes use of the C4.5 decision tree 
algorithm for the automatic generation of rules. A decision tree is a classification 
method that can be used to split a sample into two smaller sub-samples according to a 
rule. Each of these new samples can then be split further into more sub-samples. 
Spearmint is used to detect decision trees, and expects input in a tabular form, meaning 
that the type of learning involved is supervised (Kretschmann et aI., 2001). 
Both RuleBase and Spearmint carry out annotation using similar steps. Firstly 
conditions that are to be used to assign proteins to groups are extracted from InterPro 
(The InterPro Consortium 2002). Secondly the conditions are then used to group 
together the proteins in SWISS-PROT. In the third step each group from step one is 
searched for common annotation. The fourth step involves grouping the unannotated 
TrEMBL entries by the conditions of RuleBase and Spearmint and lastly the addition 
of the common annotation to TrEMBL entries (Fleischmann et aI., 1999). The Protein 
Annotators' Assistant (PAA) is another annotation algorithm (Wise 2000). The aim of 
P AA is to assist biologists with the process of assigning functions to proteins that are 
unknown making use of the SWISS-PROT database. It performs keyword/phrase 
clustering based upon protein names (or accession identifiers), drawn from the SWISS-
PROT database that the researcher enters through a web interface. A list of 
keywords/phrases is returned to the user, and with each keyword/phrase a list of 
proteins containing that keyword/phrase. P AA is able to suggest multiple categories 
that have not been specified in advance, and for this reason it performs unsupervised 
classification (Wise 2000). 
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PAA like Speannint and Rulebase uses SWISS-PROT as its source. Also, similarly to 
Speannint, P AA automates annotation for a subset of the infonnation in SWISS-
PROT, namely the KW (keyword field), but P AA additionally mines the DE 
(descriptor) and CC (comment) fields that have a controlled syntax and semi-
controlled vocabulary. Using these additional fields increases the possibility of 
concepts being described by the same names and phrases and also more controlled 
fields are better suited to the clustering carried out by PAA. Recently the limitations of 
such annotation methods discussed in this section were described by Valencia (2005). 
This author discussed how emphasis is placed on limited features of protein function 
such as their biochemical role, while others such as post-translational modifications 
and interactions with other biomolecules for instance are barely included. 
2.7 Information Retreival 
Data acquired through high throughput techniques are usually deposited into local 
databases and public resources. Data types include among others, sequence, structure 
and experimental data. Parallel to the infonnation overload of these data there has been 
a tremendous increase in the biomedical literature. PubMed the scientific bibliographic 
knowledgebase for example, contains over 15 million citations to biomedical articles 
dating back to the 1950's (Sequeira 2003). An important research area for 
bioinfonnatics experts is the development of computer-based tools for the acquisition 
of data from the vast amounts of scientific articles. Some of these techniques can be 
described under the name of text mining. Infonnation retrieval in the biomedical 
domain is particularly challenging as biological knowledge is constantly changing in 
which unknown words have to be dealt with, synonyms exist for entities, and tenns are 
composed of more than one word (Gieger et aI., 2003). Modem text mining systems 
usually begin with a collection of untagged documents that are then tagged 
automatically according to categories, entities and relationships and these are extracted 
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from the documents. These extracted elements are then used for other data mining 
tasks on the documents (Feldman et aI., 2003). A core activity in text mining of the 
biomedical literature is the extraction of biological molecules such as protein and gene 
names. 
2.7.1 Mining the literature 
In short, we want to understand the biological function and interrelationships between 
genes and proteins. If we know this, then there is hope that we can comprehend and 
prevent undesirable activities, such as infection or malignant deVelopment at the 
genomic level. Simultaneously we want to promote the growth of normal development. 
Automated interpretation methods are required, and surveying the published literature 
efficiently constitutes an important step in the interpretation process (Shatkay, 
Edwards & Boguski 2002). The main problems encountered in automatic information 
extraction can be discussed under two additional headings. These are identifying 
protein and gene names and defining relations in the literature (Blaschke & Valencia 
2002). 
Identifying protein and gene names 
The methods used to extract name entities can be split into two main kinds. These are 
the rule-based approach and the dictionary based approach. In rule-based methods, 
rules are generated on text features. Dictionary-based approaches consist of initially 
constructing dictionaries from name entities and then identifying dictionary terms in 
the documents (Ben Miled [n.d.]a). An example ofa rule-based system is the work by 
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Narayanaswamy et aI., (2003). In this system chemical entities are also extracted in 
addition to biological ones. The individual term classification part of the system 
involves identifying core terms (c-terms) and functional terms (f-terms). Core terms 
include capital letters, numbers and special symbols that can provide vital clues to the 
names but do not provide any indication as to the categories to which the identified 
names belong. Functional terms on the other hand are able to both identify biological 
names and categorise them. Within the system, names that are more than one word in 
length are extracted using concatenation and extension rules. An example of such a 
rule is two terms next to each other being allowed to merge together into one. 
Information extraction is measured using high recall, which is the amount of relevant 
information retrieved while the inclusion of non-important information is measured by 
high precision. The method devised by Naraynanaswamy et aI., (2003) returned 
precision and recall values of 90.3% and 95.6% respectively. While the rules in this 
work were developed manually, it is possible to develop them semi-automatically 
using machine learning methods. 
Collier et aI., (2000) made use of machine learning in the form of Hidden Markov 
models (see Figure 2.2.9.3 on p.74) for the task of extracting technical terminology 
from 100 Medline abstracts. In these abstract samples, words used during training were 
tagged according to name classes with a total of 11 classes being used. This algorithm 
was assessed by an F-score, combining precision and recall in a single measure and 
can be obtained by 2*Precision*Reca1V(Precision+Recall). An F-score of 0.73 was 
achieved using this system. The model created by these authors however, is limited as 
there is no function to disambiguate local structures such as parentheses. In addition 
the model does not extract additional biological entities other than genes and proteins 
(Collier et aI., 2000). The major challenge in using machine learning methods is the 
need to have a larger amount of text where the named entities are marked (Blaschke, 
Hirshmann & Valencia 2002). The creation of an annotated corpus of tagged training 
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samples that does not contain errors is not easy, with it taking time and effort. The 
algorithm created by Collier et aI., (2000), required a small corpus of text containing 
entities that were tagged by a domain expert. 
An example of a dictionary that is created semi-automatically is this work by Hanisch 
et aI., (2003). Constructing the dictionary involved extracting from the HUGO 
database gene entries with their attributes that included gene symbols, alias names and 
full names. The corresponding names from OMIM (Hamosh et aI., 2005) and SWISS-
PROT + TrEMBL (Boeckmann et aI., 2003) were also extracted. The dictionary was 
then curated through a process of expansion and pruning. Expansion consisted of 
expanding known unambiguous acronyms found in the synonyms while pruning 
consisted of the removal of redundancies, ambiguities and irrelevant synonyms. After 
the creation of the dictionary, terms were searched for against the MED LINE database 
(Sequeira 2003). 
Defining relations in the literature 
Feldman et aI., (2003) list different types of relationships that can be extracted from the 
literature, which can include gene-gene relationships, gene-gene pathways, gene-
phenotype relationships, gene-disease relationships etc. The easiest way to detect 
relationships between genes is to calculate the co-occurrence of gene symbols. It is 
believed, that the use of gene symbols due to their explicitness, are superior to natural 
language searching for information retrieval (Jenssen et aI., 2001). A prototype system 
for biomedical information retrieval and visualisation using the Saccharomyces 
cerevisae genome is based on co-occurrence. This work is based on the idea that if two 
genes have a related biological function, then the co-occurrence of two gene names 
within the bioinformatics literature is more likely (Stapley & Benoit 2000). Knowledge 
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is represented in graphical format by the clustering of genes with related functions or 
those that physically interact with one another. Jenssen et aI., (2001), used a similar co-
occurrence method for the extraction of human genes. However the authors themselves 
discuss limitations oftheir method. For instance the relationships that can be found are 
restricted to those found in titles and abstracts in MEDLINE. Using a co-occurrence 
approach has the advantage of being able to screen a large quantity or corpus of genes, 
but is not accurate in a sense that genes whose names appear in the same text may not 
even be related. The reason for this is the dependence on relationships found in the 
literature and a lack of independent verification through experimentation (Shatkay, 
Edwards & Boguski 2002). The other disadvantage is that co-occurrence does not 
provide any information about interaction type (Blaschke, Hirshmann & Valencia 
2002). 
A more sophisticated method than co-occurrence which can extract more detailed 
information and still be applied to large corpora are pattern matching systems. An 
example is the information extraction system developed by Ng & Wong (1999). This 
system has a component in it known as BioNLP, which is an extension of the rule-
based approach. It identifies protein names that are mentioned in free text, and then 
carries out function word matching to make discoveries of protein-protein interactions 
present in the abstracts. The extraction rules in this system are created manually and an 
example ofa pattern rule is "A inhibits B, C and D" (Ng &Wong 1999). 
Limitations of BioNLP and other methods discussed above are that they do not take 
account of deeper syntactical structure of sentences. This means they may miss 
relationships that are present, or incorrectly extract relationships. This is compensated 
however, by an increased efficiency through better performance (Blaschke et aI., 
1999). The argument for simple patterns in preference to more complicated grammar 
formalisms is that the latter, although giving more precision in relation to information 
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extraction, is much less efficient because of the complex nature of parsing. However, 
after the work of Ng & Wong (1999) more sophisticated methods that carry deeper 
syntactical analysis have been introduced. These addressed some of the problems 
associated with parsing, such as inefficiency and ambiguity as the following paragraph 
will illustrate. 
Taking into account the limitations of using simple subject-verb-object relationships 
and recognising the existence of variations in verbal fonns, researchers have made use 
of other methods encompassing shallow or full parsing and different grammar 
formalisms etc (Blaschke, Hirshmann & Valencia 2002). For example, Yakushiji et aI., 
(2001), made use of a full parser and a large, general-purpose grammar to analyse the 
whole structure of MED LINE abstracts. To improve efficiency, preprocessors were 
used to reduce the workload of the full pars er. For example one out of the two 
preprocessors, known as the term recogniser glues together into one chunk, the words 
found in a noun allowing the parser to handle them as one word (Yakushiji et aI., 
2001). Another system is EDGAR (Extraction of Drugs, Genes and Relations), which 
extracts drug-protein interactions (Rindflesch et aI., 2000). EDGAR makes use of a 
part-of-speech tagger, syntactic parser and a rule-based system. The source of this 
system is the Unified Medical Language System (UMLS) and semantic infonnation is 
used from it to identify noun structures in MED LINE (Sequeira 2003) and then 
detennine the interactions between drugs, genes and cells. The accuracy of EDGAR 
however is questionable, as it lacks the vocabulary needed to capture gene-drug-cell 
relationships that may be significant. 
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2.8 Analysis and presentation of bioinformatics information 
From an infonnation management perspective, this area involves the manipulation of 
infonnation and includes activities such as comparision (e.g. sequence alignment) and 
modelling (e.g. gene expression data clustering). 
2.8.1 Sequence comparison in bioinformatics 
Sequence comparison is a central activity in molecular biology. The aim of this activity 
is the generation of infonnation by making comparisons between newly discovered 
sequences and already annotated sequences in databanks. There are different zones of 
similarity and many methods exist that can be used as evaluation methods for scoring 
similarity. 
Pairwise alignment 
The fundamental process in sequence analysis is pairwise comparison (Attwood & 
Parry-Smith 1999, p.108). It involves finding the best match between two DNA or 
protein sequences. A penalty is given for opening gaps or extending gaps for each of 
the sequences or for nucleic acids that are different (Abd-Elsalam 2003a). Two main 
methods for pairwise alignment are global alignment and local alignment. 
Global alignment 
Alignments are essentially mathematical models and global alignment takes account of 
similarity across the full extent of the sequences. An example is the Needleman and 
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Wunsch algorithm (Attwood & Parry-Smith, 1999, p.119). This method computes a 
global alignment between two sequences. It defines a maximum match between two 
sequences as being the greatest number of amino acids that can be matched with the 
amino acids of another protein, and also allowing for deletions at the same time. A 
penalty is introduced, each time there is a gap opened or extended for nucIeotides that 
are different in each of the sequences (Abd-Elsalam 2003a). 
The high-scoring alignments produced by Needleman and Wunsch and other 
algorithms based on it correspond quite accurately to correct biological alignments. 
The reason for this is that optimal alignments produced, maximise the chance that 
probable functions between two protein sequences can be explained in terms of their 
evolutionary divergence from a common ancestor (Morgenstern 1999). However a 
problem often found with global alignment methods combined with clever scoring 
functions is the resulting algorithm being slow and extremely memory intensive 
(Heringa 2002). 
Local alignment 
The other main type of model is the local alignment. This considers two sequences 
related only distantly, and may only express small regions oflocal similarity. However 
there is also a chance that an overall alignment may never be found. There are many 
sequences like this, so the similarity or distance between sequences cannot be 
determined by individual evolutionary events. An example is the Smith-Waterman 
algorithm (Attwood & Parry-Smith, p.122). The Smith-Waterman algorithm like the 
Needleman and Wunsch algorithm is based upon a matrix approach where sequences 
are often compared by a two-dimensional matrix. Negative values scores for 
mismatched residues are imposed by the Smith-Waterman algorithm (Orengo, Jones & 
Thornton 2003, p.38). 
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Both the Needleman and Wunsch algorithm and the Smith-Watennan algorithm use 
dynamic programming. Dynamic programming is a technique, where a large problem 
can be solved, through its division into similar sub-problems that are small in 
magnitude (Attwood & Parry-Smith, 1999, p.12S). By piecing together these smaller 
sub-problems, an answer for the larger problem can be found (Baldi & Brunsak 2001, 
p.82). The method is an important solution for sequence comparison because it 
provides the best alignments or those alignments, which are optimal (Ignacimuthu 
2005, p.l 02). However the reliance on dynamic programming which is both time and 
memory intensive means that the Needleman and Wunsch and Smith-Watennan 
algorithms are slow and not suitable for searching large databases. 
Multiple sequence alignment 
Often, there are three or more sequences that need to be aligned and this is carried out 
using multiple sequence alignment (MSA). Multiple sequence alignment has the ability 
to reveal gene function in the way that simple sequence alignment does not. It is an 
important process, as without it other analyses such as phylogenetic reconstruction for 
example could not be carried out. Two common methods used for multiple sequence 
alignment are progressive alignment and consistency-based alignment. 
Progressive algorithms 
When MSA was first introduced there was an issue about the difficulty of aligning 
more than a few sequences, as this would add strain on to computer resources (Heringa 
2002). Progressive alignment was introduced to be able to cope with larger datasets 
and is one of the most effective and simple ways to carry out multiple sequence 
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alignment, using the least memory and time. In progressive alignment the main idea is 
the use of heuristics to build the alignment in a progressive manner making use of the 
branch order of a guide tree (dendrogram) to direct the alignments. The main 
advantage of the progressive approach is that it is efficient, fast and straightforward. 
The main disadvantage of this method is that any errors made in the initial pairwise 
alignment will be included in subsequent steps (Lambert et aI., 2003). To minimise 
such errors, sequences can be weighted to deal with the fact that they have arisen by 
non-random sampling. 
Sequences derived from unequal sampling can lead to much redundancy in sequence 
databases (Thomson, Higgins & Gibson 1994). This can make difficult the 
identification of diverse sequences as closely related ones provide less information 
than those that are distantly related. However there are often issues with sequence 
weighting schemes such as which ones to use; such schemes can also be error prone. 
For example errors can accumulate when using global sequence weighting. In this type 
of weighting a weight is assigned for each sequence, which is used to derive an 
average value from the multiple sequence alignment of a number of sequences. Often 
tree-based weights are used which assume that sequences are related by an 
evolutionary tree, which may not be the case. However, if position of the root is 
uncertain then distantly related sequences can be weighted incorrectly which can cause 
error propagation (Heinkoff & Heinkoff 1994). 
An example of an MSA algorithm that is based upon the concept of progressive 
alignment is Praline (Heringer 1999; 2002). Praline in fact is a hybrid of the 
progressive strategy and the iterative strategy. The iterative approach itself is another 
method used for multiple sequence alignment and involves computing a solution to a 
problem through the modifying of an existing sup-optimal solution. Each modification 
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corresponds to, an iteration (Notredame 2002). Praline uses a profile-based progressive 
alignment method from the initial pairwise single sequence alignment, where the 
closest pair in similarity are joined together into a profile. 
Three main components make up Praline. These are global pre-processing, local pre-
processing and local-global double dynamic programming (DDP). The global pre-
processing and local pre-processing components contain position-specific sequence 
weighting schemes. Position-specific sequence weighting involves the calculation of 
weight for each alignment position. In global pre-processing, position-specific 
sequence weighting facilitates each sequence having contained inside it, information 
from other sequences that is trusted enough above a certain threshold. Similarly in 
local pre-processing, local fragments within sequences can be added to further provide 
confidence in the selection of sequences according to their pairwise alignment scores. 
The local-global (DDP) strategy falls in the motif-based weighting scheme 
classification, which involves the assignment of weights to motifs. 
Following the weighting, iteration of the pre-profile multiple alignment is carried out 
to derive consistency scores for every amino acid in the final mUltiple alignment. 
Involved in this, is consistency iteration and pre-profile update iteration both of which 
improve the quality of the alignment. The consistency scores are derived in order to 
give consistent alignment regions preference in following alignment rounds whereas 
pre-profile update iteration involves updating the pre-profiles based upon the multiple 
alignment from the preceding iteration. Such iteration will continue until convergence 
into a single multiple alignment has been achieved. A comparison between Praline and 
another multiple sequence alignment tool called ClustalW (see Section 7.5.3 on p.206) 
showed that Praline was able to make better individual alignments. Having said this 
ClustalW did prove to be superior in terms of speed, requiring fewer rounds for 
pairwise alignment (Heringa 1999). 
52 
Chapter Two A review of the bioinfonnatics field 
Another recent multiple sequence alignment tool is MAFFT (Katoh et aI., 2005). 
Similarly to Praline, MAFFT is based upon progressive alignment and refinement of 
these alignments by iteration. A difference between the progressive strategy used in 
MAFFT to Praline is the reliance on a guide tree to construct the distances between 
sequences, and the subsequent progressive alignment according to the branching order 
of the guide tree. Three iterative options are available in the latest version of MAFFT 
(version 5.3). These are known as H-INS-i, F-INS-i, and G-INS-i. The H-INS-i 
algorithm incorporates local information using the fasta34 program of the FASTA 
heuristic search program and F-INS-i uses the fasta34 program but without 
optimisation of the Smith-Waterman algorithm (Pearson & Lipman 1988). The G-INS-
i makes use of global information. Already one of the fastest multiple alignment tools 
available, version 5.3 of MAFFT in a recent evaluation outperformed other methods 
such as TCoffee (Notredame, Higgins & Heringa 2000) (see Consistency-based 
algorithms on p.54) and ProbCons (Do et aI., 2005). 
Another fast and accurate progressive alignment package is Muscle (Edgar 2004). Like 
MAFFT, Muscle constructs a guide tree followed by the progressive alignment of 
input sequences and refinement. More specifically Muscle estimates distances between 
pairs of input sequences using a k-mer distance, which in effect is a short sequence of 
fixed length and these distances are derived through counting the fraction of common 
k-mers using a compressed alphabet. These distances are then clustered into the guide 
tree enabling the construction of a progressive alignment of sequences. After this a 
more accurate guide tree is developed, by refining the initial one and new pairwise 
sequence alignments are calculated for those sub trees that are different to the initial 
tree. Such refinement occurs until a convergence has been reached. Muscle was 
assessed on a number of benchmarks including BALiBASE in which it was ranked 
number one (Wallace, BIackshields & Higgins 2005). 
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COllsistellCY- based algorithms 
While progressive alignments are error prone as discussed in the previous section, 
consistency-based methods function on the basis of the optimal mUltiple sequence 
alignment being defined as the one that is in agreement with every potential optimal 
pairwise alignment. An example of a consistency-based mUltiple alignment program is 
Dialign. This program in essence is a local alignment tool in which alignments are 
made of gap-free pairs of sequence segments (rather than comparing each residue) and 
these segment pairs are referred to as diagonals since they would be represented as 
diagonal pairs in corresponding pairwise matrices (Morgernstern 1999). A collection 
of diagonals is referred to as consistent if an alignment exists in which all segment 
pairs match with one another. Diagonals are sorted not according to their weights but 
according to what are known as overlap weights. This method is an efficient approach 
for detecting local homology and is fairly competent in terms of time and computing 
power (Lambert et aI., 2003). 
Another program, which in fact is a hybrid of the consistency-based approach and the 
progressive approach, is T -Coffee. Like Dialign, T -Coffee carries out pairwise 
alignment (both global and local) within a collection of sequences. These results are 
combined into a primary library. The value of information in this primary library is 
then increased by examining the consistency of each pair of residues with residue pairs 
in all of the other sequences present in the sample set. The final alignment is then 
generated making use of the information in the library in a progressive manner. At the 
time of publication T-Coffee showed the highest average accuracy in 5 BALiBASE 
categories when compared to competing methods including Dialign (Notredame, 
Higgins & Heringa 2000). Related to T-Coffee, most recently there has been the 
publication of the 3D-Coffee program (O'SuIIivan et aI., 2004). This program is a 
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simple, fast and accurate method that has been designed to incorporate three-
dimensional structure information to facilitate in the creation of protein sequence 
alignments. 3D-Coffee takes advantage of T-Coffee's capability of incorporating 
heterogeneous information and improves its accuracy by including structural data into 
alignments (Wallace, Blackshields & Higgins 2005). Having said this the use of one 
structure on a set of sequences that are related distantly only increased accuracy by an 
average of four percentage points. The inclusion of more structures on the other hand 
could improve this accuracy value (O'Sullivan et aI., 2004). 
2.8.2 Analysis of gene expression data 
Due to the need to understand the functions of genes and the mechanisms through 
which regulatory pathways act, there has been an increase in the scale of studies at the 
gene expression level. The analysis of this microarray data is an important research 
area for bioinformatics specialists. Gene expression is the name given to the process 
whereby the DNA sequence of a gene is transcribed into RNA that then acts as a 
template, for the production of protein (Liu et aI., 2001). The exact number of copies 
of a gene's RNA produced in a cell is expressed by its gene expression level. A DNA 
array experiment usually consists of a hybridisation assay, where specific 
oligonucleotides or cDNA sequences (one for each gene, taken from a tissue of 
interest) are immobilised on a solid surface forming the hybridisation array (Liu et aI., 
2001). After the introduction to the array, of a labelled target DNA or RNA, these 
target sequences hybridise to the complementary immobilised oligonucleotide or 
cDNA molecules. This in turn produces simultaneous measurements of the mRNA 
levels in the sample for each gene represented in the target DNA or RNA. These array 
results can now give an indication of the protein content of the sample, as mRNA 
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levels will correlate quite neatly with levels of the proteins they translated (Bayat 
2002). 
Cluster analysis is an important tool for gene expression data analysis. Clustering can 
be based on unsupervised and supervised techniques to cluster genes into groups 
according to function under specific conditions or classifying samples (or tissues) 
based on their gene expression patterns to aid in medical diagnosis; an example of an 
important application is cancer. Unsupervised methods are particularly good at 
discovering new classes without prior knowledge of a training signal, whereas 
supervised ones carry out very well the prediction of samples into classes making use 
of predefined patterns (Butte 2002). 
Unsupervised cluster techniques to classify genes 
Hierarchical clustering 
The most popular unsupervised technique used for gene expression analysis is 
hierarchical clustering. When using this technique, data points are forced to form an 
explicit hierarchy of nested sub-sets. The data points that are closest to each other are 
grouped and are replaced by a single point that depicts the set average of the pair. This 
process occurs for subsequent pairs of data points that are close together (Tamayo 
1999). An important piece of research in this area is that of Alizadeh et aI., (2000) who 
used hierarchical clustering to analyse expression data from human lymphoma samples 
and identified two distinct subclasses of B-cell lymphomas that were previously 
unknown. 
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The output of hierarchical clustering is a tree like structure or dendrogram (see Figure 
2.8.2a below) and an advantage of the method is that the lengths of the branches on the 
tree allow statistical assessment of the similarity between the datasets. Another 
advantage of hierarchical clustering is its visual power and the ability to efficiently 
estimate the number and size of expression patterns within a dataset (Butte 2002). 
Bearing these kinds of benefits in mind, Qu et al., (2002) made use of hierarchical 
clustering for the protein function and relationship inference component, of their 
multidimensional data analysis system. Although hierarchical clustering has 
advantages such as those described, like most techniques, it also has disadvantages, 
especially when used in the context of gene expression. It is true that dendrograms are 
better applied to types of hierarchical descent like evolution in species. They are not 
designed to reflect the number of ways in which gene expression patterns can be 
similar. Neither can they handle the complexity of data sets as they grow in size 
(Shannon, Culverhouse & Duncan 2003). 
Gene 3 
Gene 5 
Gene 2 
Gene 4 
Gene 1 
Figure 2.8.2a The hierarchical clustering of a set of genes as a dendrogram. 
After: Azuaje (2003; Figure 2, p.33) 
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k-means clustering 
A non-hierarchical unsupervised method also used for cluster analysis is the instance-
based k-means algorithm. In contrast to hierarchical clustering no dendrogram is 
produced. This algorithm divides data into a preset number of categories, where the 
user specifies the categories. After this an average expression vector is calculated for 
each cluster, which is used to determine the distances between clusters. The next step 
involves assigning genes to the closest clusters. The algorithm then recalculates the 
expression vector for each cluster and reassigns genes to the closest clusters. This 
process repeats until no more genes are reassigned (Quakenbush 2001). k-means 
clustering although simple to understand, requires large amounts of computing power. 
Tavozoie et aI., (1999) showed the effectiveness of this method for the classification of 
gene expression data from Saccharomyces cerevisiae. 30 clusters were used initially 
and the authors found members of each cluster to contain genes of similar functions. 
These authors do also discuss how they over classified so that significant classes would 
not be missed out. However such over classification can also result in overestimation 
of the inherent diversity of biological expression classes. 
Self-organising maps 
Another technique similar to k-means is the neural network algorithm SOM (self-
organising map) (Toronen et aI., 1999). Like the k-means algorithm, the SOM uses a 
distance measure, so that the closest category can be determined, but unlike k-means 
SOM uses a two-dimensional grid. In this grid, a node that is associated with a weight 
vector represents a category. The weight vector of a similar node and other neighbours 
are updated in an iterated fashion to match more closely to the input dataset. The 
locations of neighbouring nodes will change and these nodes will move in relation to 
the clustering of data points. The result of this is clusters that are close to one another 
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on the grid, being more similar than those that are further apart (Bertone & Gerstein 
2001). SOM has certain advantages for the clustering and subsequent analysis of gene 
expression data, when compared to other techniques. They allow a partial structure to 
be imposed, with neighbouring nodes defining clusters that are related. This is in 
contrast to hierarchical clustering where the structure is too rigid or k-means where 
there is no structure at all (Tamayo et aI., 1999). Another benefit of SOM is that it 
enables visualisation of expression patterns in a grid format and this increases 
interpretability (Bertone & Gerstein 2001). Its disadvantages include the movement of 
clusters being random which makes it difficult to reproduce their final configuration. 
In addition genes can only belong to a single cluster at a time (Butte 2002). Recent 
work in the use of SOMs include the clustering of gene expression data from yeast 
cells by Toronen et aI., (1999) whose results showed SOM to be a fast and convenient 
method. The clustering importantly, made reliable predictions about the functional 
similarity of genes. Similarly this method has been implemented by Tamayo, et aI., 
(1999) in their system GENECLUSTER, that was used to organise genes into relevant 
clusters and shed light on genes and pathways involved in hematopoietic 
differentiation. 
Supervised techniques for gene expression data analysis 
The principle behind supervised techniques is opposite to that of unsupervised ones. 
Whereas unsupervised techniques help in determining previously unknown 
relationships with no prior knowledge of genes belonging to functional classes, 
supervised techniques on the other hand, use a training set that is used to specify which 
data will be clustered (Brown et aI., 2000). 
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Support vector machines 
An example of a supervised method used in bioinformatics, that can be applied to 
microarray data is support vector machines (SVMs) (Quackenbush 2001). Application 
of an SVM to gene expression data would mean firstly having a set of genes that have 
a function in common. An example would be genes that code for elements of the 
proteosome. A separate set of genes would also be required, composed of genes that 
are known not to be members of the functional class. The result of the combination of 
these two gene sets is, a training set in which genes will be given positive labels if they 
belong to a functional class and negative labels if they do not. An SVM can then use 
this training set to distinguish, based on their expression data, new genes that are 
members or non-members of a given functional class (Brown et aI., 2000). The 
usefulness of SVMs can further be extended through the identification of outliers in the 
training set. 
Separating class members from non-members is done by constructing a hyperplane and 
is a non-trivial task. This is because data in real-world problems are usually non-
separable and a hyperplane that can carry out this separation does not exist (Brown et 
aI., 2000). SVMs get round this separation problem by mapping the input data into a 
higher-dimensional space, simultaneously defining a simpler hyperplane. This new 
feature space is then able to make a previously non-separable training set separable. 
However, there is now a potential problem of over-fitting, which can occur if one 
considers that the convex polygons of a dataset whose points are separated in the 
feature space, do not overlap (Bertone & Gerstein 2001). SVMs overcome this 
problem by picking the maximum margin separating hyperp/ane from the many others 
in the feature space, which is able to separate members from non-members. The 
maximum margin separating hyperplane is defined as the hyperplane that is distanced 
maximally from both convex polygons. This will divide the shortest distance or line 
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connecting the two polygons. Support vectors are the name given to the data points 
that define in a unique fashion the maximum margin separating hyperplane. These data 
points are the ones that are also closest to the maximum margin separating hyperplane 
(Bertone & Gerstein 2001). 
SVMs can be used to classify genes according to related gene expression patterns, but 
also the classification of samples. An example of the former is the work of Brown et 
aI., (2000) who used SVMs to classify genes into five functional classes with the use of 
a sixth class as a control group whose members were not expected to express similar 
regulation. These authors showed how SVMs were superior to other machine learning 
methods, which among others included decision trees and the C4.5 algorithm. An 
illustration of the use of SVMs for the classification of samples is the research by 
Furey et aI., (2001). The disease in question in this study was ovarian cancer and the 
classification of samples into three types. These were cancerous ovarian tissue, normal 
ovarian tissue or normal non-ovarian tissue. The study also showed the usefulness of 
supervised learning methods at identifying misclassified samples. Having said this the 
authors, were not able to establish any outstanding performance of SVMs when 
compared to competing methods (Furey et aI., 2001). 
Artificial Neural Networks 
A common machine learning method is the artificial neural network (ANN) (see Figure 
2.8.2b on p.63). ANNs are graphical models that emulate the model of information 
processing and learning that occurs in the brain. ANNs come in different architectures 
such as recurrent (one that contains directed loops), feed-forward (one without directed 
loops) or layered, where units are split into classes and the connection patterns between 
these units are defined (Baldi & Brunak 2001, p.120). In biological terms these units 
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are analogous to neurons and the connections, which are weighted, are equivalent to 
synapses. 
They have been used in bioinformatics for a variety of applications, one of which is 
gene expression data analysis (Baldi & Brunak 2001, p.120). The application of ANNs 
to gene expression data involves presenting the ANN with samples belonging to the 
classes of interest, and the ANN is trained to recognise them through an error 
minimisation process. Gruvberger et aI., (2001) used ANNs to analyse microarray data 
from a selected group of node-negative breast cancers that differed in terms of their 
estrogen receptor Cl (ER) levels and the phenotypic consequences of these differences. 
Intitially 6726 genes were used to calibrate ANNs to classify tumour samples and 
Principal Component Analysis was made use of to reduce the dimensionality of the 
data into two or three linear combinations of the summaries of the original features 
(Bertone & Gerstein 2001). The ANN models were trained in a successful manner to 
classify the 47 training samples and 22 blinded test samples making use of 100 genes 
for the classification. These authors found ANN classification to be superior to other 
methods they also used, which included multidimensional scaling (MDS) and 
hierarchical clustering. However the authors also point out that a thorough comparison 
of methods was not possible due to the small data set used. 
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Figure 2.8.2b A simple feed-forward neural network is presented with a single 
hidden layer. The lines on the diagram are the weights and process, the patterns 
presented on the inputs and the result is a certain output pattern. 
After: Orengo, Jones & Thornton (2003; Figure 9.2, p.142) 
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2.9 Storage of bioinformatics information 
This area of infonnation management is concerned with appropriate modelling of 
processes, infonnation needs and user requirements. Other aspects relevant here 
include database design, implementation and evalutation of systems, and LIMS design 
for the capturing of work flows. 
2.9.1 Information Seeking and Use in the bioinformatics domain 
Research into studying infonnation needs of molecular biologists for the development 
of applications has been scarce, and in general many systems are designed in an ad hoc 
manner when the particular needs of scientists for a specific problem arises 
(MacMullen & Denn 2005). There has a been a lack of reporting on the actual 
processes by which scientists use resources and research methods used to collect data 
for bioinfonnatics application design. Some exceptions to this include the work by 
Hurd et aI., (1999) that carried out a citation analysis involving bibliometric techniques 
to analyse references cited by authors who were themselves members of staff involved 
in molecular biology research at the University of Illinois at Chicago (UIC). The 
findings of this study provided infonnation on aspects such as what journal titles 
should be maintained in the library and over which time periods. However the study 
was also carried out during a transition period where more journal titles were 
beginning to be published online and data were beginning to be deposited into 
sequence databases as a requirement for publication. The inclusion of more data on 
these issues may have had consequences on infonnation services and the management 
of journal collections (Hurd et aI., 1999). 
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Another study by Yarfitz & Ketchell in 2000 assessed the biological information needs 
of biomedical researchers at the University of Washington (UW), for the development 
of the UW Health Sciences Libraries (HSL) bioinformatics services program. A PhD 
biologist was used to assess the molecular biology information needs and design 
strategies to enhance library services. In essence the study began with a needs analysis 
component that included researchers having to complete a questionnaire survey about 
their experiences in using library services and biological information resources. Some 
of the questions asked in this questionnaire were similar to the questions used by 
Stevens et aI., (2001) which is discussed in more detail below. It was established that 
among other things, a molecular biological consultation service was needed, as were 
classes on sequence databases and software for analysis. This consequently led to the 
introduction of consultation services for database searching, interpretation of databases 
search results and DNA and protein sequence analysis. Bioinformatics skills training 
classes were also introduced. 
Overall, researchers' responses to the HSL bioinformatics program demonstrated that a 
health sciences library could provide a range of biological information services that are 
extensive and of a high quality. It was established through consulting services and 
training classes that there is a broad need for bioinformatics training and support. The 
program illustrated that the level and scope of bioinformatics services that a 
biomedical library can provide is dependent on the subject-specific expertise that is at 
hand. For instance, at HSL a librarian who did not have a background in molecular 
biology or relevant training, would be able to answer fewer than 20% ofbioinformatics 
consultation questions. It was also found that the number of biomedical librarians that 
have the training or relevant experience which would enable them to provide services, 
such as guidance about interpreting sequence databases search results was limited 
(Yarfitz & Ketchell 2000). 
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The studies by Hurd et aI., (1999) and Yarfitz & Ketchell (2000) focused more on 
bibliographic resources and which of these were used rather than the use by scientists 
ofbioinformatics tools. Stevens et aI., (2001) carried out a survey to gather data on the 
range of tasks carried out by biologists in academia and industry. The research 
methods used consisted of a questionnaire and follow up interviews. Results from the 
research identified the semantics of tasks or 'what is wanted' and the syntax or 'how to 
do it' could subsequently be derived from the semantics. Having such information 
could then be used to describe the patterns that are frequent in biological analysis 
queries, which in turn could drive the development of a bioinformatics query system. 
The sample used in this survey was 35 and perhaps more details could have been 
collected had the number of respondents been larger. Overall, this work was important 
as it illustrated the need of biologists for interoperation of tools and provided the initial 
user requirements for the development of the TAMBIS system (Goble et aI., 2001). 
This work was interesting as it also discusses the idea of capturing the steps in 
bioinformatics experiments as scientific workflow. According to Tran, Dubay & Hersh 
(2002) the work of Stevens et aI., (2001) is limited because while many information 
needs of biological researchers do arise during analysis stages, they are not limited to 
only the data analysis part of the research cycle. 
Another study concentrating specifically on bioinformatics tasks analysis is the work 
carried out BarIett & Toms (2005). Like the work of Stevens et aI., (2001), this 
research emphasised on the comprehension of the actual users, what information they 
require from resources, how they look for information and the ways in which they 
utilise it. Both studies were similar in that the general aim was to find the different sets 
of tasks and the components needed to be able to capture these in a tool or technique. 
In the case of Stevens et aI., (2001) this was the TAMBIS system, and for Bartlett & 
Toms (2005) it was on the development of an instructive digital tool for one task, 
which in this case was the functional annotation of a gene sequence. Patterns in the use 
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of bioinfonnatics sources were detennined and an example would be steps taken by 
researchers who were looking for characteristics within genes that were possibly linked 
with a disease. Bartlett & Toms (2005) took a qualitative approach gathering data 
through the use of semi-structured interviews, in contrast to Stevens et aI., (2001) who 
first gathered fundamental data quantitatively through the use of a questionnaire then 
used follow up in-depth interviews. The sample used by Bartlett & Toms (2005) 
consisted of 20 bioinfonnatics experts taken from research groups in universities, one 
in government and one in the private sector. As the sample size was small and limited 
to Canada and eastern United States it is questionable as to whether the protocol 
developed could be generalised to scientists involved in bioinfonnatics around the 
world. The authors themselves recognise the limitations of their study and future work 
into testing the reliability and validity of the model has been planned. 
The BioUse system is also based on a user-centred design strategy. In this study 
interviews were carried out within an ethnographic approach using a sample of 19 
participants (Javahery et aI., 2004). These users were separated into beginners and 
experts. Differences in experience between experts and beginners was found through 
the interviews with results showing that beginners found it more difficult to learn how 
to use sites such as the NCBI than they would have liked. Like in Bartlett & Toms 
(2005), the patterns involved in carrying out a task were studied in order to develop 
user interfaces tailored for the particular experience level of the users. Much like the 
work by Stevens et aI., (2001) and Bartlett & Toms (2005), the sample size was small 
and it would have been interesting to see how a larger sample may have been more 
representative of further scientists around the world using the NCBI web site (Javahery 
et aI., 2004). 
67 
Chapter Two A review of the bioinfonnatics field 
2.9.2 Bioinformatics Databases 
Facilities for storing, updating, accessmg, and querying are at the heart of 
bioinfonnatics (Searls 2000). Databases designed for bioinfonnatics usually store 
various data types ranging from genome data to gene expression data to databases 
containing infonnation on protein structure, biological pathways and the biomedical 
literature. The most fundamental bioinformatics databases will now be discussed. 
These are the primary sequence databases, for example the DNA sequence database 
GenBank (Benson, et aI., 2005) or secondary (pattern) databases such as PROSITE 
(Attwood 2000). 
2.9.2.1 Nucleotide sequence databases 
Nucleotide sequence databases receive sequence data from the community and are 
freely available to the public. The most important is the International Nucleotide 
Sequence Database Collaboration made up of the DNA Data Bank of Japan (DDBJ) 
(Tateno et aI., 2005), the European Molecular Biology Laboratory (EMBL) (Kanz et 
aI., 2005) and GenBank (Benson et aI., 2005). DDBJ, the European Bioinfonnatics 
Institute (EBI) and the National Center for Biotechnology Information (NCBI) jointly 
maintain these resources. 
GenBank is a comprehensive public resource of nucleotide sequence and continues to 
grow exponentially containing DNA sequences from over 165,000 named organisms 
(Benson et aI., 2005). In Release 150 in October 2005, 53.1 billion bases from 49.1 
million sequences were contained inside GenBank and sequence records can be 
retrieved using the Entrez retrieval system (Wheeler et aI., 2005). DDBJ represents the 
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contribution of Japanese researchers to providing sequence data into the public domain 
and the top two species whose sequence data are submitted to DDBJ after human are 
ascidian and rice (Tateno et al., 2005). These authors in the 2005 Nucleic Acids 
Research database edition reported that within a year they had collected 718 072 425 
bases or 1 055 084 entries. Important additions to DDBJ are the implementation of a 
SOAP server and web services (see Section 2.4.2 on p.26) to enable researchers to find 
easily appropriate resources, send correct queries and have an efficient outcome. The 
EMBL Nucleotide Sequence Database is the primary nucleotide sequence database for 
Europe containing sequence data from over 185,000 organisms. As of August 2004, 
Release 84 contained 47 million entries. The EMBL Nucleotide Sequence Database 
can be accessed via a number of web interfaces including an FTP server and the EBI 
SRS server (Wong 2002). 
The nature of data in these collaborative databases is variable, as they are stored in 
different data formats, containing different quality levels. For example there are 
differences in the source of material (for example genomic versus cDNA), the extent of 
annotation of the sequences etc. EBI, NCBI and DDBJ update each other with new 
sequences every 24 hours. Due to the archival nature of the three major nucleotide 
databases, the quality of the sequence databases is the responsibility of the authors or 
persons submitting data. The databases do not check for integrity of these data, which 
results in redundant data inclusion and sequences that are of a low quality. For 
instance, work that is unrelated could result in the same sequences being submitted 
independently, while submitters may not remember to check their sequences for 
contamination (Zdobnov et al., 2002, p.268). 
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2.9.2.2 Protein sequence databases 
Protein sequence databases contain the most complete information on proteins. The 
Protein Information Resource (PIR) is the oldest protein sequence database and has 
provided for decades, annotated protein data to the scientific community (Wu et aI., 
2002). The PIR in collaboration with the Munich Information Protein Centre for 
Protein Sequences (MIPS) and the Japan International Protein Sequence Database 
continue the distribution and enhancement of the PIR-International Protein Sequence 
Database (PSD). PIR-PSD contains about 283,000 protein sequences, is non-redundant 
and annotated to high standards (Wu et aI., 2003). The major focus of PIR-PSD is on 
superfamilies which have been classified using global sequence alignment (see Section 
2.8.1 on p.48), where sequences in the same families share similar domain features and 
do not differ in length by great amounts. 
In addition there are two other databases maintained by PIR, which are Non-redundant 
REFerence Sequence Database (PIR-NREF) and the iProClass (integrated Protein 
Classification) database (Wu et aI., 2001). The aim of PIR-NREF is to provide an up-
to-date collection of protein sequence data as sequencing projects progress, containing 
data with minimal redundancy and providing source attributes such as protein lDs, 
accession numbers etc from the source databases. These databases include SWISS-
PROT + TrEMBL (Boeckmann et aI., 2003), RefSeq (Pruitt & Maglott 2001) and the 
Protein Data Bank (PDB) (Berman et aI., 2000). Since the time of writing, PIR-NREF 
has been discontinued and its contents are available from UniProt (see p.71). iProClass 
is a comprehensive database of annotated protein family information together with 
extensive family relationships and protein structure and function features (Wu et aI., 
2001). The current release of this resource (release 2.81) contained 2432,109 entries 
(iProClass [n.d.]). Data from PIR-NERF and iProClass can be accessed using various 
data mining and sequence analysis algorithms via the PIR web site (Wu et aI., 2003). 
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In order to make the PIR-PSD an even more comprehensive and centralised resource, 
its contents have been merged with SWISS-PROT +TrEMBL (see below) into the 
Universal Protein Resource (UniProt). UniProt provides a rich, up-to-date solution for 
consistent and non-redundant protein information that has both been manually curated 
and annotated using automated means (Bairoch et aI., 2005). 
SWISS-PROT itself, has always been renowned for its high quality annotation, 
minimal redundancy, standardised nomenclature through the use of controlled 
vocabularies, and also its links to specialised databases for high levels of integration. 
The increased data depositing from the genome projects into sequence databases 
results in time and labour intensive challenges for researchers manually, annotating 
SWISS-PROT. To ensure that sequences were available as quickly as possible, 
TrEMBL (translation of EMBL nucleotide sequence database) was introduced. 
TrEMBL consists of computer-annotated entries (see Section 2.6.2 on pAO) and these 
are derived from the translation of all coding sequences found in the nucleotide 
sequence databases (GenBank, DDBJ, EMBL), excluding of course those already 
present in SWISS-PROT (Boeckmann et aI., 2003). Both SWISS-PROT + TrEMBL 
are now known as UniProtKB/Swiss-Prot and UniProtKBrrrEMBL and form part of 
the UniProt Knowledgebase). The August 2005 release (47.7) of UniProtKB/Swiss-
Prot, contained 190,255 entries (UniProtKB/Swiss-Prot 2005). 
2.9.2.3 Secondary databases 
Having a sequence of an unknown protein whose relation to any protein of known 
structure is so distant, that sequence alignment will be unable to find any resemblance 
is a common scenario. However, it can be determined by the occurrence of sequence 
signatures using the pattern databases (Zdobnov el aI., 2002, p.273). Pattern databases 
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are more selective when compared to sequence databases as they make use of 
discriminators to detect specific families. These discriminators are known as 
expressions, profiles, fingerprints and blocks (Attwood 2000). Each of the pattern 
databases have such a discriminator associated with it. 
For all the differences between the pattern databases, they do have one thing in 
common. They were all developed from the same principle, which is that homologous 
sequences share conserved motifs that are important for the structure and function of 
the protein. This provides a signature of membership to a family and a newly 
discovered sequence may be assigned to a family, if it matches to characteristics that 
are predefined. Pattern databases at least theoretically, provide a fast way to infer 
biological function, especially if the structure and function is already known. However, 
it should also be noted that none of the pattern databases are fully complete yet. It is 
recommended that they be used as a supplement to sequence searching instead of 
acting as a replacement (Attwood 2000). 
Examples of pattern databases are PROSITE (the oldest) (Hulo et aI., 2004), PRINTS 
(Attwood et aI., 2003), and Pfam (Bateman et aI., 2004) with all of these using 
different methods for the storing of signatures for proteins. All three, however are 
derived from the sequence databases SWISS-PROT + TrEMBL. PROSITE uses a 
single-motif method and stores proteins in the form of regular expression patterns 
complemented with the addition of profiles so that weakly conserved domains such as 
SH2 and SH3 can be detected (Falquet et aI., 2002). Such a method is based on the 
idea that a particular protein family can be characterised by the single most conserved 
region that is observed in a sequence alignment. This technique is limited due to its 
signal-to-noise ratio where patterns have a potential to make true-positive matches, but 
unfortunately will also match more false-positives. Entries are deposited into 
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PROSITE through two files. These are (a) a computer-readable file containing the 
information required by programs making use of PROSITE to scan sequences for 
patterns and (b) a second free text containing annotation file called the text book that 
contains information about each pattern (Attwood 2000). Release 19.15 in November 
2005 contained 1387 documentation entries that describe 1899 patterns, rules and 
profiles/matrices (Pro site 2006). 
While PROSITE is based upon sequence patterns representing a single motif that is 
then encoded in regular expressions, PRINTS on the other hand encodes mUltiple 
motifs (known as fingerprints) (Attwood et aI., 2003). Such an approach is more 
powerful and flexible than single-motif approaches because it is based upon the 
premise that it is common to find several motifs characterising the aligned family in a 
sequence alignment. In other words the more motifs a fingerprint contains, the more 
able it is to find distant relatives (Orengo, Jones & Thornton 2003, p.72). So far, 1900 
fingerprints have been manually annotated (PRINTS [n.d.]). This manual approach 
allows the creation of fingerprints at a number of levels including superfamily, family 
and subfamily which is important as slight changes between relatives that are closely 
associated by in large determine their functional details (Attwood 2002). The limitation 
of PRINTS is that it is manually maintained and so in terms of growth lags behind 
automatically created databases. To address this issue, PRINTS was migrated to a 
relational database management system. Although this decreases some of the burden 
created by manual annotation, it still does not address growth of the database. So, most 
recently, prePRINTS, an automated supplement has been added (Attwood et aI., 2003). 
An extension to the idea of profiles (used in PROSITE) is found in the application of 
hidden Markov models (HMMs) and their use for the interpretation of a profile. A 
hidden Markov model is a probabilistic structure derived computationally for 
describing patterns found in the families of homologous sequences 
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(Lesk 2002, pp.l94-195). A multiple alignment is found within the model and a 
number of interconnecting states make up HMMs. In effect they are linear chains of 
match, delete, or insert states that encode information about a particular sequence 
family (Lesk 2002, p.195). Each conserved column in a sequence alignment is 
assigned a match state, while an insert state allows for insertions with relation to the 
match states and, delete states skip a column in the multiple alignment. Associated 
with each omission and each transition between states are probabilities or costs. A 
sequence will be aligned where the highest probability or lowest-cost path through the 
HMM is taken (Attwood 2000) (See Figure 2.9.2.3 below). 
Figure 2.9.2.3 The organisation of a HMM in which the arrows illustrate 
transitions between states. The HMM contains match states labelled m and delete 
states labelled d. In addition insert states i emerge between residue positions. 
After: (Lesk 2002; Figure 4.6, p.195) 
HMMs are good at providing exact descriptors. However they do have their 
disadvantages. For instance HMMs may be trained well for a particular family, but an 
outlier that was not included in the training set could be missed (Attwood 2000). Pfam 
stores the conservation in gapped domain alignments as HMMs. Two types of 
alignments make up Pfam. One is the hand-edited seed alignments (sequences that are 
74 
Chapter Two A review of the bioinfonnatics field 
representative of a protein family) and the other an automatically clustered set, with the 
seed alignments being used to build HMMs. These alignments, along with minimal 
annotation in the form of textual descriptions, and links to other resources and 
literature cross-references make up Pfam (Bateman et aI., 2004). A major strength of 
Pfam is its increased sensitivity to fragmentary sequences. In release 18 (August 2005), 
Pfam contained 7973 Pfam families (Pfam 2005). 
2.9.2.4 Laboratory Information Management Systems 
Many established public databases exist, that make available gene and protein data. In 
addition, big laboratories such as Genome Centres involved in genome mapping, 
sequencing and genotyping, have set up their own databases to use as storage facilities 
for their experimental results and to prepare the data for the distribution to the 
scientific community. However, published literature on such systems is unfortunately 
scarce. Having said this, there have been some efforts to report on laboratory 
information management systems (LIMSs) particularly for microarray experiments. 
Microarrays are a functional genomics methodology that allows the measurement of 
gene expression of thousands of genes in a single experiment (Fu & Youn 2003) (see 
Section 2.8.2 on p.55). Many proprietary systems exist that are targeted towards 
corporate customers. Thermo LabSystems in the United States has developed the 
Nautilus bioLIMS and this particular LIMS was used by the Roslin Institute to support 
their Functional Genomics in Farm Animals (ARK-Genomics) project (Law et aI., 
2001). XML is used in the Nautilus bioLIMS and is able to easily export data and 
analysis files. Another LIMS is QuickLIMS a Microsoft Access database application 
that is able to process all the information for microarray production through the use of 
workflow (Kokocinski et aI., 2003). Visual Basic was used to implement QuickLIMS 
which can suffer in terms of performance, but is flexible so code can be adjusted 
quickly without too much trouble as needs change. 
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MADGE (Microarray Database of Gene Expression System) is more of a general data 
management system that contains clone collection storage data, annotation data and 
microarray data (McIndoe, Lazen & Hurtz 2003). However, it also provides 
researchers with information about experimental procedures and so is similar to a 
microarray LlMS. MADGE is a 3-tier application in which the application logic is 
separate from the database logic. This makes the system scalable, more secure and also 
easy to use (McIndoe, Lazen & Hurtz 2003). The micro array workflow modelled by 
this system is designed for the creation and use of cDNA microarrays and for making 
recordings of all the inputs and outputs created by the processes. A disadvantage of 
MADGE is that it offers no analysis component. 
Recently Sanchez-Villeda et aI., (2003) reported on the development of a laboratory 
information management system for the maize genome project known as MMP-LlMS. 
Developed primarily for genotyping, its developers compared their system to 
competing commercial systems such as the Nautilis system by Thermo LabSystems 
and Sapphire Informatics by LabVantage (LabVantage 2004) (see Section 7.5.4 on 
p.210) and illustrated the benefits of their system such as the ability to validate and 
verify genotyping scores, the ability to handle different markers such as Short Tandem 
Repeat (SSRs), Restriction Fragment Length Polymorphisms (RFLPs) and SNPs and 
insertion/deletion points (InDels) (Sanchez-Villeda et aI., 2003). 
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Chapter Three: Research Methods 
In order to study in detail the data generation, storage and retrieval and analysis 
approaches that scientific laboratories take, it is vital that an appropriate research 
design is in place. For the purpose of this investigation a qualitative approach was 
adopted, using a case study framework. Both primary and secondary sources were 
used, including semi-structured interviews, observation, existing literature and 
documents. This chapter will discuss in detail the philosophical basis to the 
research carried out and the research design (see Figure 3.2 on p.80) used in the 
study. It will also highlight the research methods used in this study, along with their 
advantages and disadvantages. A critical evaluation will also be given of alternative 
methods and the reasons for why they were not used. 
3.1 Philosophical basis for research 
The practice of social science research can be categorised in terms of philosophical 
branches. An influential view of the philosophical nature of research that can be 
used as a ground for discussion is that by Burrell and Morgan (1979). These 
authors develop the ideas of philosophical assumptions of which there are four: 
ontology, epistemology, human nature and methodology which ultimately separate 
social science research as being sUbjective or objective. In this section the meaning 
of each of these assumptions will be given along with their mappings to the 
approaches taken in the current study. 
Burrell & Morgan (1979, pA), describe the existence of realism and nominalism as 
two ontological assumptions. In realism, the individual does not create the social 
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world; it already exists with its own reality. Therefore, reality exists independently 
of our thoughts and beliefs. This world is a real world made up of hard and physical 
structures. With nominalism the assumption made is that the social world is made 
up of names, labels and concepts in order to structure reality. These entities serve as 
a convenient way to describe the social world and so no 'real' structure exists 
(Burrell & Morgan 1979, p.4). It can be noted that for this investigation, the 
research design was made up of a mixture of both the realist approach and 
nominalist approach. This is because the social environment in which the case 
studies were carried out already existed, but this social world was then 
conceptualised through the perspective of the researcher. 
The second set of assumptions as described by Burrell & Morgan (1979) relate to 
epistemology. These are objectivism and relativism. Objectivism in this context can 
be defined as the ability to prove or disprove knowledge about the social 
environment, while relativism means knowledge can be only held by an individual 
and research should be used to uncover this SUbjective knowledge. The latter 
approach was used primarily within this study, as the researcher attempted to 
capture the personal views and opinions of the participants (see Section 3.2 on 
p.79). 
According to Burrell & Morgan (1979, p.6), a third set of assumptions concern 
human nature and how human beings are related to their environment; two lines of 
enquiry can be taken which are known as determinism and voluntarism. With a 
determinist view, human beings and their experiences they have are considered as 
produced by the environment. In contrast to this, in the voluntarist approach, a 
human being is the actual creator of the environment. Both of these views were 
taken into consideration by the researcher when exploring each of the case studies. 
This point can be discussed further in terms of data collection. Ultimately it is up to 
the organisations involved in a project as to what resources can be accessible and 
what data is available for research; however once entry has been gained, the 
researcher(s) has the freedom to collect data in a manner, in order to address the 
project objectives. Such was the case in the present study. 
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The three types of assumptions discussed above have methodological consequences 
on how the researcher will obtain information about the social world. The 
nomothetic approach views the social world objectively, and as being external and 
hard. It focuses upon the identification of themes and the study of relationships 
between them. With the ideo graphic approach the subjective experience of human 
beings is of primary importance and analysing what is unique and important to the 
person rather than the general (Burrell & Morgan 1979, p.6). In general both types 
of approaches were taken in this project. For example, the researcher conducted 
semi-structured interviews (see Section 3.2.2 on p.88). This can be considered to be 
ideo graphic; however the method used for data analysis has similarities to the 
nomothetic approach (see Section 3.4 on p.95). 
3.2 Research approach 
When carrying out a research project the methods used to investigate it can follow a 
qualitative or quantitative approach, or a mixture of both approaches. Qualitative 
research concerns itself with understanding processes and events through the 
perspectives of people participating in them (Labuschagne 2003). This means that 
the data collected by the researcher is through participating in the environment and 
is contextual. Another interesting feature is that the researcher is interested in the 
whole process rather than the end result of events. The researcher in effect is a 
research instrument looking for patterns and conflicts in the data and then is able to 
develop generalisations and theories from such activities. Some of the advantages 
of using qualitative methods are that they enable the analysis of everyday events 
that occur in a social setting. Furthermore, they allow the researcher to gain insider 
knowledge of the research participants and their environment. 
Also information can be gathered about why there is miscommunication between 
certain people. However, there are also disadvantages of collecting qualitative data. 
For instance methods such as interviews are time consuming. In addition much 
time has to be devoted to data post collection and during data analysis. The 
interpretation of qualitative research can also be criticised, as it is possible for the 
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researcher to have views that are biased or to develop such thoughts over time 
(Weinreich [n.d.]). The methods used in the current study were qualitative 
approaches rather than quantitative as the emphasis was to focus on two cases (see 
Section 3.2.1 on p.81). Having said this both qualitative methods and quantitative 
methods can be used in a case study. Although quantitative methods were not 
utilised it is important to discuss their features in order to distinguish them from 
qualitative approaches. 
Quantitative approaches deal with context but only selected variables and their 
relationships are measured. A key feature in their application is the use of numbers 
and hence the focus upon objective research. This in turn facilitates the comparison 
of statistical data. Such statistically significant data is one of the advantages of 
using quantitative methods. Other benefits are that variables can be controlled and 
measured, and results based on a sample are representative of the entire population. 
Some of the disadvantages however include there often being the need for 
hypotheses at the start of the survey which are then tested and not allowing the 
researcher to establish why people act or think in the way that they do in the real 
world (Weinreich [n.d.]). 
Qualitative Approach 
Research Approach Use of Case Studies 
+ 
Semi-structured Interviews 
Data Collection Observation 
Document Analysis 
.~ 
Data Preparation 
Interview Transcription I 
+ 
Atlas. ti software 
Content Analysis 
Data Analysis Inductive Coding 
Figure 3.2 A simple feed forward flow diagram of the processes in the research 
design used in this study. 
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3.2.1 Use of case studies 
The defining feature of a case study approach is the focus on one case, which can 
for example take the form of an organisation, group, culture, or community (Yin 
2003, p.l). The case study approach enables the uniqueness and complexity of a 
case to be studied, with the case being a unit of analysis. An example of a unit of 
analysis could be a particular department in an organisation. Cases studies represent 
a means, to collect, organise and analyse data. After the collection of 
comprehensive information about a case or cases of interest, the subsequent 
analysis results in the product, this is the case study (Patton 2002, p.447). Case 
studies take a holistic perspective of the phenomena being investigated, ensuring 
that components which are important to the aspects being studied are not separated 
from the context. A common use of case studies is in evaluating complex programs 
or to track the evolution of a system (Kohn 1997). There are different types of case 
studies, which can be, sub divided depending on the questions of the investigation. 
In general the "how" and "why" questions are more inclined towards explanatory 
studies and the need to develop operational links, whereas studies that are more 
focused on the "what" questions are more exploratory and are concerned with 
frequency of incidence (Yin 2003, p.6). 
Many research methods and sources of data can be used in case studies; the term 
used for this is triangulation (Gorman & Clayton 1997, p.32). In a research project 
where triangulation is the choice of technique, usually multiple methodologies are 
used which can be a combination of qualitative and quantitative approaches. 
Triangulation has in general, two purposes. A researcher is able to extend the scope 
of the project, as the use of two or more methods allows the researcher to consider 
different aspects of the same research question. The result of this is very appealing. 
For instance, the use of different methods to come to similar conclusions increases 
the quality and validity of the research, and there is a greater chance that it is 
correct (see Table 3.2.1 on p.84 for more details on tests for validity and 
reliability). The other purpose of the use of triangulation is that it allows the 
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benefits of both qualitative and quantitative methods used to complement each 
other, while keeping at a minimal the disadvantages of each (Bowen 1996). Other 
advantages of using case studies are that the researcher is able to deal with the 
complexities present within social settings. Relationships and processes can be 
studied, which is something that isn't normally possible when using a survey for 
example. 
However, there are also disadvantages of using case studies. For example the case 
study approach can be susceptible to criticism in terms of how credible 
generalisations made from them are. Case studies are also of a SUbjective nature 
and it is important to explore the extent to which a particular case is similar and/or 
different to others like it (Denscombe 2003, pp.38-39). In addition care needs to be 
taken to define case studies so that the researcher is clear about what to include in 
the study and what to exclude from it. Another challenge associated with the case 
study approach is what is known as the observer effect. An example of the observer 
effect is people being conscious of the fact that they are being observed and 
changing their behaviour (Denscombe 2003, p.65). The researcher felt that a case 
study approach was appropriate for this research, as the two cases provided the 
opportunity for in-depth study on how key data types are generated through 
pharmacogenomics experiments, namely genetic and genomic data. It also allowed 
the researcher to explore the development of novel information systems specific to 
the two cases. Because of these reasons it was deemed logical to use a case study 
approach and to study both organisations in detail. The specific cases in this study 
were the Sanger Institute and AstraZeneca PLC (see Chapter 5 on p.120, Chapter 6 
on p.140, and Section 3.2.2.2 on p.86). 
Case study design 
The two main types of case study design are known as single case and multiple 
case designs. A single case design is similar to a single experiment. The use of 
single case studies is appropriate when the case is of critical importance in testing. 
Such unique cases often arise in the medical field where a certain disorder is so rare 
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that a single case would be worth studying (Yin 2003, p.4I). Often single case 
studies are used as a precursor or as pilots in multiple case studies. 
As more than one case study was to be carried out in this study (see Section 3.2.2.2 
on p.86), it seemed sensible to use a multiple case study design and consider issues 
of replication logic. Two types of replication logic are relevant to multiple case 
study design. One is literal replication where cases are selected on the basis that 
they will provide similar results but for predictable reasons. The other is known as 
theoretical replication where case studies are chosen as they are expected to 
produce contrasting results but for predictable reasons (Yin 2003, p.47). Both literal 
replication and theoretical replication are discussed in more detail in Section 7.4 on 
p.177). 
For this research the case study design used was of the embedded type as opposed 
to holistic. The difference between the two is that in an embedded design a case 
study may have more than one unit of analysis, while a holistic design captures the 
global nature of a company or of a program under evaluation. The two case studies 
that were carried out by the researcher each had a unit of analysis that were the 
focus of attention (Rowley 2002). A holistic case study design is useful when no 
logical subunits can be found or when the theory upon which the case study is 
based, is holistic. However, a problem with such a design is that the focus of the 
research may change during the course of the study, and so research questions that 
are different to the initial ones, become of primary importance. Such a problem can 
be addressed by the use of an embedded case study design. However this design 
also has shortcomings. The main one is that it is possible that focus upon smaller 
subunits can often result in failure to return to the wider unit of analysis (Yin 2003, 
pp.44-4S). 
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Table 3.2.1 Methods used to address validity and reliability issues. 
Test Case Study Tactic Tactic iu Practice 
Construct Validity Use of multiple sources of Data collection through 
(Correct operational measures in evidence triangulation of research 
place to minimise subjectivity) methods 
Key informants review draft case Reports sent back to clients 
study reports to read 
External Validity Use of theory in single case Literature review of 
(Identifying the domain to which studies standardisation of 
the findings of a study can be bioinformatics resources 
generalised) 
Use of replication logic for Focus on literal replication 
multiple case comparison and theoretical replication 
concepts 
Reliability Use of case study protocol Development of action 
(Displaying that the processes in plans in conjunction with 
the study can be repeated with the clients 
the same results being obtained) Development of a case study Data stored and coded in 
database Atlas.ti 
84 
Chapter Three Research Methods 
3.2.1.1 Quality issues 
Quality issues in case studies involve reliability and validity. Reliability involves 
demonstrating that the procedures used in the study can be repeated (see Table 
3.2.1 on p.84). Validity is more complex than reliability and can often be 
subdivided into different validity types. For example construct validity refers to 
ensuring that correct operational measures are in place for studying the concepts 
while internal validity refers to illustrating how specific conditions lead to another 
condition while exposing any false relationships. Incidentally this type of causal 
validity was not relevant to this study as both of the case studies carried out were 
exploratory ones (Rowley 2002). 
Reliability 
In the current study reliability would involve the observation of the same results in 
both case studies as long as they were carried out in the same manner using similar 
data collection methods. This condition however was difficult to assess due to the 
qualitative nature of the inquiry of this study and the differing learning objectives 
of the two case studies. Having said this, it was ensured that reliability was 
considered by describing the methods used to plan and implement the case studies 
along with details of how data would be analysed as is evident in the sections above 
and below. Other issues were also taken into consideration such as researcher bias 
and influence on the people being observed, and wordings of questions used in 
interviews (Jones 1998). Jorgensen (1989, p.36) states that in participant 
observation (see Section 3.3.3 on p.92) consistency of results is more likely to be 
achieved if the procedures used are simple and standardised. These issues however 
do not apply to this research study as the observation only consisted of observing 
high throughput technologies and LIMS (see Section 5.2.1 on p.125). 
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Validity 
An important part of evidencing construct validity in this study was the sending of 
case study reports back to the clients for them to check for validity and accuracy. 
Also e-mail was used as a follow up method in order to contact respondents to 
confirm understanding and correct any errors in thinking. 
3.2.1.2 Identification of the cases 
Altogether 45 letters and e-mails were sent out to potential stakeholders, as the 
objectives were focused on the development of database standards for 
pharmacogenomics. The organisations contacted were mostly pharmaceutical 
companies and biological research centres. A number of academics who had 
interests in pharmacogenomics and/or pharmacogenetics were also contacted. 
In the end, five potential stakeholders agreed to an initial discussion about the 
project. These included an employee from Astrazeneca PLC and an employee from 
the Sanger Institute. Two academics, one from the Queens Medical 
CentrelUniversity of Nottingham and the other from the University of Liverpool 
also agreed to meet the researcher. The researcher developed a semi-structured 
interview schedule consisting of about eight questions. These questions were 
general questions about their involvement in pharmacogenomics, the applications 
of the pharmacogenomics research they carried out and asking whether they would 
be interested in participating in such a study. The questions included: 
1. Would your organisation be interested in participating in this study? 
2. Which diseases/disorders describe best the focus of the research of your 
organisation? 
3. What are the key foci of research? (Or what type of drug discovery research do 
you mainly carry out?). 
86 
Chapter Three Research Methods 
4. What are the drivers and bottlenecks of the phannacogenomics research you 
carry out? 
5. How many researchers are working in the pharmacogenomics area m your 
organisation? 
6. What are the current applications of phannacogenomics? 
7. What other investment or other resources will be needed to fulfil these 
applications and when? 
8. Would it be possible to do a case study of pharmacogenomics at name of 
organisation? 
Out of the organisations visited only the Sanger Institute and AstraZeneca agreed to 
definite participation in the project (See Chapter 5 on p.120 and Chapter 6 on 
p.l40). 
3.3 Data Collection 
Methods of data collection included collecting and revIewmg critically, the 
infonnation overload literature, semi-structured interviews, observation and 
analysis of scientific documents. A limitation of the data collection in the present 
study was that a pilot study was not carried to test the suitability of the questions 
asked during interviews in the AstraZeneca case study (See Chapter 6 on p.140). 
This is important to mention as piloting can reveal any further unanticipated 
problems with the questions before they are used in the field (Hall & Hall 1996, 
p.l26). 
3.3.1 Information overload research framework 
A critical analysis of existing literature on the topic of infonnation overload was 
conducted (see Chapter Four on p.l03). The knowledge gained from this theoretical 
exercise helped to infonn the particular area of bioinfonnatics application 
development that would be centre of attention, and the focus needed to address the 
infonnation overload problem from a technological perspective. 
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3.3.2 Semi-structured interviews 
Semi-structured interview schedules were employed in this research. Normally, the 
questions to be asked in semi-structured interviews are prepared in advance, but are 
still open enough, such that following questions cannot be planned but instead are 
improvised in a careful manner. Indeed, semi-structured interviews are when an 
individual's responses cannot be predicted before hand, but the interviewer must 
improvise about 50% or more of hislher responses to what the respondents say in 
response to the initial questions that were prepared (Wengraf 2001, p.5). The 
advantages of using semi-structured interviews include allowing people to talk 
about issues important to them in detail and depth and the ability of the researcher 
to obtain responses on complex issues. In addition, the use of probes can prove to 
be useful to gain information that the researcher did not think of in advance nor had 
no knowledge of before the commencement of the interviews (Denscombe 2003 
p.167). 
Another benefit of using semi-structured interviews is that they allow one to obtain 
a response to a question immediately rather than having to wait; such may be the 
case when using others types of surveys such as postal questionnaires. They are 
also excellent for resolving any ambiguities or inconsistencies of questions. An 
additional advantage is that they allow the enquiry into why people or companies 
behave like they do. This is not normally possible with quantitative methods. 
Individuals may be more willing to take part in interviews as they place more 
personal emphasis. This is particularly important if questions being asked are 
confidential, sensitive or potentially embarrassing. Also, there is no literacy 
requirement on the part of respondents (Gorman & Clayton 1997, p.25). 
Just like any qualitative or quantitative research method, the use of interviews has 
its disadvantages. To begin with, interviews are very time consuming. The actual 
process of interviewing does not take much time but transcribing is an extremely 
lengthy process. For example a one-hour interview can take up to ten hours to 
transcribe. In the current study, all 22 interviews except two were tape-recorded in 
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both case studies. This consisted of five interviews being carried out at the Sanger 
Institute. These interviews were fairly short in duration (maximum half and hour) 
and it was decided at first to analyse the qualitative material manually. This 
involved printing off interviews and reading scientists' responses to questions and 
coding data to emerging categories in margins (see Appendix C on p.361 on CD-
ROM). However time permitted to carry out this process using Atlas.ti (see Section 
3.4.2 p.100). More specifically the approach to analysis involved using an 
adaptation of content analysis incorporating inductive coding (Thomas 2003) (see 
Section 3.4 on p.95). 
The AstraZeneca case study consisted of 17 interviews. In one of these exceptions, 
the respondent did not want to be interviewed. Transcription of the interviews was 
carried out manually using a word processor as soon as possible and then with (see 
Appendix C on p.361 on CD-ROM and Appendix D on p.378 on CD-ROM). This 
was a time consuming process, with it taking between two and six hours to 
transcribe one interview. However, transcription enabled the researcher to give 
attention to the interviewee and provide a setting in which the interviewee felt 
he/she was being communicated to as in an informal chat. Transcribing the 
interviews also gave the opportunity to listen to each interview again and compare 
the dialogue spoken to the field notes. This listening of the interviews was an 
important process as it led to the creation of new questions and areas which needed 
to be covered but were not exposed during the interviews. 
Another issue with interviewing is the travelling factor, as one has to travel to 
multiple locations that may be far apart (Gillham 2000b, pp.9-14). There are issues 
of validity that also come into play and the researcher can not know if the 
respondent is being completely truthful. It is also possible that the researcher may 
suffer from information overload through the respondent going off the topic of 
interest and discussing other factors (Livesey [n.d]). Furthermore, care needs to be 
taken to ensure that anonymity of respondents is maintained and that the data that 
are reported are holistic and not selective (Gorman & Clayton 1997, p.138). 
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3.3.2.1 Questions asked 
Due the nature of semi-structured interviewing the questions asked during the 
interviews in both case studies were mainly open-ended. 
Questions used in Sanger Institute case study 
1. Could you describe the steps you carry out when you do manual primer 
design? 
2. What pieces of information do you think are important for other scientists to 
be able to reproduce the manual primer design you do? 
3. Are those pieces of information stored anywhere? 
4. Are there any problems you face with manual primer design? 
5. How do you address those problems? 
6. In your opinion would a standard for manual primer design be useful? 
Questions used in AstraZeneca case study 
1. What part ofthe drug discovery and development cycle do you work in? 
2. What are the objectives ofthe work you carry out? 
3. What types of data are used by your team? 
4. Where are these data stored? 
5. What format are these data stored in? 
6. Do you use any hardware devices for your work? 
7. What type of data will immediately be needed by your team in 2 years time? 
8. What types of data will be needed by your team in 2 years, not immediately, 
but after a short delay? 
9. Do you any bioinformatics databases? 
10. Do you use any bioinformatics analysis tools? 
11. What are your opinions on these bioinformatics tools? 
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12. Is the scientfic workflow used by your team linked to any other team(s) in 
the department? 
Advantages of such questions are that an unlimited number of answers are allowed, 
often unanticipated findings can be produced, and that respondents are able to go 
back and check responses. There are also many disadvantages of open questions. 
Some of these are that respondents may feel intimidated and therefore, provide 
differing levels of detail etc (Borgatti 1996). The other type is a closed question 
where there are sets of predetermined possible answers (Gillham 2000b, p.13). An 
example would be: "what part of the drug discovery and development cycle do you 
work in?" With a list of four or five choose from. Closed questions are most 
commonly used in questionnaires whereas open questions are used less frequently, 
primarily as they are more difficult to answer and analyse. 
3.3.2.2 Sample selection 
Sampling methods used to determine those who would be interviewed in this study 
included purposive sampling and convenience sampling. Purposive sampling is 
usually used in a situation where a researcher has knowledge of those people who 
can provide the most relevant information and selects these individuals. The ability 
to interview information rich respondents greatly increases the ability of a 
researcher to study those issues of primary importance (Patton 2002, p.46). The 
major disadvantage of this approach is the researcher bias involved, as the 
researcher uses hislher own judgement about whether it would be beneficial to 
include certain people in the sample (Lunsford & Lunsford 1995). This type of 
sampling was used in the Sanger Institute case study (see Chapter 5 on p.120). In 
the AstraZeneca case study convenience sampling was used. Such a sample can be 
the result of a researcher only having certain people at hand, or including those who 
are most likely to respond, or when the researcher is restricted to a sample by the 
authority of an organisation (Interviewing in qualitative research [n.d. D. A criticism 
of convenience sampling is that convenience alone in scientific research does not 
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provide enough justification for its application and can be criticised for being lazy 
research (Denscombe 2003, p.17). 
Other alternative sampling methods are snowball sampling. With snowballing, 
initial respondents can refer a researcher to other respondents who may also 
provide required information. However its primary disadvantage is that the sample 
is limited to a specific group or network (Unstructured interviewing and focus 
groups [n.d.]). Another type of sampling is theoretical sampling. In this type of 
sampling, instances are selected based on the discovery of conceptual or theoretical 
categories grounded in the data. At each stage in the research, new data are 
collected to change or confirm a theory, which enables a researcher to reflect and 
select respondents for the next stage (Denscombe 2003, p.16). Theoretical sampling 
compliments the use of grounded theory in a study (see p.100 for more on 
grounded theory). 
3.3.3 Use of observation 
Observation was used as a research tool, although the extent, to which it was 
utilised, was minimal. Observation as a research method is the observing and 
recording of an event, where the researcher is also present (Allison et aI., 1996, 
p.26). It is a qualitative research method, involving recording in a natural setting, 
any observable phenomena in a systematic fashion (Gorman & Clayton, 1997, 
pp. 1 04-1 05). There are different levels of participation. One example is that of the 
complete observer. The researcher when acting as a complete observer acts as a 
simple recorder of events and activities with limited or no interaction with other 
people. With this strategy other participants are not aware of the researcher being 
present. 
Another example is observer-as-participant, where the observer does interact to a 
certain extent with subjects (Gorman & Clayton 1997, p.107). A researcher can 
also play the role of participant-as-observer who in an overt fashion interacts more 
extensively with people than ifhe/she was acting as an observer-as-participant. 
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Right at the other end of the spectrum is the complete participant who fully engages 
in the activities of the group or organisation being studied (May 2002, p.155). The 
type of observation used in the current study was participant-as-observer. Initially it 
was planned that participant observation would be used, but this proved to not be 
possible as scientific training would have been required. In general terms, the 
observation used in the two case studies was unstructured. In this approach the 
observer refers to his/her research questions and records behaviour that may be 
relevant to these questions. This is much more of an open-ended approach and is 
good for a situation where everything is not understood completely as was the case 
in the present study (Gorman & Clayton 1997, p.l05). 
More specifically in the Sanger Institute case study, PCR laboratories and 
genotyping laboratories were observed. These laboratories contained high 
throughput technologies such as robots for liquid handling and genotyping 
platforms integrated as workflows with bioinformatics software including 
Laboratory Information Management Systems (LIMS). Scientists working in the 
relevant area showed the researcher around the laboratories and facilities and their 
usage was explained. These experimental techniques were already described in 
meetings beforehand and their subsequent observation proved to be a cross-
validation of information previously recorded. Further validation of data collected 
was achieved through consultation with the primary contact and the head of the 
Pharmacogenomics group. 
In contrast to such unstructured observation, there is observational research, which 
can be structured. This involves sampling an event using a predetermined plan or 
form that is categorised. In this, the observer makes records about whether specific 
events or activities occur, and if they do, then when and how often. This type of 
systematic observation produces quantitative data, which are ready for analysis, and 
it is possible for two or more observers using a schedule to record data that are 
similar (Denscombe 2003, p.200). 
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There are many advantages and disadvantages of observation. Some advantages 
among others include (Gorman & Clayton 1997, p.l05): 
• It allows the comparison of what people say they do to what they actually 
do. 
• It is very present orientated that allows the recording of events etc as they 
occur and when they occur. 
• Behaviour can be observed and recorded in a natural environment. This is 
important when one considers that in an unnatural environment the 
behaviour of people may not be typical. 
There are also disadvantages of the use of observation (Gorman & Clayton 1997, 
p.106): 
• There is the possibility of people changing their behaviour if they know they 
are being observed. 
• It can be difficult to anticipate exactly whether an event will occur, which in 
turn means that the researcher may not be ready to observe it. 
• There is an issue of sUbjectivity of the observer that needs consideration. This is 
particUlarly applicable if the observer is an expert and is experienced in the area 
that is being observed. 
3.3.4 E-mail dialogue 
Additional data was collected through follow up e-mails after the completion of 
fieldwork. The advantages of doing this was that it enabled information extracted 
from the interview transcripts to be validated by the respondents, to clarify any 
misunderstandings and also allowed questions that were not used during the 
interviews to be asked. This process also provided confidence about the themes and 
concepts that were being studied and used during data analysis. 
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3.3.5 Alternative methods 
Other alternatives to semi-structured interviews are the use of structured interviews 
or formal interviews. Questions in such an interview are usually closed and directed 
(Allison et aI., 1996, p.82). Being recording schedules, these are in effect 
questionnaires that are administered in a verbal manner (Fontana & Frey 2003, 
p.68). These survey interviews also come with their advantages and disadvantages. 
One advantage is an increased reliability produced which is due to the greater 
uniformity achievable with structured interviews. The reason for this is that 
respondents are made to respond with answers that only fit the categories of 
responses available (Fontana & Frey 2003, p.68). 
Another viable method that could have been used in the present study was focus 
groups. A focus group involves a group discussion involving six to twelve 
participants. Such a discussion requires a facilitator who guides the meeting based 
on a set of questions that are prepared in advance. The advantages of using focus 
groups include efficiency, as sessions require modest amounts of time, and the 
encouragement of participant interaction. In addition focus groups are open-ended 
and allow unanticipated topics to be explored (Gorman & Clayton 1997, p.143). 
However there are also many challenges with using focus groups. For example the 
response time to a question is increased, as many people are present. This means 
that the numbers of questions that can be asked are limited. A major difficulty in 
conducting a focus group is that it requires much skill in group dynamics and 
ensuring that one or two participants do not dominate the discussion (Patton 2002, 
p.385). 
3.4 Data Analysis 
The analysis approach consisted of two main components. These involved content 
analysis incorporating inductive coding. Content analysis in more detail involves 
reducing the data into more manageable parts. This involves breaking the text into 
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smaller units, which in this study were sentences and whole paragraphs. After this 
the frequency with which these units occur can be counted. Further analysis is then 
carried out in which the frequency of units and their relationships to other units are 
established. From this, statements can be derived explaining why the data are 
presented in the manner in which they are. The primary advantage of using content 
analysis is that it is a clear and comprehensible method that allows researchers to 
quantify the contents of interview data. However the greatest difficulty in using the 
method lies in preventing of the removal of units and their meaning from the 
context in which they were spoken or written (Gorman & Clayton 1997, p.207). For 
example, it may be difficult for the researcher to distinguish whether similar text 
should be grouped together or kept separate (Hall & Hall 1996, p.134). 
The meaning of the concept of inductive analysis is that themes, patterns and 
categories emerge from the data rather than being decided at the beginning of the 
study. Two types of patterns may emerge from data analysis. One is where the 
researcher can use the categories developed in the study to organise the 
presentation of themes. These categories may be developed from the objectives of 
the study or from the vocabulary used by the target population. Second is the 
generation of new terms to describe categories inductively, which requires the 
researcher to search more closely in the data for themes, categories and patterns 
(patton 1987, pp.150-152). The inductive approach requires the presentation of 
clear links between the research objectives and findings derived from data analysis 
so that they are apparent and defensible to objective readers. In addition a model is 
developed or theory is generated which represents processes in the raw data 
(Thomas 2003). In contrast to this there is deductive coding development that relies 
on specific research hypotheses before the collection of data (Patton 2002, p.56). 
The current project was not based upon any hypothesis or a concrete theoretical 
framework so this would not have been an appropriate route to take. 
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3.4.1 Example of data analysis 
The example in this section has been taken from the response of a scientist to a 
question used in the Sanger Institute case study and illustrates the content analysis 
and inductive coding used. The question was "what are the steps taken when 
carrying out primer design?" and the response: 
OK. First thing to do is to take the sequence ... the sort of minimum sequence 
around the exon we want and then from that I'll paste it into RepeatMasker to look 
for any repeats. If there are repeats you have to treat them differently. But for the 
sake of argument let's say there isn't any. You then take that region ... paste it into 
Primed and take the output from there and look at those oligonucleotides that 
hit ... say they will work ... have a look at those in relation to the automatically 
designed primers. If they're the same you have to play around more and try and 
force it to design different primers and so on. That's essentially it. 1 
The above response to this particular question and those of other scientists was 
analysed looking for keywords and sentences and categories were developed from 
this process. An example of a category developed from the above quote is Check 
for Repeats. This category belonged to the theme Steps in Primer Design that was 
conceptualised at the beginning of data analysis. Other examples of categories 
belonging to this theme have been illustrated in Figure 3.4.1 on p.98. Such 
development of themes and categories was carried out for every question and 
analysed across each interview in the same manner. The frequency with which 
categories occurred was then reviewed and those categories that appeared most in 
the data were used to help in writing the findings. A similar analysis approach was 
also used in the AstraZeneca case study. 
I Interview with a Senior Research Assistant in the Pharmacogenomics Group. 
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Repeats 
Figure 3.4.1 The theme Steps in Primer Design and its associated categories 
taken from the Sanger Institute case study 
3.4.1.1 Data analysis steps 
The following general steps outline how the raw data were analysed in both of the 
case studies using an integration of content analysis and inductive analysis 
principles (Denscombe 2003, p.221; Thomas 2003): 
1. Preparation of raw data - Formatting of data by transcribing each interview 
using a common format. Each interview was printed out and backups were 
made. Interview files were then imported into Atlas.ti. 
2. The text was broken down into smaller components. 
3. Reading of text - each interview was read to identify initial themes and 
patterns in responses. 
4. Each question was analysed one by one across each interview. 
S. Categories were developed inductively. 
6. Coding of the data (e.g. quotes) with categories. This process was facilitated 
using the Atlas.ti program (see Section 304.2 on p.1 00). 
7. Category tables were developed for each question including definitions, 
criteria for inclusion and exclusion and examples using quotes (see Table 
304.1.1 on p.99). 
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8. Atlas.ti used to develop networks of categories and relationships between 
them. 
9. Development of generalisations and statements from the findings based on 
frequencies with which categories occurred. 
Table 3.4.1.1 An excerpt taken from a code table from the AstraZeneca case 
study 
Code Definition Examples InclusionlExclusion 
criteria 
Sequence Data Size at Estimates of the size of "We did about Both high throughput 
Present sequence data being 30,000 reactions last and low throughput 
generated within RDG year. And we'll do sequence data generated 
about 33,000- withinRDG 
34,000 in total by 
the end of this year. 
And the files 
themselves are ... the 
SCF files are in the 
range 200-250 K's. 
Between 
100 and 200 K. And 
the text files are 
very small ... about 1 
K. And that 
probably ... do about 
31,000 reactions 
this year and we 
would have 
produced about 400 
Gigabytes I think." 
As the learning objectives (see Section 5.1.3 on p.123 and Section 6.1.2 on p.144) 
of the case studies explored aspects such as establishing data types being used, 
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where these data are stored, i.e. having a frequency element, content analysis was 
used in preference to taking a completely theory developing approach such as 
grounded theory. Having said this, the development of categories in this 
investigation was similar to grounded theory as this methodology also takes an 
inductive and comparative approach. 
A key characteristic of grounded theory is that hypotheses are not tested at the 
onset; rather theories are developed in an incremental fashion (Pandit 1996). A 
method known as comparative analysis is used to develop these theories in an 
inductive manner through systematic collection and analysis. This is made up of 
four steps (Jorgensen 1989, p.113). In essence, it involves coding data to 
conceptual categories; integrating categories and their properties using common 
headings; the development and verification of theory; and then it's writing up. The 
use of grounded theory has its benefits. It is an established methodology whose 
reputation justifies its use and can downplay criticism often faced by qualitative 
research. The systematic structure to grounded theory is particularly useful for 
novice researchers to follow. Even more importantly, the theories developed are 
grounded in reality meaning that they are based on evidence that is solid in 
foundation. Some of the challenges with using grounded theory are that the 
researcher requires open-mindedness, although he or she may have prior influential 
thoughts and beliefs from their own experiences. In addition the systematic 
structure, which is beneficial, itself can cause problems due to the complexity of 
the steps involved (Denscombe 2003, pp.127-128). 
3.4.2 Use of software 
Computer programs can be used for the efficient storage, coding and sorting of 
data. The qualitative data analysis software Atlas.ti was used in this research study. 
Atlas.ti was specifically designed to aid qualitative analysis of large pieces of data 
including textual and multimedia data. Documents that are textual are assigned to a 
project known as a hermeneutic unit. These then become Primary Documents upon 
which analysis is carried out. The researcher is now able to develop code lists and 
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assign these to words, phrases and whole responses to questions. In addition, 
groups of categories can be clustered together into families through networks. 
(HenczeI2001, p.121) (see Figure 3.4.2 below). The benefit of these particularly to 
the analysis of case studies is that they enable the comparison of whole cases and of 
specific parts of the case and allow patterns in the data to be established (Kern 
2004). Having said this, a drawback to this software is the inability to directly 
manipulate Word documents and then need to transform them into Rich Text 
Format (Kern 2004). An advantage of using Atlas.ti is the ability to search through 
numerous interviews to quickly find answers to questions. In addition, in a 
networked environment, multiple researchers can access the same study files and 
contribute to interview transcripts (Cresswe1l2004). 
Is associated with 
Genetic Data Size 
at Present 
Is associated with 
Is cause of 
Clinical Data Size 
at Present 
Is cause of Is 
associated 
with 
Is associated with 
Study Size 
at Present 
Sequence Data 
Size at Present 
Genotyping Data 
Size at Present 
Is associated with 
Figure 3.4.2 A network illustrating the categories and relationships between 
them regarding the sizes of different data types used at present, taken from the 
AstraZeneca case study 
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The decision to use Atlas.ti as opposed to others such as Nudist was made due to 
prior knowledge and some training in its application. Nudist is a major competitor 
of Atlas.ti. This qualitative data analysis tool has a Document System that is used to 
store text files containing responses to questions and an Index system that is able to 
store coded data that enables the development of concepts, storage of ideas and the 
organisation of nodes as hierarchies. A recent study compared the two pieces of 
software and reported on the advantages and disadvantages of both (Barry 1998). In 
essence both are similar in that they enable the coding of data and theory building. 
Atlas.ti and Nudist can be compared along a number of factors. For example a 
beneficial characteristic of Atlas.ti lies in its visual functionality and the display of 
all the data on an effectively designed user interface. This in turn encourages the 
creative process of developing ideas and identifying patterns. However Atlas.ti is 
loosely structured which may actually put off some researchers who would prefer a 
more structured organisation. While the user interface of Nudist is not as attractive, 
its main strength is that it operates in an environment that is more structured, and is 
also more verbal which some users may prefer. Additionally, Atlas.ti offers the 
ability to link memos to multiple codes while in Nudist only one memo per code is 
permitted. Nudist on the other hand provides tools for project management such as 
progress logs, which is an area where Atlas.ti is, limited (Barry 1998). 
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Chapter Four: Information Overload - A review of 
the literature 
4.1 Introduction 
Most people experience infonnation overload. Infonnation is like water streaming 
in from thousands of taps. Whether it is from TV signals, radio, mobile phones, 
laptop PCs, fax machines, (Bj0rner 1998), newspapers; the huge amounts make us 
create a perception of infonnation overload (Edmunds & Morris 2000). However, 
with these sources we still have a choice: we can ignore them. In a working 
environment it is different. Here infonnation is seen as the input to success and you 
cannot, take no, notice of it. This means that people at work become overwhelmed 
by the amount of infonnation they have to assimilate. Causes of this include having 
too much paper, out-of-date infonnation, slow access to mission critical data, the 
stressful task of updating manually, loose out-of-date infonnation that is paper-
based. In addition, over recent years the e-mail overload phenomenon is 
increasingly becoming problematic. These are just a few examples, and there are 
many more (Walker 2001). 
Individuals and organisations from all industries and academia feel the effects of 
infonnation overload, be it civil engineering, banking, phannaceuticals, biology or 
food production. All these fields have extreme amounts of infonnation in common. 
Take the example of biology further, and more specifically bioinfonnatics (see 
Section 2.1 on p.12 for a historical perspective on bioinfonnatics and Section 2.2 
on p.19 for detailed discussions on current research in the bioinfonnatics field). A 
risk of an enonnous amount of genetic data overwhelming researchers has meant 
that data warehousing companies nonnally associated with creating solutions for 
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infonnation and data intensive fields like banking and airlines are now being 
consulted to address such issues (Dennis 2002). 
This is a critical literature review of the infonnation overload topic. Firstly a 
definition of infonnation overload will be given, followed by a discussion on the 
history of the subject. After this the causes of infonnation overload will be 
discussed and its effects. Examples will be taken with reference to employees, 
particularly managers and the wider organisations they work for. The review will 
finish with a discussion on solutions to the problem and conclusions. 
4.2 A definition 
Many definitions ofinfonnation overload exist. According to Butcher (1998, p.53), 
it can mean quite a number ofthings, one of which is having more infonnation than 
an individual can absorb. This certainly is the view taken by Bawden (2001), when 
he defines infonnation overload as typically being the state a person finds 
himselflherself in, when they are unable to use infonnation efficiently to do their 
work, as they have been weighed down by the size of infonnation that is potentially 
valuable and significant to them. According to Chan (2001), too much infonnation 
plus, a limited infonnation processing capacity equals to infonnation overload. A 
more imaginative tenn is data smog, to describe the reality of the infonnation age 
in which we are in (Shenk 1997, p.31). The infonnation floating in this data smog 
can be relevant to us, but can also mean to be a burden with a large supply of 
unsolicited mail arriving on a frequent basis through our letter boxes and e-mail 
boxes (Butcher 1998, p.53). Whatever view one has on infonnation overload, 
something that cannot be denied, is the undesired feelings of stress (Reuters 1996, 
p.8). In fact the effects (see Section 2.5 on p.1 09) on health can be so negative, that 
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infonnation overload III a more severe fonn, has another reference, called 
infonnation fatigue syndrome (Goulding 2001). 
4.3 History of information overload 
Infonnation overload is in no way a recent phenomenon, although it may seem so, 
especially with the advent of e-mail and the Internet. The issue of infonnation 
overload has existed well before the 1950's and has since continued to be seen as 
an increasingly problem issue. For example during the late 1950s and subsequently 
during the early 1960s scientific and technological publications increased 
simultaneously as did the increasing use of computerised infonnation handling, all 
contributing to the creation of more infonnation As the years went by, during the 
1970s and 1980s, matters only got worse because of an increase in academic and 
professional papers. Parallel to this increase in infonnation overload through the 
decades, can be seen an increase in pUblications mentioning the word infonnation 
overload. An analysis showed that publications mentioning the phrase could be 
found as early as the 1970s. It has to be admitted though that the numbers were 
minimal during the 1970s, but gradually increased during the 1980s and peaked 
during the late 1990s (Bawden 2001). 
4.4 Causes of information overload 
The literature shows that infonnation overload is predominately caused by factors 
such as having too much information that can also be diverse in nature, and 
information and communication technologies (leTs) (Bawden 2001). 
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Having too much information 
Much of the literature on infonnation overload, focuses on its effects on individuals 
and the organisations they work for. The most common type of individuals that 
research has focused on, are managers and their perceptions of the phenomenon 
have been surveyed. Perhaps the most well known one is the Reuters survey 
published in 1996 (Reuters 1996). The main effect of infonnation overload for an 
individual is caused through a sensation of losing control of the amount of 
infonnation he or she has at their disposal. The results from the Reuters survey 
showing amounts of unsolicited mail received by managers certainly prove this. It 
was shown that across all the regions of the world that were surveyed, 60% of 
senior managers, 59% of middle managers and 54% of junior managers received a 
lot of unsolicited infonnation. In addition to this, 31 % of all managers received 
enonnous amounts of unsolicited infonnation (Reuters 1996, p.16). However the 
sample was made up of 1,313 company executives across the UK, USA, Hong 
Kong, Singapore and Australia. Therefore it is not clear whether these results could 
also explain the situation that employees found themselves in companies, in other 
countries around the world. 
The issue of unsolicited mail as described above are obviously annoying because 
this is infonnation, which managers are not requesting on their own accord. 
However, this is only one piece of the puzzle. Managers also request lots of 
infonnation that they do require and all of this contributes to the overabundance of 
infonnation collected. This can lead to the argument that it is the managers who are 
contributing to their own infonnation overload, and so why should they complain? 
According to Butcher (1998, p.53), there are seven main reasons why managers 
collect excess amounts of infonnation and end up being overpowered by it. These 
are: 
106 
Chapter Four Information Overload - A review of the literature 
1. Due to western tradition- collecting infonnation proves a commitment 
to rationalism and is considered to indicate competence which managers 
and organisations believe will enforce better decision-making. 
2. Receiving huge quantities of unsolicited infonnation. 
3. Infonnation checking, meaning that more infonnation is collected to 
verify the infonnation already obtained. 
4. To justify decisions, by believing that producing large quantities of 
infonnation can be used to demonstrate decision correctness because the 
decision was based on a very large quantity of infonnation. 
5. Collecting infonnation, just in case it might be useful at another time. 
6. By playing safe and asking for all infonnation possible, as managers are 
aware that important decisions will need to be made in the future, but 
are not sure of what infonnation will be required. 
7. To make sure they are not left behind their colleagues. 
Most of the reasons for infonnation overload felt by managers mentioned above are 
based upon the premise of fear and this fear of one kind or another can have dire 
effects as will be discussed in Section 2.5 on p.I6 
Information and communication technologies 
There is a universal perception that infonnation and communication technologies, 
whose aim it is to provide fast and rapid access to infonnation, in-fact are a cause 
of a high-proportion of the infonnation overload effect. A survey carried out by 
Bawden et aI., (2000) was aimed at assessing and measuring the changes in 
infonnation-related behaviour of scientists as a result of the provision of desktop 
infonnation systems. In the survey there was a component on infonnation overload 
and the scientists' perceptions on it. It was reported, understandably that 
infonnation technology had to a certain level solved the problem, but it was also a 
serious cause. The sample used in this study was 30 people at the UK site of a 
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multinational phannaceutical research organisation. Such a sample is particularly 
small and the generalisability of the results of this study to other sites belonging to 
the organisation around the world could be scrutinised (Bawden et aI., 2000). 
Internet and information overload 
The Internet is considered to be a cause of infonnation overload and this is due to 
its enonnous information content that is highly diverse (Bawden, Holtman & 
Courtney 1999). Berghel (1997) acknowledges that the search engine was the first 
attempt to deal with infonnation overload on the web, but continues by saying that 
in their present form they are primitive, and finding decent documents (that do 
exist) is similar to finding a needle in a haystack. In the 1996 Reuters survey, it was 
reported that almost half, of managers (48%) believed the primary cause of 
information overload, over the following two years would be the Internet (Reuters 
1996, p.7). 
Having said this, the follow up study two years later by Reuters in 1998, reported 
that a mere 19% believed that the Internet had made matters worse, and 
surprisingly half believed it had improved the situation (Reuters 1998, p.9). This 
study had more depth to it than the initial Reuters survey in 1996, as more countries 
were sampled but the size of the sample was 1,072 company executives. In a more 
recent empirical study, 40% believed that the Internet from an external perspective 
(faxes, e-mail, business related news, advertising coming in from external sources) 
was the main contributor to infonnation overload, but a larger amount (60%) cited 
internal sources. These included interpersonal and inter-department 
announcements, letters etc (Farhoomand & Drury 2002). The credibility and 
generalisability of the results from this study are increased by the fact that 124 
managers from a worldwide sample took part in the study. These individuals 
belonged to various industries including manufacturing, financial services, 
government organisations etc in the UK, US, Australia and Hong Kong. 
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It seems that others, also, are not concerned about the connection between the 
Internet and information overload. For example a study by Nicholas et aI., (1997) 
showed that editors, journalists and media librarians were not bothered with 
information overload, and that users of the Internet were actually bored with 
questions about it (Nicholas et aI., 1997). 
Electronic mail overload 
E-mail has been a huge success, firstly as a communication medium, and second as 
a computer application. It is simple and this means that users with the basic of 
computer skills can use it. It is also cost effective, convenient and speedy (Mallon 
& Oppenheim 2002). The role of e-mail however as a contributor to information 
overload can be illustrated further and more specifically by findings from a study 
commissioned by AutonomyTM. The aim of this study was to report on the way 
organisations were trying to manage the increasing amounts of information 
available to them, and failing in the process (Parnell, 2001). 
The study commissioned by AutonomyTM reported the impact of e-mail on UK 
business. The evidence gathered showed that nearly half (44%) of participants 
(from a sample of 200 managers in leading UK companies across various sectors) 
said that they had taken up network infrastructure upgrades to handle the volume of 
e-mail. 87% of the companies interviewed said that e-mail alone, since its 
introduction had contributed an average 39% increase in the amount of data 
flowing through computer networks. It was also reported that four out of every ten 
e-mails received, had no or very little relevance. Having said all this, companies did 
ask employees to archive e-mail folders and general document folders, so that 
amounts of old data may be reduced for file servers, databases and desktops. But 
nearly half claimed that employees asked to have files restored back onto the 
network (pame1l2001). 
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4.5 Effects of information overload 
The effects of infonnation overload impose serious problems for the individuals 
and organisations who feel its impact. For example, poor perfonnance can often 
result due to stress (Butcher 1998, p.55). Interviews in the 1996 Reuters survey, 
showed that two out of three managers claimed that stress caused by infonnation 
overload was to blame for the tension with fellow colleagues (Reuters 1996, p.8). 
However, results concerning effects on personal lives seem to be improving. For 
example in 1996, it was surveyed that 62% of managers claimed that their personal 
relationships were strained and 60% said they were too tired for leisure activities. 
In 1998, these figures had dropped to 40% and 33% for both components 
respectively (Reuters 1998, p.9). In a more recent survey, 72% of managers 
complained about loss of time, but very few (17%) said that it damaged their 
personal lives (Farhoomand & Drury 2002). These findings suggest that it is 
possible indeed, that people are becoming more accustomed to dealing with large 
volumes of infonnation and finding a balance with their personal lives. 
Other stress related facts from the Reuters 1996 survey are that as a consequence of 
stress, ill health was suffered by 42% of managers. Such stress and its adverse 
effects would in turn force managers into making unfavourable decisions (Butcher 
1998, p.55). Indeed in the Reuters survey in 1996, nearly 50% of those surveyed 
thought that the ability to make important decisions was affected as a consequence 
of having too much infonnation at their disposal (Reuters 1996, p.8). There has 
been other work carried out looking at the effects of infonnation overload on 
decision-making. A report published by Informix interestingly showed that the 
public sector particularly, thOUght there is too little infonnation available for 
decision-making. Others such as the media suggested there is too much 
infonnation. Either way, it seems reasonable to say, that either too less or too much 
infonnation can make decision making a problem. Quality could certainly be an 
issue here. The results gathered in the report showed there are strong correlations 
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between poor infonnation, stress and poor decision-making (Mc Queen 1999). 
There are others who advocate that it is not the volume of infonnation or the use of 
technology that is causing the undesirable consequences in individuals; 
alternatively it is organisational environments that are extremely stressful places to 
work in (Allen & Wilson 2003). Factors such as aggressive management practices, 
which manager's implement in order to reach Health Service goals could result in 
increased pressure on employees who worry about the security of their job or suffer 
from increased workload (Wilson 2001). 
4.6 Solutions to information overload 
Just as the causes of information overload being versatile and not concrete, so are 
the solutions. From the literature it is clear that there is no single answer to the 
problem. Managers associate infonnation overload with losing control over 
infonnation, and so it only seems obvious that a cure would be to take control of 
infonnation or data on a managerial level and on an organisational level (Pamell 
2001). In a recent paper Eppler & Mengis (2004), discussed how many of the 
infonnation overload solutions offered in the literature do not provide specific 
details of the combination of personal, organisational, technological and task 
improvements. Some of the solutions will now be discussed under three general 
headings: these are personal level, organisational strategies and information and 
communication technologies. 
Personal information management 
Personal infonnation management (PIM) includes training for the most common 
tasks undertaken by the majority of employees in a department or organisation. 
This can include effective use of e-mail, to more advanced techniques such as skills 
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m classification and indexing, especially for those always keeping very large 
amounts of information (Bawden 2001). A study was carried out by Jones & 
Thomas (1997) into the use of personal information management (from a 
technology point of view) and the survey reported quite unexpected results, such as 
the very infrequent use of electronic PIM technologies. These results were 
contradictory to the expectation that more PIMs would be used because of previous 
characteristics of the sample which were high ownership of computer based 
products (Jones & Thomas 1997). The results from this study are limited however, 
as they were only valid within the South West of England as the sample of 23 
people was taken from this area. 
Information filtering 
Information filtering seems like a useful way to manage information on a personal 
level (Bawden 2001; Farhoomand & Drury 2002; Walker 2001). In a survey on 
information overload it was reported that 40% of managers filtered information 
including incoming documents or e-mail (Farhoomand & Drury 2002). A practical 
example of filtering is reading only the information to make decisions that an 
individual feels is from a credible source, (Bawden 2001), called meta-information, 
meaning information about the information being used for the decision. Having 
said this there is evidence that people may pay less attention to source credibility, 
when under pressure from time constraints (Higgins 1999). 
Information literacy 
It is true that people have access to many sources of information covering a huge 
number of topics, available in both print and electronic forms (Bowden & 
DiBenedetto 2001). For example, these days it is custom for employees to have 
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desktop access to the Internet. But this does not mean these same employees have 
increased levels of information literacy. 
Information literacy is a conception that is gaining more and more attention as a 
partial solution at least, to information overload. It is a much wider concept than the 
more commonly known computer literacy, where individuals have a certain degree 
of competence in the use of word processors, spreadsheets, databases and so on 
(Butcher 1998, p.56). In general information literacy is the name given to 
information handling skills that go beyond simpler techniques like retrieving 
information and include skills for evaluation, organisation and use (Bawden, 
Holtman & Courtney 1999). According to Pedley (2001), a study had reported on 
how typically web users would type in shorter queries, most looking at only the 
first ten results and no more, and only a minority making use of Boo lean characters. 
It seems that librarians especially (see Information Professionals on p.114), are still 
needed to play a continuing role to pass knowledge to employees as to how to carry 
out more effective, focused searches (Pedley 2001). 
Organisational strategies 
Organisational strategies at a simple and low level could include for example, e-
mail etiquette. This would involve simple protocols for handling e-mail, for 
example not sending forward messages without thinking properly or more, stricter 
policies like length restrictions on e-mail messages or adding charges for sending e-
mail etc. However, such formal strict policies need to be introduced with care. It is 
vital that individual and group preferences are taken into account, as people and the 
teams they form handle information differently to one another. For example some 
in a group may take time to read and absorb large amounts of information, while 
others may read much less. There is also the possibility that standardisation that is 
enforced, although carried out with the best interests at heart, could make matters 
worse (Bawden 2001). Other important solutions that come under the heading of 
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organisational strategies are knowledge organisation using metadata for example 
and information professionals as the discussions below will explain. 
Metadata 
Rather than needing less information to combat the problem, we may indeed need 
more information or metadata (Farhoomand & Drury 2002). According to Sturdy 
(2001) there is a need to create an atmosphere where there is a striking balance 
between knowledge that is organised in an efficient way and the problem of 
information overload. He believes that a more practical solution is needed in 
preference to software approaches (see Section 2.7 on p.1l5) or traditional 
information approaches like highly skilled people organising content by indexing, 
abstracting and segregating information from a bulk. Metadata, although not meant 
to be a replacement to other approaches is a complementary solution. The 
advantages of using metadata are that completeness is gained about particular 
issues and ambiguity is reduced. Using a metadata approach will allow the user to 
choose relevant information from a list, preferably a hierarchical list or taxonomy 
(see below), which have direct links to information that is relevant. The metadata 
will also allow the presentation of other listings of alternative relationships to the 
required information (Sturdy 2001). According to Robinson (2002), time creating 
valuable resources could be wasted if metadata is not utilised, as they could 
potentially get lost in overloaded web search results. 
Taxonomies 
Information overload and the fact that traditional search engines seem to be poor at 
effectively dealing with large databases, has renewed interest in the use of 
taxonomies (Gilchrist 2003a). Taxonomies can be defined as classification or 
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categorisation schemes and each one, groups together similar entities into topics 
that can themselves be grouped together into broader hierarchies (Scherer 2001). 
Taxonomies can be used in web directories, be used to support automatic indexing, 
be used to filter large databases before the search engine is turned on and can be 
created by automatic categorisation. At the organisational level, you have what are 
known as corporate taxonomies (Gilchrist 2001). Organisations are providing their 
knowledge workers with navigation tools that hold indexes to people, to the content 
of documents and indexes to the actual organisation itself (Gi1christ 2003b). 
Examples of organisations that have corporate taxonomies include British 
Broadcasting Corporation and Unilever (Gi1christ 2001). 
Information professionals 
A worry that is causing concern is that the role of information professionals or 
specialists is not a part of the strategy for combating information overload. There is 
substance in this argument, when one considers the part played by information 
technology professionals, which is to provide access to information that is fast, 
rather than looking for information that is of worth and is useful (Edmunds & 
Morris 2000). The Reuters 1996 survey showed that with all the problematic issues 
faced by managers, there was no mention of information professionals, be they 
librarians, information scientists etc. So, there seems to be an opportunity here for 
the information management profession (Oppenheim 1997). According to Hall & 
Walton (2004), the contribution of clinical librarians is important to ensure that 
electronic solutions for information overload do not have an opposite effect in the 
health care field. 
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4.7 The use of technology 
There is debate as to whether technology is the answer or actually the cause of 
infonnation overload. There are conflicting views like that of Parnell (2001) who 
thinks that in the end, technology is the key to managing infonnation overload, and 
that we have entered a time when automatic delivery of infonnation to all of us is 
starting to revolutionise the way we undertake our work. On the other hand, there 
are views like that ofDenning (2002), who believes technology is not a solution for 
infonnation overload, but instead, making use of commitment management 
practices will help (Fasoranti 2000). AlIen & Wilson (2003) believe that technology 
should not be blamed for causing infonnation overload, as technology only 
provides the means by which infonnation is accessed or distributed to other levels. 
According to Edmunds & Morris (2000), we need to use technology as a tool and 
not a driver, so that we make the situation better for ourselves and not worse. It 
must be remembered that machines and systems, say for example a database can be 
very helpful when businesses have to make decisions, but very often it is up to a 
human being to firstly assess the infonnation, and then make a decision as to which 
course of action should be taken. In general, a system is unable to have the 
experience or understanding to make the decision that will be of most benefit if 
there is no mediation from people. 
Intelligent Agents 
Intelligent agents have been seen as a radical infonnation overload solution (Tudor 
1997). More sophisticated than traditional search engines, they have certain 
attractive advantages like the fact that they are autonomous, meaning they can act 
on behalf of the user, obtaining data by interacting with its environment, rather than 
just taking instructions. Intelligent agents are also able to learn from their users; an 
example is personal preferences, so that over time they can make more accurate 
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predictions that may be of interest to the user when the agent encounters relevant 
information (Belfourd & Fumer 1997). As Abbott (1999, pp.139-140) says, info 
junk can be removed through the use of intelligent agents but users may be 
apprehensive about using them, when they think that these agents will be deciding 
on what we should read, view or listen to. 
Portals 
The reason why this section is on portals is because they are directly related to 
intelligent agents. Portals offer an environment for agents to function (Parapadakis 
2001). Before the application of portals to the issue of information overload is 
discussed, it would be useful to explain what a portal exactly is, as there is often 
confusion when defining one. According to Sturdy (2001), a decent portal worth 
having should combine access to the largest possible range of external and internal 
sources and the metadata specifically recorded about an organisation's valuable 
assets. 
Portals were firstly introduced due to business problems, such as information 
overload, and in particular due to issues such as the impossibility to navigate or 
condense web information that was too big in size. What portals do is provide 
personalisation (Hyams 2002) (see Intelligent Agents on p.llS) and relevance 
functions that partially solve the problem by delivering to the user, only the 
information content required (Parapadakis 2001). 
Push technology and information customisation 
Another technology that needs to be given consideration is the use of Push 
technology (Edmunds & Morris 2000). Push is an alternative model for information 
retrieval across the Internet and intranets. Normally, users point and click on web 
pages and in doing so are pulling information to their desktops from remote 
computers. Due to this, users may have to wait a few minutes or longer before a 
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web page is downloaded which can be very frustrating. Push, on the hand, means 
that users subscribe to channels and have information pushed to their machines 
(Cerami 1998, p.6). Users are alerted, when new or updated information is 
available (Edmunds & Morris 2000). It may actually increase traffic problems, but 
downloading that is automatic and masked from the user, along with overnight 
downloads may create a perception for the user of the process being quicker. 
There is still debate as to whether Push will help with information overload. It may 
in fact make it worse, when one considers that people already suffering from 
information overload, may view Push as a technology that really does not add much 
in terms of value (Cerami 1998, p.18). Bergel, et aI., (1999) are others who have 
their doubts as to whether Push can be a tool for information overload. These 
authors believe that an additional step is needed to what current information and 
retrieval technologies like Push do. While Push technology aids the user in getting 
documents with a high probability of being interesting, another process is needed to 
manage individual documents, customising the user's view of the document so that 
it matches to the user's primary needs and interests. 
This additional step, another strategy for handling information overload is 
information customisation (Bawden, Holtman & Courtney., 1999). Information 
customisation lets the user, interactively and in real time, take control of the way in 
which documents are made smaller in size or transformed into a more beneficial 
format, and finally displayed on a screen (Berghel et aI., 1999; Berghel 1997). 
Rather than filter and retrieve, information customisation software is designed to 
capitalise on information uptake, and another of its unique features is that it is 
never carried out autonomously; something in complete contrast to the way 
intelligent agents work. XML is an environment that allows information 
customisation (Berghel et aI., 1999). 
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4.8 Semantic web concepts and standards 
The current state ofthe web is far from ideal to say the least. The next generation of 
the web and the hope that the semantic web brings, is one of improving in a 
dramatic fashion, services and products available. The idea is that of an 
environment where software agents carry out tasks on behalf of the user. The 
semantic web means making use of taxonomies (see Taxonomies on p.1l3) and 
ontologies, which are often used as synonyms (see Appendix A on p.271). 
According to Benjamins et aI., (2002), one of the six challenges of the semantic 
web is intuitive visualisation to help aid with the problem of infonnation overload. 
They believe that users will increasingly demand that their required content is 
easily recognisable, meaning that alternative techniques to the hypertext structure 
used for visualisation currently will be needed (Benjamins et aI., 2002). 
For the semantic web to become a reality, among other things, new web languages 
will be needed like RDF that presents a more sophisticated presentation than 
HTML, and XML to tag documents (Hendler 2003). However, fundamental for the 
semantic web will be the use of ontologies and the shared and common theories 
they provide. Ontologies can be thought of as metadata (see Metadata on p.1l3) 
that represent in an explicit manner, and in a machine processable way, the 
semantics of data. Currently there is a lack of metadata standards for syntactic and 
semantic communication both from a human and computer point of view. 
Bioinfonnatics a particular field where this is such an issue (see Section 1.3 on p.5 
and the publications in Appendix A on p.271). The lack of such standards means 
the existence of unstructured infonnation that continues to increase and hence the 
interest in ontologies to provide consistent understanding (Ding 2001). In a recent 
paper, the use of metadata standards as providing some of the infrastructure for 
filtering technologies designed to address infonnation overload has been dicussed 
(Dealing with an Infonnation Glut [n.d.]). 
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Chapter Five: Case Study One - Pharmacogenomics 
research at the Sanger Institute 
5.1 Introduction 
The major topic of this case study is the pharmacogenomics field, which can be 
defined as the use of genetics and genomics research to determine interindividual 
responses to drugs. In the 21 5t century, it is common practice to carry out 
pharmacogenomics research in academic and industrial laboratories making use of 
in silica methods along side in vitro and in vivo studies. These studies can be large 
and complex in scale, involving the use of various hardware devices for data 
generation and processing and Laboratory Information Management Systems 
(LIMS) and database resources for data management and analysis. For these 
reasons it is important to integrate these components and the data flows through 
them as workflows (Buttler et aI., 2002). Vitally it is important that such workflows 
increase quality, reliability, accuracy, comprehensibility and productivity of efforts. 
If these benefits are to be realised, then it is essential that a sophisticated 
informatics infrastructure is in place which is standardised for accurate acquisition 
of experimental data, has a data exchange mechanism that can handle format 
conversions, while at the same time ensuring that software components are re-
usable (Berman & Westbrook 2003). The bioinformatics community under a 
number of open source initiatives tailored for specific high throughput -omic 
studies have been developing such standards. 
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5.1.1 Data Standards 
If experimental results are to be of any use then they must be amenable to 
independent validation; this is the primary principle behind scientific publication. 
Parallel to the generation of sequence data through genome sequencing projects, 
strict rules have evolved with regard to data release, with research groups 
sUbmitting consensus sequences attached with individual sequence reads, their 
quality values, and raw DNA trace files (Quackenbush 2004). Submission of such 
data to sequence repositories can have numerous applications; an example of one is 
during drug discovery where databases are screened for polymorphisms during 
target validation. As genomics has transitioned into transcriptomics, proteomics 
and metabolomics and as studies in these fields progress, the resources storing 
these data of increasing complexity will need to be built using community accepted 
standards. Such standards will facilitate the integration of different biological data 
and enable the study of biology at a more holistic level. Much progress has been 
made with regards to standardisation of micro array and proteomics experiments. 
MGED 
The Microarray Gene Expression Data Society (MGED) (MGED Society 2005), 
based at the European Bioinformatics Institute (EBI) was formed in order to 
develop standard database components for the development of information systems 
for gene expression experiments. Firstly a data content standard for the descriptions 
of all aspects of micro array experiments from data generation to analysis was 
introduced and given the name Minimum Information About a Microarray 
Experiment (MIAME) , to enable the validation of micro array experiments and 
enable their reproduction (Brazma et aI., 2001). To ensure consistent sharing and 
understanding of micro array data, terms from the MGED Ontology (MO) have 
been used in MIAME (Stoeckert & Parkinson 2003). MO provides the vocabulary 
to annotate microarray experiments and to facilitate easier interpretation of 
microarray annotations, while enabling efficient querying of micro array resources. 
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Having said this it is not enough that certain data and their associated metadata are 
provided. If such standards are to maximise their potential it is vital that a standard 
transmission format exists for the data. MGED have also developed the MAGE 
standards, one of which is a standard transmission format for data using the 
Extensible Markup Language (XML) technology known as MAGE-ML (Spellman 
et aI., 2002). This exchange format is based upon MAGE-OM an object model the 
captures micro array experiments. The successful use of these standards in a 
harmonious manner has been illustrated by the ArrayExpress database (Brazma et 
al.,2003). 
HUPO-PSI 
In 2002 a similar organisation to MGED was created for the proteomics community 
by the Human Proteomic Organisation (HUPO) known as, the Proteomics 
Standards Initiative (PSI) (HUPO Proteomics Standards Initiative 2005). The first 
of two international meetings, argued the urgent need for standards for the 
representation and exchange of data and metadata generated through proteomics 
experiments (Orchard et aI., 2003a). The second meeting reported on progress 
made in the development of standards projects (Orchard et aI., 2003b). The 
Proteomics Experiment Data Repository (PEDRo) was the first·effort, involving the 
development of an object model to capture a proteomics workflow, including steps 
involved in sample origin, separation methods, mass spectrometry protocols and 
mass spectrometry results produced in silica (Taylor et aI., 2003) (see Section 2.5.1 
on p.32). 
PEDRo while focusing mainly on mass spectrometry analysis neglects other 
important identification methods such as 2D gel electrophoresis (and their analyses) 
and is unable to capture these data holistically enough. To address such issues, a 
UML object model for two-dimensional gel electrophoresis has been developed 
(Jones et aI., 2003). Another analogous production has gone one step further, 
converting a UML model into an XML format known as the Annotated Gel 
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Markup Language (AGML) (Stanislaus et aI., 2004). Although similar in content 
the object model developed by lones et aI., (2003) is able to capture more 
information on the experimental cycle, allowing the annotation of statistical 
analyses. Raving said this, both of these 2D gel electrophoresis based components 
could be incorporated into PEDRo. 
5.1.2 Standards for pharmacogenomics 
As pharmacogenomics progresses as a field though better understanding of 
phenotypes and as technologies for the field mature, community wide standards 
will be needed to develop resources. These would facilitate information integration, 
sharing, seeking and discovery of knowledge in pharmacogenomics and other 
related domains, such as functional genomics and proteomics. Up until now the 
only resource developed specifically for pharmacogenomics and pharmacogenetics 
research is the Pharmacogenetics Knowledge Base (PharmGKB) (Rewett et aI., 
2002) (see Section 1.4 on p.8). The current study will explore the development of 
standards for pharmacogenomics workflows. The reusability of classes and objects 
developed for other -omic fields by MGED and PSI will also be studied. 
5.1.3 Learning objectives for the case study 
The learning objectives for this case study are listed as follows: 
1. To study the types of data used in each process of the workflow. 
2. To determine where these data are stored. 
3. To determine how these data are represented. 
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4. To develop an upstream-decision making tree for one component of the 
workflow. 
5.2 Case study set up 
Within the case study, the research methods used were semi-structured interviews; 
observation and document analysis (see Table 5.2 for an action plan of this case 
study below). 
Table 5.2 An action plan of the case study. 
Subject Plan 
Time Period 6tn -1 t n September 2004 
Research instruments Semi-structured interviews (tape-
recorded), meetings (no tape 
recordings), reading relevant documents, 
observation of genotyping laboratories. 
Respondents Scientists working on each process of 
the Pharmacogenomics experimental 
workflow. 
Head ofthe Pharmacogenomics group. 
Results Collect data to highlight any areas ofthe 
Pharmacogenomics workflow that could 
be standardised. 
Establish information seeking and use 
behaviour of scientists involved in the 
workflow. 
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5.2.1 The Sanger Institute 
The mam reason for choosing the Sanger Institute as the client was that 
pharmacogenomics research was being carried out within the institute, which meant 
that it would be possible to collect data about information management activities 
within this discipline. The case in this instance was the Sanger Institute and the unit 
of analysis was the Pharmacogenomics group who utilised the experimental 
workflow shown in Figure 5.2.1a on p.127. 
In 1992 the Sanger Institute for genome research was set up by the Wellcome Trust 
and the Medical Research Council in order to increase public knowledge of the 
human genome and of other organisms, playing a major part in the sequencing and 
annotation of these. The Sanger Institute is a non-trading and non-profit making 
registered charity involved in large-scale analysis, focused research and 
collaboration programmes that highlight cutting edge biomedical research 
worldwide. The institute boasts sophisticated data mining software and databases to 
analyse and manage sequence data generated daily. These resources are vital in 
enabling the identification of genes and other features of sequences allowing the 
comparison of the human genome to those of other organisms; the name given to 
this is comparative genomics. 
Such computational approaches are complimented with experimental data 
generated using high throughput technologies such as DNA microarrays. In 
addition the Sanger Institute is also involved in researching the consequences of 
genetic variation on disease. A small number of DNA sequence variants occur in 
functional units known as exons, which can influence the susceptibility of humans 
to developing disease, and how people respond to drugs (The Wellcome Trust 
Sanger Institute 2003). 
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At the Sanger Institute high throughput genotyping approaches are taken to search 
for genes that may contribute to a disease. Vital to these studies are the use of 
statistical genetics tests such as association studies to test for association between a 
specific allele variant and a particular phenotype such as epilepsy or cardiovascular 
disease. Also of interest to the Sanger Institute is the investigation of sequence 
variants on drug action, metabolism, and clearance. 
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Figure 5.2.1a The processes that make up the Sanger Institute 
Pharmacogenomics workflow. The first part of the workflow covers SNP 
discovery by sequencing and the second part is SNP genotyping. 
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List of PGx genes 
The study begins with a list of genes that are phannacogenetically relevant in 
disease. These genes are accessed from the Ensembl database (Bimey et aI., 
2004a), Entrez or the literature. 
Experimental gene annotation group (EGAG): to annotate all genes 
NCBI's LocusLink (pruitt & Maglott 2001) is used to retrieve the Human Gene 
Nomenclature Committee (HGNC) name, reference mRNA and protein of the gene 
of interest. Ensembl is then used to identify the genomic location and accession 
numbers of the gene of interest. Following this, sequences are Blasted for protein, 
mRNA and EST homology. The two main tools for annotation are Lace and 
Spandit that can be used to create gene objects. The annotators make use of the 
AceDB database (AceDB 2004) finding areas of GC rich content and 
RepeatMasker (RepeatMasker 2003) is also used to mask out repeats. The Havana 
Group will carry out additional supporting annotation manually. 
Exoseq Primer design 
The annotated genes will have exons that needed primers designed for them. The 
first step of primer design involves checking around the exon to make sure there are 
no repeats. Software used for primer design is Primer3 (Rozen & Skaletsky 2000) 
and there are a number of parameters for the design of primers using such 
programs. Primers are then ordered. 
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Primer Prescreen 
Primers are either produced in house or by Sigma Genosys (Sigma Genosys 2005). 
PCR reactions will then be carried out amplifying exons using PCR across 48 
individuals of Caucasian origin. Exons are amplified at 60°C and the products are 
visualised on a gel to confirm that products of expected size have been amplified. 
PCR reactions that fail will have primers redesigned for them. Altering the values 
of parameters using the Primer3 program can do this. Again prescreening will be 
carried out and if primers continue to fail three times, they will be redesigned by 
eye. Primers that keep failing after this may need to undergo different PCR 
protocols, or be sent to R&D. An important component of this process is the 
Exoseq system. 
Exoseq system 
The Exoseq system is an Oracle database (Oracle 2005), which acts as a Laboratory 
Information Management System, tracking the entire PCR process, from 
automatically creating the information that needs to go onto PCR plates to the 
resulting products visualised on agarose gel. 
Primers re-synthesised onto new plate format: "Reference Set" 
At this stage fully working primer sequences covering all exons in the genes of 
interest are available and re-ordered onto a plate. The plate is in a format ready to 
go into the sequencing process. Reference sets of primers are entered into an Excel 
spreadsheet connected to an Oracle database back-end. 
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Exon resequencing 
Plates are then sent to the sequencing facility for resequencing. The status of 
sequencing can be visualised using the Exoseq database (LIMS). 
Exon Sequencing Case DNAs 
Exons from other samples and diseases of interest can also be sequenced using 
primers designed for the CEPH reference set. 
Glovar 
Glovar is an in house developed database (Glovar Genome Browser [n.d.]). Based 
on the Ensembl schema (with a front end also similar to Ensembl), it stores 
information on known SNP's and also new SNP's identified from the Exon 
sequencing project. Genotyping data are also entered into Glovar. 
Choosing of SNP's 
Which SNP's are chosen is dependent on the project being carried out and factors 
such as spacing are taken into account. For the HapMap project (Deloukas & 
Bentley 2004) the SNP's are chosen every 5Kb along each of the chromosomes in 
the populations being used. For other smaller scale disease projects existing 
knowledge about Linkage Disequilibrium is taken into account or those SNP's are 
looked for which alter the proteins coded for by genes. In addition SNP's are 
selected where both alleles have been seen in at least 2 different DNA samples or 
those, which have previously been found to be polymorphic. 
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IIIumina Assay design 
In many cases a SNP will fail assay design due to the flanking sequences 
containing repetitive sequence. Also, SNP's very close to the SNP of interest can 
cause problems. The Illumina assay design takes these factors into account and 
produces a score, which estimates the likelihood that the SNP will work. 
IIIumina Genotyping 
The Golden Gate Assay Protocol is used (Illumina, Inc 2003). Involved in this 
method is allele specific hybridisation, then amplification via PCR using Cy3 and 
Cy5 primers, and then hybridisation of DNA products to the complement bead. 
Light emissions from the Cy3 and Cy5 fluorescence are recorded in high-resolution 
images of the fibre optic bundles. This consists of visualising the raw data and then 
running the training algorithm, calculating where clusters are and making 
genotyping calls for individual samples. The Golden Gate assay is automated 
through the use of Tecan robots (Tecan 2006) controlling liquid handling and also a 
Laboratory Information Management System which controls sample tracking. Each 
sample is tracked real time and facilities for file and data management are also 
provided. 
Figure 5.2.1 b A explanation of the processes in the Sanger Institute 
Pharmacogenomics workflow (see Figure S.2.1a on p.127). 
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5.3 Findings 
The need to concentrate on primer design and DNA preparation standardisation 
was established early on in the case study. It was apparent that many of the 
processes in the experimental workflow (e.g. ex on resequencing and Illumina 
genotyping) were already well standardised (see Figure 5.2.1a on p.127 and Figure 
5.2.1 b on pp.128-131). 
5.3.1 Attitudes to standards for Primer Design 
A limitation of this case study was that the findings were based on the opinions of a 
restricted number of scientists. However all those interviewed agreed that a 
standard set of guidelines for primer design would be useful. For example one 
scientist during an interview said: 
It would be useful. Its sort of what were trying to establish ... is what the protocol 
that we're going to use is. So at the moment there are two or three of us doing it. 
But when there are more of us doing it, that there is a set of guidelines to follow. 
So, yes it is useful. 2 
5.3.2 A decision making tree for Primer Design 
From the data collected through semi-structured interviews, observation, studying 
of peR protocols (Delidow et aI., 1993), and reviewing the field notes it was 
possible to develop a decision making tree for primer design specifically for the 
exon resequencing project (see Figure 5.3.2a on p.134). Further details regarding 
information needed before primer design for exon resequencing can be carried out 
2 Interview with a scientist involved in the development of primers for exon resequencing. 
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and problems and solutions when peR products fail are contained in an MIAME 
influenced set of guidelines (Brazma et aI., 2001) (see Figure 5.3.2b on p.135-137). 
Both the content of Figure 5.3.2a and Figure 5.3.2b, are works in progress and 
should not be considered as exhaustive. The information provided in the guidelines 
would enable other scientists to reproduce each step of primer design and is 
especially important if primers are to be designed manually or for scientists new to 
the primer design process. The information available to a scientist before designing 
primers will influence which parameters are used in a primer design program (see 
Section 5.3.3 on p.l36) .. 
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Some primers fail PCR for no 
discernible reason 
Minimum 
information 
about 
sequence 
Problem 1 
Primer Design 
\ r-----L---' 
Unusual 
Sequence 
/ 
(Unusual base 
composition) 
GC rich region 
Repeat Family 
Standard PCR 
I 
Different 
experimental 
options 
Long Range 
PCR 
NestedPCR 
Figure 5.3.2a An upstream decision making tree for the problem of primer 
design developed for the exon resequencing project. 
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Experimental Design 
• The origin of the sequence (Lace AceDB database) 
• Accession number of exon 
• The sequence of the actual exon 
• The exon co-ordinates 
• The sequence after the first 20 or 30 bases 
• The sequence of the 100 bp outside of the exon 
• The flanking sequences 
• The splice branch consensus sequence 
• Quality ofthe sequence 
Is it a finished sequence? 
Quality Score 
Problems associated with designing primers 
The design of primers has difficulties associated with it such as unusual base 
composition and unusual sequence. Unusual base composition incorporates issues 
including unusual sequences such as GC rich regions. A high GC rich region 
renders the sequence difficult to PCR because of the strong formation of secondary 
structures at the annealing temperature. The points below highlight what measures 
can be taken when such problems are encountered: 
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1. Unusual Base Composition 
GC rich regions 
• Use normal PCR amplifying exons at 60°C, making use of additional 
treatments 
Use ofDMSO (Dimethyl Sulfoxide). 
Use of glycerol. 
Use of 7-deaza dGTP (prevents formation of secondary structures). 
2. Unusual sequences 
Repeat Family (e.g. High copy repeats and Multigene Families) 
• Use Nested PCR 
This is a variant of normal peR, where peR amplification is carried out 
using one set of primers and then some product is retained and re-amplified with an 
internal or "nested" set of primers. The result is increased specificity. 
• Use Long Range PCR 
In the case of there being interspersed repetitive elements it is possible to 
amplify a larger region of the target DNA using Long Range peR which is able to 
amplify regions of 42kb DNA making use of a mixture of two polymerases. One is 
a polymerase enzyme such as Taq and the other is a proofreading enzyme such as 
Pwo. 
3. Primers that fail manual redesign 
• Alternative peR protocols and use of different temperatures. 
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• Exo-start PCR protocol. 
• Carry out at 55 0 C. 
Figure S.3.2b Guidelines for the minimum information needed before 
designing primers for peR in the exon resequencing project. Problems that 
can occur are also stated along with solutions. 
5.3.3 Automated programs for Primer Design 
The more experienced a scientist is at developing primers manually by eye, keeping 
in mind the basic primer rules (see rules below), the more likelihood of developing 
better primers. However, to keep up with demands of current throughput associated 
with biological discovery, automated primer design programs are vital 
bioinformatic tools that enable scientists to produce many more primers than would 
be possible when developing them manually and to develop these much more 
efficiently. Such primer programs can help relieve the burden of carrying out 
difficult calculations for the scientist. Many such tools have been produced for 
different types of studies such as PRIDE for large scale sequencing (Haas et aI., 
1998), to PrimeArray for amplification of genes as required for DNA microarrays 
(Raddatz et aI., 2001). More recently additional tools have been introduced such as 
SNPbox (Weckx et aI., 2004) and Primer Design Assistant (PDA) (Chen et aI., 
2003) which allow multiple target sequences to be queried and the designing of 
multiple primer sets. Despite differences in objectives and throughput, most 
programs have evolved to take into account a core set of parameters: 
Primer length - Specificity is a key for successful PCR reactions along with 
annealing temperatures and these are dependent on the length of the primer. Primer 
lengths of about 17-28 bases in length are recommended. 
Melting Temperature - It is vital that primers added to a PCR reaction have similar 
melting temperatures T m. The preferred TIllS are of 55-80 0 C. If primers are 
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mismatched in tenns of T m then the result will be less efficient amplification or no 
amplification at all in the worst scenario. For accurate calculations of this 
temperature a lot of the primer design programs use the nearest neighbour method 
(Ch en et aI., 2003). 
Primer-primer interactions - Primer-dimer and cross primer interactions need to be 
avoided, as these can show up as false positives in the PCR reaction and give 
misleading results (Burpo 2001). The probability of these interactions can be 
figured out by computing the highest number of neighbouring complementary 
bases (Haas et aI., 1998; Raddatz et aI., 2001). 
GC content - Certain sequences should be avoided. For example it is best to keep 
GC content of the primers to 50-60%. Primers of 20 bases long with a GC content 
of 50% in general will have Tm values of around 56-60 0 C that will provide 
sufficient stability for efficient annealing. If primers have GC content less than 
50% then expanding the primers to beyond 18 bases can help (Abd-Elsalam 
2003b). 
3' end of primers - Having a "G" or a "C" at the 3' end of the PCR primers is 
desirable as this GC clamp helps to ensure correct binding at the 3' end because of 
the strong hydrogen bonding of GC residues, resulting in efficiency of the PCR 
(Burpo 2001). 
5.3.4 The standardisation of DNA concentrations 
It is important that if high throughput genomics technologies such as genotyping 
are to produce consistent results then the amount of DNA template used, as input is 
the same across each sample. It is common that final DNA product isolated from 
various biological samples can result in inconsistent yields (Porter 2002). Many 
protocols for DNA extraction exist (Sambrook et aI., 1989) and people often carry 
out this process according to experience and how they did it previously. Such DNA 
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needs to be nonnalised in order to get it into a constant concentration. During 
meetings with scientists at the Sanger Institute, they referred to DNA of bad 
quality, which is a sign that protein has not been extracted, making the DNA 
difficult to get into solution and quantitate. DNA in this fonn is particularly 
challenging, as it is viscous. It can be heated or sheared to help transfonn it into a 
condition suitable for quantitation. 
5.4 Summary of the case study 
A case study was carried out of pharmacogenomics research being carried out at 
the Sanger Institute, UK. The Phannacogenomics workflow in use at the Sanger 
Institute is made of two main sections that are SNP discovery by sequencing and 
SNP genotyping. The infonnation flows through the processes that make this 
workflow were studied with regards to types of data that were used, where these 
were stored and how data were used for subsequent steps and analyses. 
With regards to standardisation, two areas were identified for further exploration. 
These were the process of manual primer design, and DNA quantitation including 
how DNA was perceived (see Section 7.2.2 on p.184). Preliminary work was 
carried out using the data collected through infonnal semi-structured interviews, 
into the development of a minimum infonnation standard for manual primer design. 
This minimum content has been captured as part of a wider upstream decision 
making tree for the problem of manual primer design. The tree is a visual aid, 
which highlights problems associated with developing primers, and routes that can 
be taken to solve these, in the context of the exon resequencing project. This 
context dependence is important to make explicit, as primers designed for peR for 
other study types would require different minimum infonnation. It is hoped that the 
decision making tree will be extended by more branches capturing the infonnation 
needed for primer design in other laboratories for different biological study types. 
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Chapter Six: Case Study Two - Use of Genetic Data 
in the Pharmaceutical Industry 
6.1 Introduction 
The background to this case study is the pharmaceutical industry who continues to 
search for new strategies to bring drug development costs down, while increasing 
productivity, decreasing the time taken to develop drugs and also increase the 
number of drugs that receive marketing approval (Essioux et aI., 2002 pp.72-73). 
This is not surprising considering the current cycle of developing a drug, with 
hundreds of millions of dollars being required per market drug; a process that not 
only is costly but uncertain and time consuming where the drug development 
process itself can take up to a decade (See Figure 6.1 on. p.141). This cost actually 
varies depending on the type of drug being developed. For example an estimated 
$479 million is required to develop an HN drug while the development of a 
rheumatoid arthritis drug can cost up to $936 million (Adams & Brantner 2004). 
These variations in cost are dependent on the nature of the disease being targeted 
for therapeutic intervention, the type of drug being developed for the disease and 
the size and scope of the clinical trials needed for regulatory approval (Sweeny 
2002). The basic Drug Discovery and Development cycle is made up of a number 
of processes (See Figure 6.1 on p.141) that are highly complex and versatile in 
terms of their data content. These components and their brief descriptions are as 
follows: 
• Target Identification - identification of biological drug targets that play 
roles in disease. 
• Hit Identification - High Throughput Screening to identify compounds 
that display confirmed activity against the target. 
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• Lead Identification - conversion of hits into lead series. 
• Lead Optimisation - process of optimising compounds from several lead 
series according to pre-set criteria, resulting in a few pre-candidate drugs. 
• Candidate Drug Prenomination - candidate drug evaluated in terms of 
safety, method of administration and bioavailability. 
• Principle Testing - demonstration of the desired biological effect in man 
(normally patients). 
• Concept Testing - Demonstration of clinical linkage between the putative 
target and disease endpoint and outcome in one or more human diseases. 
• Development for Launch - Clinical studies in patients to confirm safety 
and efficacy for regulatory approval. 
• Launch Phase - All data from all the pre-clinical and clinical studies are 
collated and submitted for review to regulatory authorities. 
• Product Maintenance and Life Cycle Management - Phase IV trials used 
to evaluate long-term effects and health economics issues. 
< __ D_eve_lopm_ent ___ > 
D;scovery >-
Z>L>B~E>~~B2§ 
Genetics in support of 
Discovery 
< Pharmacogenetics :> 
Figure 6.1 The processes involved in the drug discovery and development 
cycle and the areas where genetics research can make an impact. 
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Many of the drugs prescribed for common diseases are limited by a lack of 
understanding of the molecular basis of disease and action of a drug. An 
improvement of this situation will require a greater understanding of the inter-
individual differences in the mechanisms of disease and drug response. The 
integration of genetics research into drug discovery and development can enhance 
knowledge of inherited predispositions and susceptibilities to disease and responses 
to drugs. This in turn can lead to the development of specific therapeutics and 
diagnostic tools to further progress health care (Lindpainter 2001). 
6.1.1 The Impact of Genetics on Drug Discovery and Development 
Research into genetics can be used during drug discovery and development (see 
Figure 6.1 on p.141). 
Genetics in Discovery 
During target validation, genetic association studies can be carried out on candidate 
drug targets. Drug targets can be obtained through the use of genomic technologies, 
the literature or other in-house research. The potential drug targets are then 
screened to search for common polymorphisms, which are then genotyped. The 
DNA samples genotyped are usually taken from similar populations of people with 
and without the disease. The primary objective of carrying out such studies is to 
determine any statistical significance between the presence of particular sequence 
variations and incidence of disease. 
142 
Chapter Six Case Study Two - Use of Genetic Data in the Pharmaceutical Industry 
Genetics in Development 
Pharmacogenetics, which is defined as the study of how genetic variation among 
individuals affect drug response could be used during drug development. For 
example in Phase I clinical trials it is possible to evaluate DNA samples from 
subjects and help explain issues to do with drug metabolism. In Phase 11 where up 
to 200-300 patients maybe treated, genetics can be used to gain a deeper insight 
into the drug's mechanism of action. Phase III involves testing the efficacy and 
safety of the drug in up to thousands of patients and can take many years. 
Pharmacogenetic data generated during this phase can enable scientists to 
determine polymorphisms that play a role in the effectiveness of a drug m 
individual patients (Essioux et aI., 2002, p.73). 
The purpose of this project is to study in detail the impact of genetics research on 
the drug discovery and development process. Attention will be given to genetic 
data (and their associated data types) management from generation of data, their 
storage and organisation, through to subsequent analysis and interpretation. These 
data related issues, will be explored by taking a case study approach, focusing on a 
genetics department in a leading pharmaceutical company. The findings of the 
study will give an overview of a genetics department in a pharmaceutical company 
and the ways in which scientists handle and store data. From these issues 
recommendations will be provided, stating any improvements, which could be 
made through the use of advanced information technologies. An outline of the 
situation in the next two years will also be given highlighting any changes that are 
recommended in terms of data storage and processing. 
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6.1.2 Learning objectives for the case study 
Learning objectives for this case study emerged from discussion between the 
author, the supervisor and the client. They can be captured as follows: 
13. To uncover the objectives ofthe different research and development teams. 
14. To determine the different scientific workflows used by each team and 
establish any similarities and differences between these. 
15. To establish the different types of data used by each team and their sizes. 
16. To determine where these data are stored. 
17. To determine in which formats data are stored. 
18. To establish the types of data that wiWwill not be needed in 2 years time. 
19. To determine any changes that will need to be made in terms of data storage 
solutions and processing methods in the next 2 years. 
20. To determine bioinformatics databases used by each team. 
6.2 Case study set up 
The client chosen was AstraZeneca PLC a leading pharmaceutical company, who 
holds the reputation as being influential in applying Pharmacogenetics research to 
the drug discovery and development cycle. AstraZeneca PLC is a pharmaceutical 
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company supplying first class medicines and health care products around the world. 
58,000 people are employed worldwide who work on various areas of medical 
needs. These include cardiovascular, cancer, central nervous system, 
gastrointestinal, respiratory and inflammation and infection. AstraZeneca UK is a 
major component of AstraZeneca PLC with over 10,000 people employed across 
eight main sites. Manufacturing facilities are catered for at plants in Macclesfield in 
Cheshire and at Avon close to Bristol. These provide cutting edge process research 
and production capabilities. This ensures that products are manufactured in a safe 
and consistent manner and can then be transformed into suitable medicines for 
patients and packaged in a format according to strict regulatory criteria. Sales and 
marketing are based near Luton, while there are two major R&D centres in the UK. 
One is in Charnwood near Loughborough employing 1,200 people. These people 
work on areas including cardiovascular diseases, respiratory disorders and 
inflammation. The other UK R&D site and the focus of this case study is Alderley 
Park in Cheshire where a 2,800 workforce exists. Scientists at Alderley Park focus 
on developing new medicines for cancer, inflammation and cardiovascular diseases 
(AstraZeneca United Kingdom 2005). 
The case study was carried out during the last two weeks of October in 2004 and 
the actual unit of analysis was the R&D Genetics (RDG) department at Alderley 
Park (see the case study action plan in Table 6.2 on p.146). Entry was gained 
through an initial meeting with the client and continual dialogue via e-mail. A two-
week plan consisted of 15 interviews and two informal meetings with senior 
members of RDG. In addition a meeting was held at the end of each day with the 
primary contact, who was debriefed about progress made and offered support and 
advice. 
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Table 6.2 An action plan of the case study. 
Subject Plan 
Time Period Two weeks 
Research instruments Semi-structured interviews (tape-
recorded), meetings (no tape 
recordings), reading relevant documents, 
tours of genotyping facility. 
Respondents Associate Directors of Genetics in 
Target Discovery, Genetics Supporting 
Projects and Pharmacogenetics. 
Project leaders working in these three 
main genetics areas. 
Results Collect data to establish any problems in 
current data management strategies of 
the client and to suggest and recommend 
improvements and solutions for the 
present situation and in two years time. 
6.3 Findings 
The findings in this section are based on the analysis of scientist's responses to the 
basic questions asked and also through reviewing of the field notes a number of 
times (See Section 3.3.2.1 on p.90). The main title headings in this section have 
been derived from the theme names and their definitions, and subsection headings 
are based on the names of categories that were used during data analysis (Thomas 
2003). 
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6.3.1 The objectives of the teams 
The organisational structure of RDG is split into three main sections: Genetics in 
Target Discovery, Pharmacogenetics and Genetics Supporting Projects (see Figure 
6.3.1 below). 
Discovery 
Objectives 
Figure 6.3.1 The theme RDG Objectives and its associated categories. 
Genetics in Target Discovery 
Geneticists working in Target Discovery were mainly trying to identify new genes 
involved in disease processes. One scientist working in this area during an 
interview said the following: 
So we're trying to identify novel genes or to take genes where there's already some 
biological rationale or previous evidence and link them to a disease process ... so 
that they can hopefully become a target to fuel into the drug discovery pipeline. 3 
3 Interview with a Genetics in Target Discovery project leader. 
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Such research involved the use of linkage analyses, linkage disequilibrium (LD) 
mapping, and genetic association studies and relied heavily on a vital genotyping 
service provided by what is known as the Research Genotyping facility. 
Pharmacogenetics Projects 
These projects involved geneticists applying their expertise to drug development 
projects. As one scientist described in more detail: 
In Pharmacogenetics ... so that's any kind of genetic analysis that we might be able 
to carry out that could help explain adverse drug reactions or safety issues or 
variations in (untranscribable) PK. 4 
Particular therapeutic areas (TA) in which studies were focused upon included 
oncology and respiratory disorders. Due to the nature of work carried out in drug 
development, it is vital that an appropriate infrastructure is in place, and 
Pharmacogenetics scientists must ensure that all the relevant rules and regulations 
are adhered to. A Pharmacogenetics project leader described this as: 
So that we have all the appropriate paper work, all the procedures because 
working in a strictly development side of things there are certain rules and 
regulations that are necessary for the type of work that we carry out to 
support ... activities in drug development. 5 
Genetics Supporting Projects 
These projects had geneticists working on them who would support both Target 
Discovery and Pharmacogenetics projects. A scientist supporting both discovery 
and development described the objectives ofthe project that he was overseeing: 
4 Interview with a Pharmacogenetics project leader. 
5 Ibid. 
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Ok, so the principle objective is to work with the project's capabilities to ensure 
they've got the most appropriate technologies and platforms to perform their work. 
Keeping abreast of the market, technologies that are under development or come 
into market or are being marketed, which might be superior to the ones, we operate 
here. Making the case for evaluating new approaches or running a pilot with them 
perhaps or (untranscribable) exercises if there's a case to change. 6 
Further sequencing research can be carried out during lead optimisation (see Figure 
6.1 on p.141) as the target progresses further through discovery. Other projects 
involve studying the effects of polymorphisms in terms of function (see Section 
6.3.9.1 on p.170). Such polymorphisms can potentially have pharmacodynamic 
effects, which may be seen during early development (See Figure 6.1 on p.141). 
Other teams were service orientated and provided technology platform evaluations 
such as the Technology Development Group and the Clinical Genotyping Group 
(eGG) who would provide DNA sample storage facilities and carry out genotyping 
for Pharmacogenetics projects. A scientist working in CGC described his team's 
objectives: 
There are really two workjlows. There is sample processing. So for every genetic 
sample that is collected in a clinical trial we extract the DNA and store it in an 
automated DNA archive downstairs. So that's probably over half the work we do in 
fact. Then the other half is when we need to generate this genetic data we will 
perform those analyses and that can be for inclusion/exclusion from a Phase I 
trial ... a small trial, basically taking safety information. The majority of the work is 
at that level but goingforward ... it could be more samples, more SNPs ... 7 
6 Interview with a Genetics Supporting Project project leader. 
7 Interview with a Genetics Supporting Project project leader. 
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6.3.2 Scientific workflows 
The majority of work carried out within RDG was based around genotyping of 
SNPs in DNA samples and this resulted in an extensive sharing of scientific 
workflows (see Figure 6.3.2 on p.152). Methodologies and technologies used were 
very much the same but utilised for different purposes depending on whether the 
project was supporting discovery or development. These differences were normally 
found in study design. An example of this could be in the number of samples used, 
with fewer samples being used when studying an adverse drug reaction compared 
to that needed in discovery where the focus would be on population based research 
and the processes occurring in a complex disease. Other differences could also be 
on how SNPs are selected and this could include criteria for the inclusion/exclusion 
of exons, for example if promoter sequences or other regulatory regions were also 
to be studied in addition to coding regions. As one scientist from Target Discovery 
put it: 
It's more I guess ... methodologies, technologies. That's shared very much right 
across the department. Because basically we're all working on SNP genotyping for 
the most part in DNA samples and whether you're doing that to support discovery 
or development projects. The technologies underpinning that and the way we'd use 
them is the same. The fundamentals of the statistical analysis are basically the 
same. And obviously whether its development or discovery you might have subtle 
things that you want to do different and the analysis (untranscribable). So from that 
point of view share workjlows quite a lot from that sort of technological, 
methodological basis. In terms of then study design and things like that and how we 
actually process them they do differ. But it's more numbers and how we do it as 
opposed to there being fundamental differences. So essentially it's very similar. So 
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in terms of·.ifsomeone's studying an adverse drug event then the numbers we need 
to have in the study is different to something from discovery where you're working 
on a complex disease and trying to define what's going on there. But fundamentally 
the way that we approach it is very, very similar. 8 
A similar view was taken from a project leader working at the other end of the 
spectrum in Pharmacogenetics: 
I think by and large we tend to have very similar workjlows. Different teams may 
have a slightly different strategy in terms of the number of samples or how they 
select their SNPs, i.e. do they want things just in exons or do they want exons and 
introns. Do they want them equally spaced or do they want just SNPs that change 
amino acid sequence, do they want to include promoter sequences or regulatory 
regions. So where the workjlow differs I think is related to the objectives of the 
. 9 proJect ... 
8 Interview with a Genetics in Target Discovery project leader. 
9 Interview with a Phannacogenetics project leader. 
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Clinical 
Databases 
e.g. (I) Analysis 
tool 
(2) Type of 
conversion 
Gene Catalogue 
Hardware/ 
Software 
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study type, type of 
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needs and size, SNP's, 
disease, drug 
e.g. (1) DNA 
Archive 
(2) Taqman for 
research and clinical 
genotyping and also 
database searches 
e.g. (I) Raw genotypes 
(2) Sample ID, 
volume, 
concentration 
Figure 6.3.2 A generalised genotyping experimental workflow carried out in 
RDG which is applicable to both Target Discovery and Pharmacogenetics 
projects. 
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6.3.3 Use of hardware for data generation 
The main types of hardware platforms used were those for generating sequence 
data, genotyping data and sample data (see Figure 6.3.3 below). 
Figure 6.3.3 The theme Hardware and its associated categories. 
Sequencing Data Hardware 
The sequence data utilised within RDG was produced using two main platforms. 
The bulk of the sequencing data was generated using Applied Biosystems (ABI) 
3730 Sequencers (Applied Biosystems 2005) in a high throughput fashion. Lower 
throughput sequencing data was also produced, using another capillary 
electrophoresis system by Beckman Coulter (Beckman Coulter [n.d.]) but the 
resulting sequences were not used within the department. 
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Genotyping Data Hardware 
The Applied Biosystems Taqman technology was used to generate genotyping data 
to support both discovery and development projects (Applied Biosystems 2005). 
Sample Data Hardware 
The Clinical Genotyping Group managed the DNA Archive, which is a robotic 
storage and retrieval system that stored extracted DNA samples under Good 
Laboratory Practice (GLP) conditions. Two components make up the DNA 
Archive, and these are known as the Automated DNA Archive and Manual 
Archive. Multiple tubes per each sample can be stored in the Automated DNA 
Archive with at least one back up being deposited in the Manual Archive. During 
an interview a scientist described data flow through the DNA Archive and 
associated genotyping Laboratory Information Management System (LIMS): 
You're moving DNA samples and things like that. But it will feed data back into the 
LIMS. So its taking say 10 microlitres out of a particular tube, although the LIMS 
has told that it wanted to do that it will feed back to say that its done it. So it will 
feed data back ... but obviously ... its not complex data. Its just really saying ... this is 
what the LIMS will tell it. This is what we want you to do. And it will confirm that 
it's done it. So the DART is actually connected to the AstraZeneca network. It's a 
separate little network on its own. And it just communicates via a secure link. Its 
like shared database tables. So it will feedback basic information about the tubes 
and what it's taken. So we have a series of computers that controls DART. And I 
couldn't even begin to explain .. .1 think, there's about, 9 computers. 10 
10 Interview with a Genetics Supporting Project project leader. 
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6.3.4 Types of data used at present 
The main types of data used by teams within RDG were gene data, genotyping 
data, phenotype data, sequence data, sample data and analysis results (see Figure 
6.3.4 below). See Table 6.3.5 on p.162 for a more comprehensive list of types of 
data used within the department and where these data are stored. Types of data are 
defined as: 
Gene Data: This type of data, are primarily graphical and textual. 
Sequence data: Sequence data are usually in binary format and text format. 
Genotype data: Genotype data are usually found in binary format. 
Phenotype data: These data are represented as numbers, free text and encoded 
data. 
Sample data: These data are represented as numbers and free text. 
Analysis results: These data are represented as numbers and free text. 
C~e~ 
---...:::------
Data 
Figure 6.3.4 The theme Data Type and its associated categories. 
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Gelle data 
If studies on genes of biomedical interest are to be effective, it is vital that scientists 
have all available information on those genes. A key type of data used by scientists 
working in RDG were gene data. Specific types associated with gene data include 
DNA sequence maps, genetic variation data such as SNPs and other types of 
polymorphisms including micro satellites. Additional data to be included in this 
category include annotation data such as details on exons, introns, regulatory 
regions etc. One scientist described the importance of gene map data: 
I guess the thing that we use now and will always need to use in the future is data 
about a particular region for a gene in terms of a physical map of what that gene 
looks like. I I 
Gellotypillg Data 
Genotyping data was a key data type used by scientists working in Target 
Discovery and Pharmacogenetics. For example a scientist during an interview said: 
And we have at the moment two types of genotyping data. One is what we call GLP 
genotyping data. So it's the type of data that might go into regulatory approvals. 12 
This type of clinical genotyping data would be generated by the Clinical 
Genotyping Group (CGG) who played a genetics supporting role by genotyping 
clinical samples for Pharmacogenetics project teams. The other type was research 
genotyping data that was utilised by teams in Target Discovery and generated by 
the Research Genotyping facility. 
11 Interview with a Genetics in Target Discovery project leader. 
12 Interview with the Associate Director of Pharmacogenetics. 
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Phenotype Data 
Data in this category included phenotypic data from Target Discovery projects and 
clinical trials data from Pharmacogenetics projects. A scientist described the 
former simpler type as: So it's really just age, sex, disease status, age of onset of 
particular diseases. So that's phenotype data. 13 Another scientist described clinical 
data as: 
pharmacokinetic, pharmacodynamic safety data. So any kind of measurements that 
are generated ... any clinical measurements that are generated by the study teams is 
the data we try and correlate with the genetic variability. 14 
Sequence Data 
Sequence data are generated through sequencmg of genes to identify 
polymorphisms. Such sequencing is carried out during Target Discovery. More 
sequence data are generated and utilised by project teams that support Target 
Discovery research. A project leader for a Genetics Supporting Project described 
his team's sequencing activities and their impact on discovery projects: 
And so what we do is identify the most common sequence version of that target 
(untranscribable) sequence analysis of genomic DNA. So we would provide that 
information to the project teams so that they are able to make sure the clone 
they're using to actually go into the high throughput screen is actually the most 
common variant of it. Just in case on the off chance they've got a rare amino acid 
change in a polymorphism within their clone that may affect the reaction between 
the chemical entities. So we do that work at pre MS 1 and for the high throughput 
screen. 15 
13 Interview with a Genetics in Target Discovery project leader. 
14 Interview with a Pharmacogenetics project leader. 
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Sample Data 
The data handled by eGG included samples from clinical trials (which can also be 
used for discovery projects), information on studies carried out in the past, and 
genotyping data requested by the Pharmacogenetics teams. A scientist from eGG 
said the following about sample data: 
Probably not a huge amount at all. We're very low level compared with a lot of 
other teams. A lot of the information we might want to get is information that is in 
the LIMS. So sample data to find out that .. for QC purposes to make sure that 
everything is running properly, how many samples have come out, how many times 
samples have been accessed ... those sort of information. So most of the data about 
the samples ... 16 
Analysis results 
The generation of data from statistical analyses and its storage was an issue for 
concern in RDG: 
So the last stage of this as well is that you've got hold of this raw data and raw 
data is exactly what it is and it has to be analysed. So for each raw data point we 
generate an output and the output is the link between the polymorphism and the 
disease. So there is lots of (untranscribable) analysis. So for each polymorphism 
that we might study we get SNP disease association data. 17 
IS Interview with a Genetics Supporting Project project leader. 
16 Interview with a Genetics Supporting Project project leader. 
17 Interview with the Associate Director of Genetics in Target Discovery. 
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6.3.5 Data Storage 
Data used by scientists in RDG were stored mainly in local resources and 
proprietary databases (see Figure 6.3.5 below and Table 6.3.5 on p.162). 
Figure 6.3.5 The theme Data Storage and its associated categories. 
Genotyping Data Storage 
The resulting genotypes generated by Research Genotyping were fed back to 
projects in discovery and stored in MS Access databases, alongside simple 
phenotype data. In addition Excel spreadsheets were also used to store these data 
sets. While Access databases for each project are set up within a shared drive, 
individual scientists may have their own additional standalone Access databases 
and these are not generally standardised. The Associate Director for Genetics in 
Target Discovery described these resources: 
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So most of the raw genotyping data are put into an Access database. And the 
Access database really serves right now as a repository for our raw genotyping 
data. And we have different Access databases for different diseases, which is the 
way in which we are to bring some order and organisation to this process. 18 
Similarly the genotyping data generated for Pharmacogenetics projects by eGG 
would be downloaded into Access databases. The content of these would be 
slightly different as Pharmacogenetics projects are concerned with clinical trial 
samples rather than case-control samples as in discovery. 
Sequence data storage 
The data from gene sequencing were stored as flat files on a storage area network 
(SAN). Both high throughput and low throughput sequence data were stored on this 
network. A scientist described the transfer of data from sequencing machines to 
local resources: 
So its generated on sequencing machines that are then manually transferred onto 
project storage areas, which are then manually transferred into individuals' own 
files in a Unix based system for analysis. 19 
Clinical data storage 
The clinical trial data needed for Pharmacogenetics studies would be extracted 
from separate clinical databases such as AMOS which is implemented in Oracle 
Clinical (Oracle 2002): And individuals' data are kept in AMOS which is the drug 
development database ... clinical database. It's a highly regulated databasio. These 
data are provided by clinical development teams and stored in RDG in Excel 
spreadsheets and Access tables. 
18 Ibid. 
19 Interview with a Genetics Supporting Project project leader 
20 Interview with the Associate Director ofPhannacogenetics. 
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Examples of clinical data that may be correlated with genetic data included 
pharmacokinetic parameters that again could be found in Excel spreadsheets. 
Pharmacokinetic profiles can be used primarily to assess safety and efficacy (Kurth 
2003). Clinical data in RDG was also stored as Statistical Analysis Software (SAS) 
files (SAS 2006). In addition to clinical parameters such as pharmacokinetics, and 
pharmacodynamic responses, demographic variables and magnetic resonance 
images (MRJ) were also being used within Pharmacogenetics projects as 
phenotype data sets. 
Sample data storage 
Samples used for projects within RDG were deposited using the genotyping LIMS 
into the DNA Archive (see Section 6.3.3 on p.153). The genotyping LIMS is a 
LabVantage Laboratory Information Management System (LabVantage 2004) used 
to track GLP standard samples through processing and extraction. Specific 
parameters associated with samples that were handled by the LIMS include 
metadata such as how the DNA was prepared, and its volumes and concentrations 
etc. Clinical genotyping is carried out according to GLP standards, which mean 
these data are ready for regulatory submission if required. Teams in RDG could 
access the LIMS, pulling out information as reports although the number of people 
that had access rights was limited. The LIMS, capable of holding terabytes of data 
is implemented in Oracle and also acts as an interface to the DNA archive. Samples 
can be entered and tracked in the LIMS real time using workflows. As a temporary 
measure while the LIMS is being implemented, the data produced by CGG is 
actually stored on paper-based records (sometimes in Excel files) at present. This 
genotyping data will be stored in the Genotyping LIMS from early 2005. The LIMS 
is also in the process of being extended to track samples for Research Genotyping. 
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Table 6.3.5 Teams in RDG and the types of data used and the storage of these. 
RDGTeam Types of data used Data Storage 
Genetics in Target Discovery Gene data (DNA sequence Biological databases (Gene 
maps, SNPs and other Catalogue), graphical files 
polymorphisms, functional 
units) 
Sequencing data Server on SAN 
Raw Genotype data Access and Excel 
Phenotypic data Access and Excel 
(patient/subject description, 
including clinical and 
demographic variables) 
Analysis results Excel 
Pharmacogenetics Genotype data Access 
Phenotype data Access and Excel 
(patient/subject description, 
including clinical and 
demographic variables) 
Clinical trial data Clinical databases (e.g. 
AMOS), Excel, CSV files, 
SAS 
Genetics Supporting Projects Gene data ( DNA sequence Biological databases (Gene 
maps, SNPs and other Catalogue), graphical files 
polymorphisms, functional 
units) 
Sequence data Server on SAN 
Genotyping data Access and Genotyping LIMS 
DNA samples DNA Archive and 
Genotyping LIMS 
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6.3.6 Data processing and analysis 
Raw data would undergo specific processing actions and then be analysed using 
certain analysis programs. 
Genetic data processing 
In Access databases and Excel spreadsheets, data on SNPs were represented in 
binary code such as 1_1, 1_1, and 1_2, owing to their biallelic nature. This 
illustrates only one way to represent genotype in binary code. It was common for 
geneticists to use slight variations to this depending on the format requirements of 
the subsequent statistical analysis packages to be used. A common theme from 
scientists working on Genetics in Target Discovery projects, Genetics Supporting 
Projects supporting discovery, and Pharmacogenetics projects was the carrying out 
of manual re-formatting of genetic data which could involve for example the 
transfer of an Excel file into Access tables or to transform data into a format 
suitable for analysis packages. This was something that scientists had learnt to cope 
with but viewed it as a problematic step with such manual processing being 
susceptible to cutting and pasting errors. In addition there was potential for 
problems with analysis to occur if correct re-formatting had not been carried out. 
Having said this, these tasks were considered easy to do as one scientist put it: 
It's actually quite easy to do. But it is tedious. And also of course once you start 
extracting raw data and you do things to it so the opportunity for introducing 
errors for converting all the 1 's into 2 's etc and vice versa arises. So, obviously the 
less manipulation, the better. But I would say it's not overly burdensome right 
21 
now. 
21 Interview with the Associate Director of Genetics in Target Discovery. 
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More specific examples of such processing were the selecting of relevant datasets 
from the many clinical sets provided or the annotation of sample IDs with 
haplotype pair information. The situation however, was improving, with 
informatics experts developing scripts for scientists that would re-format data 
automatically and research was also being carried into new methods of analysis that 
would side step these tedious tasks, making the process more seamless. Examples 
of analyses that were carried out included Hardy Weinberg Equilibrium (HWE) 
tests to identify any genotyping errors (Hosking et aI., 2004) and working out odds 
ratios and confidence intervals for each SNP. Such analysis techniques could be 
carried out quite straightforwardly in Excel. 
Manipulation o/Clinical data 
Clinical data management within AZ was overseen by the Clinical Information 
Management group (Cl G), and part of their work was to represent clinical 
phenotypes in a standard manner. For example, codes would be attached to free 
text, so when placed in databases, the differences between free text was limited. 
Internal AZ clinical ontologies would be used with appropriate mappings to those 
vocabularies found externally. Data from clinical trials databases needed for 
Pharmacogenetics projects were downloaded as CSV files. At the time this case 
study was carried out, clinical data for each study, were held in separate CSV 
folders and the statistical genetic analysis would be carried out for each study at a 
time. 
An important package for the analysis of clinical data is SAS/Genetics (SAS 2006), 
which also acts as a storage medium for clinical data. Although difficult to use and 
requiring much re-formatting, it is able to store huge amounts of clinical data. 
When Pharmacogenetics project teams received genotyping data from Research 
Genotyping or CGG, members of the Statistical Genetics team are able to analyse 
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the data using SAS/Genetics. The Statistical Genetics team would carry out a 
number of manipulations on the data. For example in a project, demographic 
variables may be of interest and these would be subset into another file and then 
merged with the genetic data, each variable being represented as a separate column. 
Statistical Genetics Group for key support 
The Statistical Genetics Group provided vital support to the whole of genetics 
throughout discovery and development. This group supports all aspects of data 
management from data generation, to analysis, post analysis and their subsequent 
storage and archiving. Scientists in this group played a key role in statistical 
analysis by providing methods by which to correlate genetic data with phenotypes 
such as disease in case-control studies and clinical trial data from clinical studies. 
6.3.7 Form of data most useful 
Data in their raw format was stated with the highest frequency as being of most use 
(See Figure 6.3.6 below). 
Figure 6.3.6 The theme Data Format and its associated categories. 
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Raw data 
In general most scientists stated that raw data was most useful as you can carry out 
any manipulation you like on them. A quote from an interview with a 
Pharmacogenetics project leader was as follows: So it's obviously ... best form of 
any data is raw data because then you can do anything you like. 22 Sequence data as 
raw traces however, were considered to be meaningless unless they had undergone 
some processing, enabling scientists to understand the variability in genes. 
However the sequencing machines (see Section 6.3.3 on p.153) had no mechanism 
for automated batch processing and this would have to be done locally by the 
scientist. It was agreed that adding additional information to the annotated genome 
databases (such as Gene Catalogue) resulted in a richer source of information. 
6.3.8 Size of data at present and in two years 
Estimates of data being generated and used at present and in two years were given 
for sequence data, sample data, clinical data and genotyping data. 
Sequence Data Size 
Estimates of sequence data were obtained in terms of file size from those working 
on Genetics Supporting Projects supporting Target Discovery. The size of a file 
containing sequence traces at the time of this study was 15.4 megabytes and about 
60 of these were being created in a week, which totalled to 924 megabytes of data 
generated in a week. The amount of sequencing data generated within the 
department was not expected to remain constant and would grow although not 
dramatically. There were also predictions of less sequencing having to be carried 
22 Interview with a Pharmacogenetics project leader. 
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out within the department as more data becomes available in the public domain. 
This statement is supported in the following quote: 
It will increase because we will obviously be doing new projects so several new 
demands coming through. So ok in theory it won't double. The amount of work will 
partly depend on new targets coming through. So that's a growth side of it. But 
more and more information is becoming available in the public domain. And we 
are finding now that at some point ... the hit rate in the public domain is going to be 
such that we're going to be saying we don't need to be doing this work. So it might 
well increase for a little while but as we get an increase in other applications ... 23 
Another scientist working on Genetics Supporting Projects reiterated such an 
opmIOn m a response: 
I would say fairly constant. So one of the points I talked about earlier on ... as time 
goes by more and more information is available in the public domain. So there may 
come a point within a couple of year's time, where some of the core work which we 
are doing now, we just don't need to do. You can just align sequences; you can take 
data from the various databases. So that would actually see the amount of work 
that we do decrease.24 
Genotyping Data Size 
Some genotyping projects were small in scale and others were larger studies, which 
reflected the size of data being used. For example, a smaller study was described by 
a scientist working in Target Discovery as: so we're talking about 2-3000 
individuals generating genotype data from 500-1000 SNPS. 25 In contrast to this a 
scientist in Pharmacogenetics described a typical Phase 1 clinical trials study as: 
23 Inteview with the Associate Director of Genetics Supporting Projects. 
24 Interview with a Genetics Supporting Projects project leader. 
25 Interview with a Genetics in Target Discovery project leader. 
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You only have very few people and its mostly pharmacokinetics so we know the 
drug metabolising enzymes. Drug metabolising enzymes generally have one or two 
SNPs and all them are going to affect function. 26 
This difference between the sizes of the genotyping projects makes sense. The first 
scientist was talking about research genotyping that is carried out on a much larger 
scale than the clinical genotyping required for Pharmacogenetics projects. 
Although the amount of genotype data will increase over the next few years, (see 
whole genome association in Section 6.3.9.1 on p.170) a drastic increase is not 
expected to be witnessed in RDG within the next two years. At present the 
Research Genotyping facility is producing around 5 million genotypes, and this will 
increase, but only by about 20%. Larger projects, including not only large numbers 
of SNPs but also large numbers of samples are likely to be outsourced, and the data 
generated from these may not be brought in internally in the next two years. 
Clinical genotyping was carried out on a much smaller scale with CGG currently 
generating about 20-30,000 genotypes a year and it was predicted that a 20% 
increase might also be seen in the number of genotypes of clinical trial significance. 
Clinical data size 
The average size of clinical data from a Phase III study would take up many 
megabytes of file space. Pharmacogenetics scientists predicted that the clinical data 
that they deal with would increase but not rapidly. The basic data types such as 
clinical response parameters would remain the same but further detail could be 
added. Greater need for biological understanding (which was still lacking) and 
economics influenced these opinions. On the one hand more understanding of 
disease processes would mean better-defined phenotypes, which could increase the 
26 Inteview with a Pharmacogenetics project leader. 
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amount of data being collected. On the other hand the industry was following a 
trend to streamline clinical trials where to keep costs down and increase efficiency, 
the amount of clinical data being collected was kept to a minimum for regulatory 
purposes. 
6.3.9 Data requirements in the next two years 
Most scientists agreed that there was not any data that were used at present, which 
would not need to be accessed in two years time. 
Genotyping data and Gene data 
Scientists working in RDG would still need access to raw genotyping data in the 
next two years as it was likely that these data would need to be withdrawn from 
databases to be re-analysed. Genotyping data would also be needed to support 
questions from teams outside RDG. In addition to raw data, analysed data would 
also need to be accessed. This could include more data on linkage disequilibrium 
for example. Data on gene annotation (which are one of the most critical data 
needed at present) such as physical maps of genes, providing scientists with 
information as to the location of exons, protein coding regions, SNPs, 
micro satellites etc would need continuous access. In addition detailed phenotypic 
data on genetic samples will be needed to enable whole genome association studies. 
Clinical data 
Scientists in both Target Discovery and Pharmacogenetics said they would like 
more access to clinical data, particularly as statistical analysis methods become 
more sophisticated. In addition more samples may be collected during clinical 
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trials, particularly as more interest in genetics supporting Phase III studies 
increases. These samples could also be used in a retrospective manner for discovery 
purposes. A scientist from Genetics in Target Discovery described how more 
clinical data could be used for research in this area: 
You could see if we're to start using that clinical trial material for discovery 
purposes that you would have a much more extensive (untranscribable) of 
phenotype or end phenotype data associated with that which you obviously have to 
store. 27 
6.3.9.1 Additional data types 
The data types below are a synthesis of opinions from scientists spanning the whole 
ofRDG: 
• Functional genetics data 
• Pathway data 
• Biomarkers 
• Better defined phenotypes 
• Better defined clinical outcomes 
It was the view of scientists spanning the whole of RDG that data on functional 
genetics would need to be accessed in the next two years. A pilot project in this 
area had been started, which would have progressed within the next couple of 
years. This Functional Genetics project studies an additional level of biological 
complexity using information about heritable inter-individual differences such as 
SNPs and their effects on gene regulation and hence disease phenotype. One 
scientist described the usefulness of this type of data: 
27 Interview with a Genetics in Target Discovery project leader. 
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I think linking in functional genetic data could be very powerful if there's an 
opportunity. Because more and more people are getting interested and there's an 
internal effort to look at that. It's very difficult. There's often artificial systems used 
that ... who knows what the relevance is. But there's a move in the industry and 
externally around this idea of translational science to make sure that we try and 
move things from the in vitro to the in vivo in man where we can. So it's likely that 
although functional stuffwill start off like in the lab ... doing in vitro stuff and then 
animal stuff where we can do that. It would be great if when things start to pop up 
around the functional relevance in man like the disease situation or whatever, we 
can capture that because that's what is really important. It's not really the genetic 
variation that's important. It's what it means. 28 
The functional consequences of such polymorphisms would probably be displayed 
in relation to biological pathways and more access to these network data types 
would be required. For instance teams may become increasingly interested in 
studying the role played by certain combinations of polymorphisms in genes and as 
one scientist put it: 
Like gene-gene interactions, gene-environment interactions, whether if you look at 
a region are there multiple genes contributing to a disease rather than one gene. 29 
In terms of new clinical data, imaging was becoming an important tool for drug 
development projects and it was predicted that MRI images in the next two years 
will continue to be used more as a phenotype, acting as a biomarker to correlate 
with genetic data partiCUlarly in tumour studies. Biomarkers can be used to study 
all aspects of a disease from its diagnosis, staging, prognosis and then monitoring 
28 Interview with a Pharmacogenetics project leader. 
29 Interview with a Genetics in Target Discovery project leader. 
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(Ilyin et aI., 2004). These MRI images can take up large amounts of disk space and 
memory and were stored by clinical study teams. It was not expected that these 
images would be utilised locally within RDG. 
Whole Genome Association 
Whole genome association studies make possible the carrymg out of genetic 
association analysis across the genome using a dense map of SNPs in a hypothesis-
free fashion (Carlson et aI., 2004). Using such an approach it will be possible to 
identify the majority of alleles that are contributing to a phenotype under study. 
Specific applications of whole genome association studies include the identification 
of genes that underlie complex diseases, and the discovery of genetic profiles that 
may help predict toxicity and efficacy of treatment (Syvanen 2005). Making use of 
parallel genotyping methods such as DNA arrays, these projects require many 
SNPs and it could be common in the next two years to see 500,000 SNPs being 
genotyped in a few thousand people. Pilot whole genome association studies have 
already been set up by the client, in which 250,000 SNP's are being genotyped for 
250 people. It is estimated that the data set produced typically from one such study 
could occupy 2-6 Gigabytes of disk space. One scientist raised concerns about data 
management strategies for whole genome association data: 
We really are considering a whole genome approach. And there are some pilot 
studies that have begun to address this. But in this kind of study your not looking at 
20 polymorphisms in a hundred genes. Your looking at a million polymorphisms 
against the genome and if you multiply that again by 2000 DNA samples your 
looking at 2 billion raw data points. So there's a huge problem there in capturing 
that data, having that data available, retrievable in a system we can use in the 
future. 3o 
30 Interview with the Associate Director of Genetics in Target Discovery. 
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6.3.10 Bioinformatics resources 
Most of the questions asked about bioinfonnatics resources were m tenns of 
databases and analysis tools used by teams within RDG. 
Bioinformatics Databases 
The mam bioinfonnatics resource used by all teams within RDG was the 
AstraZeneca Gene Catalogue which is a proprietary integration system that 
integrates a number of external databases such as those containing sequence, SNP 
and haplotype data (Thomas et aI., 2004). Scientist's opinions from all areas of 
RDG on this system were very positive and many were satisfied with its powerful 
and flexible search facility and efficiency of infonnation retrieval. One scientist had 
the following to say about Gene Catalogue: 
It's very easy. The search engine is pretty powerful, flexible so you can find 
whatever you need. The indexing is effective. Fast responses ... in seconds it will 
return your data. It's well presented on the screen, very intuitive. So a lot of 
complex stuff is boiled down to the essentials. You can find Affymetrix data. So 
you've got the gene and all the tissues its expressed in and different cell types and 
see where its high and low expressed, disease state, drug studies combined with 
polymorphisms, SNPs in the same gene or in the vicinity of the same gene. You can 
map that back on (untranscribable) Ensembl (untranscribable) context of the gene 
(untranscribable) genes ... microsatellite data. You know it's a fully integrated 
package. But you can navigate your way around it very effectively. 31 
31 Interview with a Genetics Supporting Projects project leader. 
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XML (Extensible Markup Language (XML) 2005) is used to describe data in Gene 
Catalogue and the system employs a novel method of mapping public and cDNAs, 
SNPs, proteins and probe sequences onto the genome through enhancements of 
public alignment algorithms. Users are able to access data on sequences and SNPs 
using what is known as the Mutation Catalogue, while expression data on genes can 
be obtained from Expression Catalogue. Although a complete package, scientists 
believed they would benefit if more information could be integrated into Gene 
Catalogue such as data on linkage disequilibrium found in the public domain and 
genome data from other organisms to enable comparative genetics analyses. 
Bioinformatics Analysis tools 
The bioinformatics analysis tools used, were mainly sequence analysis packages. 
Lasergene for example was a popular suite used in the department. Lasergene is a 
PC-based package which provides facilities for many types of analyses including 
coding analysis, structure and comparison of DNA and RNA, restriction site 
analysis, PCR primer and probe design, and pairwise and multiple sequence 
alignment (Ignacimuthu 2005, p.88) (see Section 7.5.3 on p.206). 
6.3.11 Resources needed 
From the interviews an important bioinformatics theme was the need for better 
integration of more datasets, such as the incorporation of data on pathways and 
functional data on promoters, transcriptional regulators etc for example. There were 
initiatives to integrate these data into Gene Catalogue. Many scientists believed that 
the key datasets to be integrated in the next two years would be clinical data with 
genetic data (and methods would need to be developed to do this), either in 
resources such as Gene Catalogue or the genotyping LIMS. As pharmacogenetics 
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matures as a field it will be necessary to build more resources specifically for this 
field that provide accurate information and provide easy access to these. There are 
many unknowns in pharmacogenetics although some areas are relatively better, 
defined and understood, such as the pharmacogenetics of drug metabolising 
enzymes (Evans & Johnson 2001). These are being addressed by the client through 
a drug transporters database being developed as a pilot study within RDG to 
support pharmacogenetics studies. 
6.4 Summary 
A case study was carried out to explore data management issues in the genetics 
department at AstraZeneca PLC in Alderley Park, VK. The primary research 
method to be used was semi-structured interviewing to collect details about data 
use, storage and handling within the department and to capture this as scientific 
workflows. 
The main findings drawn from these interviews are that the workflows used by 
teams working in Genetics in Target Discovery, and Pharmacogenetics are very 
similar in terms of the methodologies and technologies used but differ in terms of 
objectives and study design. For example the sample size needed for a popUlation 
based disease study would be far greater than the number of individuals needed in a 
pharmacokinetics clinical trial study. Because of such reasons, the data used by 
geneticists whether working during the earlier or later stages of discovery or during 
development were very similar with the main primary data used being genetic 
variation data in the form of SNPs. Those scientists working on Genetics 
Supporting Projects would support both discovery and development projects. 
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Teams in Genetics in Target Discovery and Pharmacogenetics used MS Access 
databases as their primary data storage medium with regards to genotype data, 
phenotype data and gene maps. In addition, MS Excel was also being used both as 
a storage and analysis medium for these types of data (see Section 7.3.1 on p.188). 
Genotype data requested by discovery projects would be provided by the Research 
Genotyping facility, and this same facility would also provide data for exploratory 
Pharmacogenetics projects which were non GLP. Data from the Clinical 
Genotyping Group (CGG) would be utilised when the samples being genotyped 
were from clinical trials (although these samples could also be genotyped by the 
Research Genotyping facility). Once raw data were stored in MS Access and/or MS 
Excel, it would be common for scientists to manually re-format these to put them 
into the required format for analysis packages. This was considered to be easy to 
do, but rate limiting. In addition scripts were available to automatically carry out 
such manipulations. The analysis of clinical trials data and genetic data combined 
together was more complex and was carried out using SAS/Genetics, requiring a 
number of data manipUlations. 
The main bioinformatics resource available to scientists within RDG was the Gene 
Catalogue system developed to support Genetics in Target Discovery and 
Pharmacogenetics. However, there was a loop hole in the scientific workflow as 
data downloaded from Gene Catalogue was not put back after being annotated (see 
Section 7.3.3 on p.191). 
An important component in the generation of genotyping data for both Genetics in 
Target Discovery and Pharmacogenetics projects is the service provided by CGG. 
CGG manages the Genotyping LIMS, which is capable of holding terabytes of data. 
Currently in its infancy, scientists believed that after becoming more familiar with 
its use, this would prove to be a vital resource for research carried out right across 
RDG. The LIMS provides a complete laboratory informatics solution in support of 
high throughput genotyping processes, being able to manage samples and their 
associated metadata (data about data). Possible advancements that the LIMS may 
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bring include being able to generate output files of genotyping data in a format that 
could be automatically fed into statistical analysis tools, thus removing the 
manipulations that are carried out on the data pre-analysis at present and making 
the process faster. This would certainly improve efficiency. It seems that the LIMS 
could also be a storage solution for the data generated through whole genome 
scans, although thought would be needed as to how and where to analyse this data. 
The capacity of the LIMS at present may be sufficient, but additional disk space 
and memory may need to be upgraded. 
Data that will need to be accessed in the next two years will not differ significantly. 
Less sequencing data may be generated, which may mean less work as more 
information will become available in the public domain. Genotype data will 
certainly increase, but only by about 20% for genotyping data produced by both 
Research and Clinical Genotyping facilities. Certainly the scale of certain projects 
will increase and plans will need to be made of adequate solutions for storage and 
analysis of these data. Additional data from functional genetics will produce data of 
increasing complexity as more components of sequences are studied. Gene 
Catalogue would be an ideal place to store such data. 
An important issue over the next two years will be looking at new ways of 
integrating clinical data from clinical trials with the genetic data produced within 
RDG. Pharmacogenetics project teams utilise data from clinical trials databases but 
it is likely that only subsets of these data will be provided to the Pharmacogenetics 
team involved in the project. It is common for this data to be downloaded into 
Excel spreadsheets. Once in this format no audit trail exists for the data which 
means that there is the potential for data to be altered or deleted by mistake (see 
Section 7.3.4 on p.192). Additional problems identified from this study are also 
discussed in Section 7.3 on p.185 onwards). 
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Chapter Seven: Discussion 
7.1 Use of qualitative and quantitative methods in 
bioinformatics research 
Research in the literature was found to be similar to the case studies carried out in 
the current study. For example, the BioUse system (Javahery et aI., 2004) discussed 
in Section 2.9.1 on p.63 was designed upon a qualitative research design that made 
use of ethnographic interviews. Ethnographic research involves describing people 
or cultures. More specifically the main assumption behind ethnography research is 
that a group of people interacting together for a time period will evolve a culture 
(Patton 2002, p.81). Encompassing in a culture are beliefs, behaviour patterns and 
ways ofliving. In the development ofthe BioUse system, two types of culture were 
distinguished which were novice users and expert users. 
Some of the benefits of ethnographic research are very similar to the advantages of 
case studies. For example rich and detailed information can be collected on issues 
that are often complex and sensitive. Similarly to case studies, ethnography aims to 
achieve holistic understanding through study of processes and relationships that 
contribute to certain events; perhaps in ethnography this is more so than the use of 
case study methodology (Denscombe 2003, pp.92-93). These are very close 
parallels and hence confusion between the use of case studies and ethnography can 
arise. However they are different approaches and their distinguishing features need 
to be highlighted. For example, in contrast to case studies, ethnographic research 
requires long time periods in the field, and a lot of emphasis is placed on the 
collection of data through observation (Yin 2003, p.II). 
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Bartlett & Toms (2005) (see Section 2.9.1 on p.64) also used a qualitative approach 
making use of semi-structured interviews. There were differences however in the 
sampling methods used in this study to the two case studies carried out in the 
current study. For instance, Bartlett & Toms (2005) made use of interviewing key 
informants and snowball sampling. Snowballing is usually used where no sampling 
frame exists and involves the researcher asking the initial respondents to suggest 
other respondents who could provide relevant information. In contrast, the type of 
sampling used in the Sanger Institute case study was purposive sampling. When 
using purposive sampling, a researcher has the flexibility to pick respondents 
according to how likely they are to provide the most valuable information 
(Denscombe 2003, pp.15-16). Although a convenience sample was used in the 
AstraZeneca case study, the justification for doing so was that the scientists that 
were interviewed were all relevant informants, being members of the genetics 
(RDG) department. 
Importantly, points captured in the current study that were supported by similar 
research showed that in terms of bioinformatics development the integration of 
different datasets was a common theme that came up (see Section 6.3.11 on p.174). 
In addition, there were other issues such as data having to be formatted differently 
for entry into specific data analysis tools. This notion is supported by studies such 
as Stevens et aI., (2001), who used quantitative and qualitative research methods to 
define the user requirements of the T AMBIS system. As the work by these authors 
was focused primarily on the development of a bioinformatics resource, and as they 
made extensive use of questionnaire methodology before follow up interviews, 
their results were far greater generalisable to the wider bioinformatics community. 
The current study of course took a case study approach and so results were more 
inclined to the needs of the scientists working within RDG at AstraZeneca in 
Alderley Park and the Pharmacogenomics group at the Sanger Institute. 
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Another area where the case studies carried out in this study can be compared to 
those similar types of research in the literature is in the objectives of the study. For 
instance the research by Stevens et aI., (2001) and Bartlett & Toms (2005) focused 
on asking questions on the specific tasks carried out by biologists and 
bioinformaticians. Information was also obtained on the workflows used for 
specific biological tasks such as sequence analysis and gene mapping for instance 
and the steps involved in these tasks along with the bioinformatics resources used. 
Similarly Javahery et aI., (2004) used a pattern-oriented approach. Such data 
collection resembles those questions asked to scientists in the Pharmacogenomics 
group at the Sanger Institute where specific information about the steps taken when 
designing primers was needed (see Appendix Con p.361 CD-ROM). This type of 
detail was not needed in the AstraZeneca case study, as focus was more on a higher 
level, such as departmental workflows although some document data were 
collected on specific tasks carried out such as SNP selection. 
One of the more earlier papers in this area, is the research by Cole & Bawden 
(1996). There are a number of similarties in this study to the two case studies 
carried out in the present study. For example Cole & Bawden (1996) focused firstly 
upon determining the information environment of the molecular biology 
community in the pharmaceutical industry and then carried out a more detailed 
study at Celltech Group PLC. The first part of the study included an in depth 
review of the types of users involved in bioinformatics, methods used for current 
awareness and the types of tasks that require the use of bioinformatics databases; 
data being collected through the use of a questionnnaire. 
An interesting result from this survey was the need for integration of genetic data 
with other data types such as protein structure data and those data generated 
through pharmacology and toxicology for a research project to be successful. Ten 
years on, it was established in the current study that data integration remains a top 
issue for life scientists, as studies in fields including pharmacogenomics and 
toxicogenomics progress. In the more detailed user study of Celltech Group PLC, 
Cole & Bawden (1996) examined issues such as the existing information 
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infrastructure and infonnation requirements for specific areas of study. Some of the 
results which are now considered outdated included their being limited access to 
the Internet at that time and the use of applications such as Entrez on CD-ROM 
fonnat; such integration resources now are easily accessible over the web. 
Respondents to the questionnnaire saw that their was a bright future for infonnation 
professionals to faciliate molecular biology studies though activities including 
integration and end-user training. However, to this day, it seems that there is still a 
lack of infonnation professionals applying their expertise to biomedical 
infonnation management problems (Vyas & Summers 2005). 
7.2 Implications of Sanger Institute case study 
A case study was carried out of the Pharmacogenomics group at the Sanger 
Institute, UK. The Pharmacogenomics workflow in use at the Sanger Institute is 
made of two main sections that are SNP discovery by sequencing and SNP 
genotyping (see Section 5.2.1 on p.l25). The infonnation flows through the 
processes that make this workflow were studied with regards to types of data that 
were used, where these were stored and how data were used for subsequent steps 
and analyses. Two areas were chosen to be explored further, which were the 
development of a standard for manual primer design and the design of a standard 
for DNA preparation. The significance or importance of these two problems will 
now be discussed along with how much impact any changes introduced would 
make, bearing in mind the primary goal of the Sanger Institute which is biomedical 
discovery. 
7.2.1 Significance of the primer design issue 
A lack of a standard for manual primer design was the only process in the SNP 
discovery by sequencing part of the Phannacogenomics workflow, where a 
loophole existed. An introduction of a primer design standard would certainly fill 
this gap. In addition the development of such a standard would bring some 
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consistency to the process of developing primers by eye, which could aid in the 
capturing of accurate and comprehensive information required by this process. In 
turn, this would aid reproducibility of experiments and facilitate the development of 
any primer databases. The people who would be affected by the inclusion of a 
primer design standard into the workflow would be those scientists involved in the 
development of primers by eye. Cost would be manifested in a few ways if such a 
standard were to be introduced. Firstly time would be needed, as informatics 
specialists would have to be brought in to determine the user requirements for such 
a standard. After this a testing period would be needed where scientists would be 
introduced to the standard and given training in its use. 
Although it was interesting to study the need of guidelines for manual primer 
design from a research point of view, there is doubt over the magnitude of the 
problem and how a lack of such a standard affects the achievement of the goals of 
the Pharmacogenomics group. From the meetings and interviews with scientists it 
seemed that the problem did not affect the efficiency of the workflow. The reason 
for this could be that most of the primers were designed computationally, but those 
which did fail and had to be designed by eye were not significant enough to slow 
down the workflow. In addition, following a standard and recording what 
information has been used to design primers could actually have the opposite effect 
with it taking longer to carry out the process. For example, scientists would have to 
spend time entering values into standardised fields rather then focusing on their 
research. Indeed this time scale was also the reason why AZ scientists were 
reluctant to put data back into Gene Catalogue (see Section 7.3.3 on p.191). It did 
seem however, that if the primer problem became an issue for concern then either 
the scientists working on the workflow or bioinformatics experts could develop an 
appropriate standard component. 
There are other limitations regarding this whole problem. Because the results were 
based on the opinion of four people, there is question as to whether other scientists 
involved in primer design in the organisation or external research centres or 
companies would have the same opinions and requirements for such a standard. In 
182 
Chapter Seven Discussion 
addition if a standard were set for the design of primers by eye it would be limited 
to PCR reactions as primer development is a context dependent process. It would 
be interesting however, to see if other scientists carrying out PCR reactions for 
other projects within the Sanger Institute could use such a standard. Carrying out 
primer design, particularly by eye is a sUbjective process and the usefulness of a 
standard guideline would become more or less apparent if more people began to 
design primers. 
There has been some open source work carried out on developing standards for the 
process of PCR and a minimum information guideline for PCR reactions has been 
developed known as the Minimal Information for PCR Experiments (MIPE) (Aerts 
& Veenendaal 2005). This is a standard format that is able to store information 
associated with peR experiments in XML format. Some e-mail dialogue with the 
developer of MIPE has been conducted including discussion about the extension of 
this standard to incorporate a minimum information guide for manual primer design 
along with problems involved and solutions (see section 5.3.2 on p.132). A 
database for PCR from the MIPE object model or XML Schema could 
consequently be developed. Such annotation standards are increasingly becoming 
important to ensure experiments are recorded consistently using controlled terms 
and comprehensively capture all the processes in an experiment to ensure scientists 
around the world can reproduce them. MIPE has in fact been modelled upon the 
internationally recognised standards for gene expression experiments such as those 
developed by MGED as discussed in Section 3.5.1 on p.49 including the MIAME 
data content standard. MIAME also contains information about primer design in 
relation to microarray experiments and this includes the sequence of the PCR 
primers and their lengths for each reporter (a gene sequence). For proteomics, a 
similar standard to MIAME is the Minimum Information About a Proteomics 
Experiment (MIAPE) and other standards include an object model (PSI Object 
Model) and the XML Molecular Interaction Format (PSI-MI); along with additional 
tools for data entry and conversion of format (Orchard et aI., 2005). 
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7.2.2 Significance of the DNA preparation issue 
In general it seems that inconsistencies in DNA preparation supplied between 
laboratories seems to be a universal problem, but also one for which no satisfactory 
solution exists. The greatest difficulty lies in getting collaborators to adhere to any 
standard set of guidelines that have been set. These guidelines at the Sanger 
Institute were in place but collaborators did not always stick to them. Reasons for 
inconsistencies include there being no particularly good wet method for 
determining the concentration of DNA, many protocols for extraction are in 
existence (Sambrook et aI., 1989), and other issues also need to be taken into 
account such as cost and time. 
A big limitation of the DNA preparation line of enquiry was that the processes 
involved, namely DNA quantitation and DNA normalisation proved difficult to 
understand. More time to discuss further with scientists to understand this problem 
better from a biological point of view and from an experimental processes 
perspective would have helped. This would have enabled further evidence to be 
gathered on why a standard would be useful. From an organisational point of view, 
receiving DNA in bad states was seen as more of an annoyance rather than having 
any major impact on the goals of the Sanger Institute. However, it could be said 
that if collaborators of the Sanger Institute supplied DNA in the appropriate form 
then some time would be saved and the experimental process could be carried out 
at a quicker pace, as scientists would not have the added burden of transforming the 
DNA into solution. 
There are further points regarding this issue that need to be discussed. For instance, 
the data gathered on what information to include in a standard for DNA preparation 
was limited by the input of two scientists and was only relevant to genotyping using 
the Illumina platform (Illumina, Inc, 2003). A standard for other genotyping 
platforms would not be the same, as different working concentrations of DNA 
would be needed which rendered the usefulness of the standard to other platforms. 
In addition the techniques used for DNA quantitation is another aspect that needs to 
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be discussed here. These are the actual methods that can be used to measure the 
concentration of DNA. Accurate DNA quantitation is extremely important for the 
efficiency of genotyping to ensure that completion rates are maximised and are 
reproducible. Quantitation that is imprecise leads to inconsistencies in PCR product 
and decreased confidence in genotyping scores (Haque et aI., 2003). 
The primary method used for quantitation at the Sanger Institute was PicoGreen, 
which is an ultra-sensitive fluorescent nucleic acid stain that allows scientists to 
measure accurately the concentration of double stranded DNA (Ann et aI., 1996). 
However it is also important to recognise other methods that exist and are being 
used such as Quantitative Genomic PCR another fluorescent based approach and 
spectrophotometric methods such as the Optical Density (OD) method. In a recent 
survey of DNA quantification methods, it was revealed that specific methods varied 
in terms of their accuracy and precision and the preference of one method over 
another was primarily dependent on the requirements of the workflow. However in 
this particular study it was found that the OD method was most precise (Haque et 
aI., 2003). 
7.3 Implications of AstraZeneca case study 
The results discussed in this section are based upon the application of ideas 
discussed in Henczel (2001), which describes the use of the information audit 
model. The Information audit is a management method that organisations can use 
to identify their existing information environment. This involves identifying what 
information is required to satisfy the needs of an organisation, establish what 
information is supplied at present, allowing gaps to be identified along with flaws 
such as inconsistencies and duplications (Henczel 2000). Although this 
methodology did not form a part of the research design, some of the stages of the 
information audit are similar to the processes carried out in the current study. The 
stages in the information audit are briefly described below (HenczeI2000): 
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Planning -Aspects that need to be considered during the planning step include 
those such as understanding objectives, establishing resources available, choosing a 
methodology to collect and analyse data, ensuring a strategy is in place for 
communication etc. 
Data Collection - This stage involves collecting data using research methods such 
as questionnaires and interviews. Data that would usually be collected are those 
related to information required to carry out tasks, how critical information 
resources, tasks and activities are, the strategic significance of information 
resources etc. Such information is contained in an information resources database. 
Data Analysis - The Analysis stage can expose gaps in resources, along with 
duplications, the use of inappropriate resources or over provisions etc. Depending 
on the resources available, the analysis can be carried out in house, or externally. 
Tools to aid in analysis can range from Microsoft Access and Microsoft Excel to, 
more specialised applications such as Atlas.ti. 
Data Evaluation - After data analysis, problems and opportunities established are 
interpreted according to the situation of the organisation. There will be some 
problems that will need addressing and others that cannot be due to constraints such 
as money, personnel etc (some of these problems will be discussed in the next 
section). Addressing such problems will improve information provision, and 
enhance the quality of knowledge being created. 
Communicate Recommendations - People will be affected the most by any new 
implementations and so it is important that changes are communicated in a positive 
light. Common ways to do this include writing a report or giving a presentation 
orally. 
Implement Recommendations - It is important to have appropriate plans in place 
for the implementation of recommendations. This also needs to include a post-
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implementation road map to ensure the smooth employment of change and minimal 
resistance. 
The Information Audit as a Continuum -The first audit can be considered the 
initial information baseline, which acts as a guidance, as to the current situation of 
the organisation in terms of information. Any subsequent audits add to this baseline 
reassessing its validity in light of changes in the organisation. They can also add 
information about any changes in significance, tasks and activities, business units 
etc. Problems associated with the Data Evaluation stage of the information audit 
methodology in Henczel (2001), will be used as headings in the following section 
to aid in structuring the discussion of the findings. 
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Data Collection 
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Data Analysis 
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Data Evaluation 
.. 
Communicate 
Recommendations 
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Implement 
Recommendations 
... 
The Information 
Audit as a 
Continuum 
Figure 7.3 The Information Audit Model. 
Source: Henczel (2001; Figure 2.1, p.23) 
7.3.1 Use of inappropriate resources 
Discussion 
This problem can include resources which are outdated or out of context or lack 
sufficient authority (Henczel 2001, p.133). The resources used within RDG at 
AstraZeneca were developed using outdated technologies, which included MS 
Access and MS Excel. For example, there was a consensus within members of 
RDG that these applications although effective, were not the best option in terms of 
technology and efficiency of use. However, it seems that the use of MS Office 
applications within industry is widespread and for the work carried out within 
RDG, applications developed using these technologies were sufficient. Having said 
this, these same scientists were concerned about information overload from studies 
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that would grow in magnitude over time and recognised that alternative data 
management solutions would be needed. 
It appears that the strategic significance of this issue is minimal but would still need 
to be addressed at some point through consultation with the Informatics and 
Information Systems departments. State of the art informatics and information 
systems support while available would not be used until members of RDG asked 
for assistance. Communication would be required between members of RDG to 
reach an agreement to seek assistance and become knowledgeable about new 
system technologies and data formats as projects became larger. Important factors 
that would need to be taken into consideration are cost which in this case would 
manifest itself in terms of budget. What would be even more costly however it 
seems is the time taken to train scientists in the development of more sophisticated 
databases and the time needed for scientists to adapt to, the change. Having said 
this, the introduction of improved databases would make sense as high throughput 
technology developments become more sophisticated particularly through the use 
of an array approach to whole genome association, which is expected to increase 
data generated by considerable amounts (Ogren 2003). 
A barrier to the migration to better database management systems with increased 
data storage and analysis power however, could well be a reluctance of scientists to 
participate in such training. In terms of solutions, a possibility could be the 
development of a single storage and retrieval system based upon the concepts and 
ideas of the semantic web. The use of the semantic web for the development of 
bioinformatics resources has been evaluated (see Appendix A on p.267). The 
development of one main resource would also remove the need for separate 
resources, which are currently scattered within the department. 
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7.3.2 Duplication of information handling 
Duplication of information handling can involve information flows from one 
department to another not being as direct as they could be (Henczel 2001, p.134). 
In RDG for example there was the issue of errors in the genotyping process being 
introduced via e-mails sent by project teams to the Research Genotyping facility 
such as the selection of incorrect polymorphisms and/or DNA samples. These can 
potentially result in failed assays that could slow down productivity. The reason for 
this problem is a reliance on unreliable information exchange media, which in this 
case is e-mail. This problem could be considered both a people issue and a flaw in 
the workflow, where there is potential for human error through the use of an 
inappropriate communication channel. Again the strategic significance of such a 
problem is not major but ifthese errors could be eliminated or minimised, then time 
could be saved as assays would not have to be repeated and the workflow would 
become more efficient. A solution to the problem could be further communication 
where the Research Genotyping facility could confirm with project teams that the 
information they received was correct. This could be done by sending a 
verification/confirmation e-mail in reply which would allow project teams to check 
the information entered in the initial e-mail (Blumberg 2002). 
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7.3.3 Information hoarding 
Infonnation hoarding involves a person or department not passing the infonnation 
in their possession to others in its original fonnat or in a filtered representation 
(Henczel 2001, p.132). An important point captured from interviews was that 
genetic data and sequence data were being downloaded for annotation and analysis 
from the Gene Catalogue system into local Access databases, but were not being 
put back into Gene Catalogue to make it available company wide. From the case 
study it was identified that this was a people problem rather than a loophole in the 
process and scientists felt there was too much cost involved in tenns of time to pass 
on infonnation into Gene Catalogue. Scientists recognised that this was an issue 
that needed to be addressed and one scientist had further discussions with the 
researcher as to how the problem could be resolved. One possible solution that was 
discussed was the introduction of a data content standard similar to the MIAME 
guidelines (Brazma et aI., 2001) which would capture the minimum infonnation 
required to aid other scientists to study association studies or carry out experiments 
to detennine the validity of any previous results obtained. Costs of bringing in such 
a standard would include time taken to capture requirements and training scientists 
in its use. Barriers to its provision would be scientists themselves still reluctant to 
put infonnation back into the Gene Catalogue system. 
This problem is more significant than the others discussed in the sections above, as 
scientists within the company having access to complete and up to date infonnation 
can only facilitate the progress of studies being carried out. Such a change would 
complement the work ethics of the department and AstraZeneca at an 
organisational level, which include efficiency and completeness. Those who would 
be most affected by introducing a data content standard for this problem would be 
teams in Genetics in Target Discovery and those working on Genetics Supporting 
Projects that supported Target Discovery as this issue was raised by scientists, 
working in these two areas. 
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7.3.4 Lack of information traceabiJty 
Issues regarding confidence in infonnation are involved with infonnation 
traceability such as how much can a user in a particular level of the organisation be 
confident of the validity or source of the transfonned or filtered infonnation passed 
on from another level of the company (HenczeI2001, p.13S). From the study it was 
detennined that Pharmacogenetics teams utilised data from clinical trials databases 
but only subsets of these data would be provided to the Pharmacogenetics team 
involved in the project due to data sensitivity, ethical issues and need for adherence 
to regulations. It was common for this data to be downloaded into Excel 
spreadsheets. Once in this fonnat no audit trail existed for the data, which meant 
that there could be the potential for data to be altered or deleted by mistake. If a 
situation did arise where data may have been changed, then the regulatory 
authorities would have no knowledge of this occurrence. An audit trail mechanism 
would be ideal here and software for such functionality could be evaluated. 
7.3.5 Gaps in resources 
Gaps in resources refer to infonnation needs that have been established, but for 
which no resources have yet been developed (Henczel 2001, p.134). It was 
established that data from clinical trials databases needed for Pharmacogenetics 
projects were downloaded as CSV files (see p.164). At the time ofthe study clinical 
data for each study were held in separate CSV folders and the genetics would be 
carried out for each study at a time. In the future the carrying out of meta-analyses 
involving the correlation of genotype data with the results of phenotype data from 
multiple studies would result in there being many separate CSV files. This could 
prove to be problematic particularly in tenns of infonnation related activities such 
as integration, exchange and retrieval when you consider the existence of 
inconsistencies in the units and nomenclature used by different study teams 
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across the world. The current IS infrastructure within RDG would not enable meta-
analyses to be carried out easily or in a time saving manner. Difficulties in carrying 
out meta-analyses has also been discussed in the literature such as the inadequate 
and non standardised indexing of adverse drug reactions and the subsequent 
difficulty in retrieving this type of information (Aronson 2005; Derry et aI., 2001). 
During the AstraZeneca case study an important verbal communication issue was 
discovered, which was the lack of understanding of genetics by the Clinical 
Information Management Group. What is required to address this issue is scientists 
from RDG to raise awareness to members of Clinical Information Management 
about basic genetics and its application to the drug discovery and development 
process, so that they can be better prepared for Pharmacogenetics studies and 
prioritise these with competing projects. There was also a slight loose terminology 
issue that was revealed through interviews with scientists. For example some 
scientists would say 'DNA samples' or 'genetic samples' or 'blood samples' to 
refer to clinical samples. Perhaps people in the domain would know that both terms 
refer to the same thing but to an outsider there is potential for misunderstanding. 
Another term used in this manner was SNPs. Some scientists would say 'snips' and 
others would say 'markers' to refer to the most common type of genetic variation. 
Overall though, this is a minor problem. 
7.4 Cross-case study 
Although the learning objectives of both case studies were different (see Section 
5.1.3 on p.123 and Section 6.1.2 on p.144), they still followed a multiple case 
design, i.e. they were selected on the basis of replication logic (see Section 3.2.1 on 
p.81) Some of the issues that the researcher found would be useful to compare in 
terms of replication were: 
• How efficient work was carried out. 
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• How similar the workflows were. 
• Communication between people. 
Firstly those areas where literal replication was achieved will be discussed followed 
by those areas associated with theoretical replication (see p.83 for more on 
replication). 
7.4.1 Literal replication 
Literal replication was established in terms of similarities in workflows. 
Similarities in workflows 
Due to the similarity of work being carried by the two organisations, it was 
expected that some of the processes and workflows would be similar. Literal 
replication was actually achieved through the comparison of the Sanger Institute 
Pharmacogenomics workflow and the workflows used by Genetics in Target 
Discovery in RDG at AstraZeneca. Both these groups were carrying out the same 
type of work, which involved similar processes. These processes were studied in 
more detail at the Sanger Institute as only one workflow was focused upon. 
However the workflows used by Genetics in Target Discovery essentially had the 
same objectives involving the identification of novel SNPs through sequencing that 
may be involved in disease processes. Association studies would then be carried 
out involving the testing of sequence variants in control and case individuals to 
determine association of a particular SNP with the disease, making use of 
genotyping. A major difference between the two was that the genes identified to be 
associated with disease in the projects carried out within RDG could actually end 
up as drug targets that could progress further in the drug discovery and 
development process. 
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7.4.2 Theoretical replication 
Theoretical replication was achieved in tenns of differences In workflows, 
efficiency of work flows and attitudes to primer design standards. 
Differences in workflows 
Due to the phannaceutical research carried out at AstraZeneca it was anticipated 
that phannacology studies would be integrated into scientific workflows and this 
was evident through the Pharmacogenetics projects being carried within RDG. In 
contrast the focus of the Phannacogenomics group at the Sanger Institute was more 
on genomic research and phenotype was incorporated minimally, with parameters 
including the subject either having the disease or not having the disease. Indeed it 
was found that RDG was carrying out a far greater number of projects both at the 
disease level and drug response level, while at the Sanger Institute, the projects 
were primarily focused at the disease level. Because of this more phenotypic data 
were made use of within RDG along with data from clinical trials. Differences were 
found in genotyping platfonns used. For example at the Sanger Institute bead-based 
Illumina genotyping machines were used while at AstraZeneca the Taqman assay 
was utilised. The major difference between the two is in tenns of throughput. For 
example, 50,000 genotypes could be generated a day using Taqman, while the 
Illumina platfonn has a potential throughput of 500,000-1 million genotypes a day 
with the Sanger Institute's current throughput being 400,000 genotypes a day. 
These differences in throughput are due to the multiplex ability of the Illumina 
bead-based approach enabling 1,520 SNPs to be genotyped in each sample in a 
plate simultaneously (Ogren 2003). The Taqman assay lacks such multiplexing 
ability. The Sanger Institute needs the bigger throughput as it is involved in large 
international projects such as The SNP Consortium (The International SNP Map 
Working Group 2001) and The International HapMap project (The HapMap 
Consortium 2003). 
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Efficiency or workflows 
It was predicted that the efficiency of work carried out would be greater at 
AstraZeneca than at the Sanger Institute, particularly as AstraZeneca has both 
internal and external customers whose demands had to be met. There were certain 
results that supported this impression. For example it was established that within 
RDG up to 200 primers could be ordered at one time. AstraZeneca scientists relied 
far greater upon automated tools to design primers more quickly to keep in demand 
of customers. In contrast, at the Sanger Institute although automated primer design 
programs were used, emphasis was given to the design of primers by eye also. It 
seemed that tirnescales had to be adhered to more strictly at AstraZeneca than at the 
Sanger Institute; where overall there was a more relaxed atmosphere. 
There are a number of reasons, which could explain the need for automated tools 
for the development of a considerable number of primers at anyone time. It could 
be due to more candidate genes under investigation with exons needing primers 
designed for them. Additional primer development is needed for target 
amplification via peR for genotyping reactions and more genetic association 
studies for target discovery were carried out within RDG than the number of 
similar case-control studies at the Sanger Institute. In addition Pharmacogenetics 
projects at AstraZeneca were carried out during different stages ofthe clinical trials 
process with varying numbers of SNPs being genotyped in differing sample sizes. 
Having said this, it could be possible also that the carrying out of mUltiple projects 
simultaneously within RDG may have given the perception of an efficient working 
environment. 
Primer design standards 
Another example of theoretical replication is the difference in opinion for the type 
of standard needed for primer design. For example in the Sanger Institute case 
study it was found that a standard for manual primer design may be of use as their 
was none in existence, and as automated primer design was well standardised 
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particularly through the use of the Primer3 program (Rozen & Skaletsky 2000). At 
AstraZeneca primers were also designed by eye but the numbers being designed 
manually were minimal compared to the number designed using automated 
programs. It was also the opinion of one scientist that a standard set of guidelines 
for automated primer design may be more useful than one for manual primer 
design. The reason being, that both commercial and proprietary programs were 
used at AstraZeneca, but scientists were not sure about which ones to make use of 
and were uncertain of the correct steps involved in using them. How much 
confidence can be placed in this argument is questionable however, as it is the 
opinion of only one scientist. 
Overall in the Sanger Institute case study, there was a slight misunderstanding on 
the actual use of a primer design standard. For instance, the researcher was hoping 
to develop a standard that would not only be used as a standard set of guidelines but 
could also be used for the development of a database. However, after meetings with 
other scientists and reviewing the existing information management infrastructure 
in place the researcher realised that scientists were perhaps negotiating only the 
standardisation ofthe manual primer design experimental process. Having said this, 
such a development can consequently become the blueprint for a database. 
Communication between people 
How communication between individuals would differ between the two 
organisations was not considered beforehand so communication cannot be 
discussed in terms of case study replication. However it is useful to discuss the 
differences found in verbal communication after the carrying out of both of the 
studies. Differences were found in the levels of productive communication in both 
of the organisations. Overall the verbal information exchange between scientists at 
the Sanger Institute seemed adequate enough so as to ensure the functioning of the 
workflow was carried out in an effective and timely manner. The primary reason 
for this could be the flow of information being transported via only a few people. 
The number of people who were working on the workflow was eight and this could 
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have aided in information being communicated swiftly. Having said this no 
questions about the existence of flaws were asked to the scientists so these 
impressions cannot be confirmed. During the AstraZeneca case study an important 
communication flaw issue was discovered, which was the lack of understanding, of 
genetics by the Clinical Information Management Group (see Section 7.3.5 on 
p.192). Having said this, RDG seemed to be a well-organised department and good 
verbal communication was an important factor in this. 
7.5 Implications of the case studies within the wider 
discipline 
The scientists interviewed in both case studies made use of spreadsheets as their 
first port of call in terms of data management, which is also supported by the 
literature. For example Nadkarni et aI., (2002) describes a typical scenario where 
biomedical researchers who are not informatics specialists by trade but make use of 
spreadsheets as their primary tool for the storage of data. Retzel (n.d.) uses the term 
private databases to refer to those resources designed to address the needs of a 
laboratory or a LIMS, and how the implementation of these can vary from a 
spreadsheet to the use of a relational database management system (RDBMS). In 
the Pharmacogenomics group at the Sanger Institute, spreadsheets were also used 
for inputting data and metadata about exons such as the source of the gene, its 
sequence, working primers for its amplification etc, but from meetings with 
scientists and interviews it was apparent that not many of these existed for the exon 
resequencing project (see Chapter Five on p.120). 
After analysis of the data, it seemed that a spreadsheet for exons and a spreadsheet 
for primers were in place. In RDG more spreadsheets were being developed to store 
laboratory data than at the Sanger Institute to cater for the multiple disease projects 
and clinical trial projects being carried out. Scientists found them easy to use but 
also recognised their limitations such as restricted storage capabilities and 
difficulties involved in other researchers from teams understanding the 
198 
Chapter Seven Discussion 
spreadsheets developed by researchers in other teams and departments. Nadkarni et 
aI., (2002), also discuss issues such as limited column size per spreadsheet being 
255 and how the number of measurements per subject can exceed this value quite 
easily. In addition they mention how mistakes can easily be made during data entry 
and how there is risk when distributing spread sheets to other researchers; the 
accident-prone nature of spreadsheets through data corruption, and no support for 
differential security where data access permission rights to different parts of the 
data can be set depending on the type of user. This issue was also brought up by a 
member of the Clinical Information Management Group at AstraZeneca (see 
Section 7.3.4 on p.192) who raised concerns about the lack of an audit trail in the 
MS Excel application to track any data that could have been changed. 
7.5.1 The use of Human Genome resources 
It was discovered that the research carried out by teams in Genetics in Target 
Discovery at AstraZeneca and the activities undertaken by scientists working on the 
Sanger Institute Pharmacogenomics workflow were for the most part similar. The 
common bioinformatics resources used by these teams were human genome 
resources and resources containing information on genetic variation and genotypes. 
For example, a common information need for scientists working on the 
Pharmacogenomics workflow and the scientists working in Genetics in Target 
Discovery would be to have knowledge of exons that may play a part in a disease 
process. Involved in this process would be the gathering of all information about 
the gene(s) through a process of annotation. Bioinformatics databases would be 
used that contain information about genome sequence and protein sequence, protein 
structure, and mRNA expression levels in specific disease states. A resource used 
both by scientists at the Sanger Institute and AstraZeneca (brought in internally 
through a proprietary interface) is Ensembl, which is a more value added resource 
compared to the sequence databases described in Section 3.9.2.1 on p.85. These 
sequence databases are considered more as repositories. They do however provide 
data to genome resources like Ensembl and other more specialised tools designed 
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specifically for genome browsing. At the Sanger Institute both computational and 
manual annotation are carried out. 
Ensembl 
Ensembl is a database system created through collaboration between the Sanger 
Institute and the European Bioinformatics Institute in Cambridge UK (Bimey et aI., 
2004a). It is one of the most well known sources of automatic analysis and 
integration, providing easy access to genome sequence data of eurkaryotic 
orgamsms. Ensembl is able to perform ab initio gene prediction using Genscan, 
which is the most important aspect of genome annotation. The use of ab initio 
prediction to identify genes in DNA sequence involves using only properties of the 
DNA sequences themselves (Lesk 2002, p.77). Other gene prediction methods that 
use homology and Hidden Markov Models are also used (Bimey et aI., 2004b). 
After using Genscan to predict gene locations, Ensembl uses analysis programs to 
annotate the predicted genes. These results in Ensembl can be accessed through a 
number of views. For instance there are the main contigview web pages that allow 
both the scrolling of data that comprise the entire chromosomes and also the views 
associated with specific features in a given region of the chosen chromosome. 
There are also the protein view web pages, which provide information about 
Ensembl translations with functional annotation from InterPro (The InterPro 
Consortium 2002). BLAST is also integrated into Ensembl for sequence similarity 
(Birney et aI., 2004a) (see Section 7.5.3 on p.206). 
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After sequences are brought into the system, assembly and annotation are 
completely automated and subsequent results are prepared for browsing and 
analysis automatically, in an attractive user interface (see Figure 7.5.1 on this 
page). New interfaces have also been introduced such as goview. In this view, the 
standard Gene Ontology (GO) browser from the GO consortium has been 
integrated into Ensembl (The Gene Ontology Consortium 2000). Although an 
extremely important resource, the limitations of Ensembl become apparent when 
assessed from an integration point of view (see Section 2.4.1 on p.23). For example 
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there is no flexible data model nor is there a data exchange fonnat. The 
consequence of the fonner is a difficulty in integrating new data sources, and that 
of the latter is only being able to export data from Ensembl in the fixed export 
fonnats. Examples ofthese are FASTA files and EMBL and GenBank fonnats. 
Manual annotation 
At the Sanger Institute automated annotation was carried out using Ensembl. 
Recently however, Ensembl has been extended to handle manual annotation 
through the Otter manual annotation system, whose database schema is based upon 
the relational model, has an application-programming interface to access it, and, 
crucially a data exchange fonnat developed using XML. This exchange fonnat 
communicates with a server to allow a number of users to access the resource from 
multiple machines (Searle et aI., 2004). In addition two client applications have 
Otter support. These are known as Apollo and Otter/Lace. Otter/Lace is a wrapper 
written in Perl that wraps the AceDB annotation editor FMap of the AceDB 
database, which is a commonly used tool for human genome annotation storage 
(Stein & Thierry-Mieg 1999). EGAG (see Figure 5.2.1b on pp.128-131) at the 
Sanger Institute uses FMap in the annotation process of genes of medical interest 
for the Phannacogenomics group. In addition to FMap, Spandit is also an editing 
tool that can be used to create gene structures. 
Another browser similar to Ensembl is found at the University of California Santa 
Cruz, USA known as the University of California Santa Cruz (UCSC) Genome 
Browser Database (Karolchick et aI., 2003). The annotations in this resource 
include a number of entities, which include mRNA, expressed sequence tag (EST) 
alignments, gene predictions and SNPs. Also, like Ensembl, UCSC provides a fast 
interactive interface (Genome Browser) for users where both text and visual views 
of annotations and sequence data are available. The user is able to make use of the 
BLAT (BLAST-like alignment tool) (see Section 7.5.3 on p.206) search algorithm 
to look for areas of DNA or protein sequences which may be homologous and can 
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then be visualised and navigated using buttons. This browser also has links to 
complimentary annotations in the Ensembl Genome Browser. Similar to Ensembl, a 
significant portion of the UCSC Genome Browser database is accessible using the 
DAS web services application (see Section 2.4.2 on p.26). 
7.5.2 Genetic databases 
Data on SNPs are perhaps the most important resource for scientists who are 
studying the contribution of genetics and genomics to disease and drug response. In 
format they are similar to sequence data and are commonly represented in binary 
code in flat files. At the Sanger Institute new SNPs identified during sequencing 
would be deposited into Glovar, which is a database of human genetic variation in a 
genomic context built upon the source code of Ensembl (Glovar Genome Browser 
[n.d. D, but is also able to store curation metadata. In addition Glovar contains 
newly discovered genes from Ensembl and Vega (Ashurst et aI., 2005). Vega 
stands for Vertebrate Genome Annotation and is a high quality database of manual 
annotation of vertebrate genome sequence SNP data from public databases such as 
db SNP , aligned against genes from Vega and Ensembl. 
dbSNP was created in collaboration between the (US) National Center for 
Biotechnology Information (NCBI) and the (US) National Human Genome 
Research Institute (NHGRI), and is the largest public repository of SNP data in the 
world (Sherry et aI., 2001). It is considered the genetic component of GenBank and 
sources of data in dbSNP come from individual laboratories, collaborative genetic 
variation discovery projects, large scale sequencing centres and industry sources. 
Although the majority of nucleotide sequence variations in dbSNP are classified as 
SNPs, also included are lesser variations such as small insertion/deletion 
polymorphisms, microsateIlite repeats, and named variants. Two important 
identifiers are used for submission of data and their subsequent querying. These are 
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unique submission identifiers (ss identifiers) or reference SNP IDs (rs identifiers). 
ss identifiers are used to describe each separate submission of a SNP, while rs 
identifiers are used to describe a set of independent submissions of that same SNP 
(Sherry et aI., 2001). 
Internal integration with other NCBI sources such as GenBank, dbSTS (dbSTS 
2001) and LocusLink (Pruitt & Maglott 2001) requires a number of computations 
making use of BLAST (Altschul et aI., 1990) and Electronic-PCR (E-PCR) 
(Schuler 1997) similarity analyses, the results of these being annotated onto the 
resources. dbSNP itself can be accessed through Entrez (Wheeler et aI., 2005), 
making use of the LinkOut integration mechanism for interoperation with external 
resources such as the SNP Consortium (TSC) data repository (Thorisson & Stein 
2003) and HGVbase (Fredman et aI., 2004). The quality of data in dbSNP is 
questionable. A recent survey showed that the majority of SNPs in dbSNP are 
unvalidated and unclassified (Marsh, Kwok & McLeod 2002). 
The primary purpose ofHGVbase is to place high quality human genome sequence 
variation data into the public domain (Fredman et aI., 2004). Strict data quality 
criteria are used to maximise the possibility of SNPs being truly polymorphic. Data 
for HGVbase are acquired from public databases and the literature. It is a unique 
database as it handles phenotypic descriptions in relation to human polymorphisms. 
Low quality sequences such as repetitive elements are screened, giving scientists 
the option to remove them from genotyping studies. Queries can be made using a 
retrieval system called HGVSearch, which is accessed using web interface and 
command-line tools. HGVSearch has a flexible search mechanism; its modes of 
action include being able to make keyword and chromosomal positional searches. 
The system design is based upon a relational database back-end. The developers of 
HGVbase have recognised the importance of standard transmission formats for 
genetic variation data with the primary data export format being Extensible Markup 
Language (XML) (Extensible Markup Language (XML) 2005). 
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There are also resources designed specifically to integrate genetic data from 
multiple sources. For example, there is the SNPper application for SNP research 
(Riva & Kohane 2004). A mySQL relational database contains SNP data and a set 
of user-friendly tools for querying and visualisation. The main data source is 
dbSNP, and others include LocusLink (Pruitt & Maglott 2001), the Gene Ontology 
(GO) database (Camon et aI., 2003) and SWISS-PROT (Boeckmann et aI., 2003). 
Queries can be made to SNPper by specifying dbSNP ss or rs identifiers. More 
standardised searches are possible through specifying genes of interest through GO 
classes allowing SNPs that may be linked to a biological process to be studied. In 
addition SNPper allows the export of data in multiple formats including XML and 
tab-delimited text files, while SNP information can be retrieved in XML format. 
This gives rise to the potential of variation data sharing through web services, 
which allow distributed applications to communicate with each other over the 
Internet using standard web protocols (see Section 2.4.2 on p.26). 
7.5.2.1 Gene Catalogue 
The source of data on genetic variation at AstraZeneca was contained in the Gene 
Catalogue system. Gene Catalogue was developed to address the issue of redundant 
sequence databases being delivered on AstraZeneca's internal platform, known as 
E-Lab. More specifically data on genetic variation is contained in a component 
known as Mutation Catalogue. Other entities that are included in Gene Catalogue 
include RNAs, ESTs and probes. These are mapped onto the public genome 
assembly through the use of algorithms taken from the public domain. Mappings 
are then grouped together into clusters that are annotated with information 
including gene summary information, ontology, InterPro domains, pathways, 
expression profiles, orthologues etc (Thomas et aI., 2004). Sequences can be 
viewed using the Gene Catalogue viewer where alignments of RNA sequences to 
the genome can be seen, as can, corresponding translations into proteins. Gene 
Catalogue is built upon the publicly available SRS integration system 
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(Etzold, Ulyanov & Argos 1996) allowing complex queries to be formulated 
quickly (see Link Integration on p.23). It does not however replicate all the SRS 
functionality, such as the concept of composite views which link entries from the 
main query databases to other related databases in a dynamic manner. In such 
views external data are displayed graphically as if they were original database 
attributes. 
Another similar system in the public domain is the Entrez integration system 
developed by the NCBI. Like Gene Catalogue and SRS, it is based upon link 
integration and this retrieval system enables search facilities over 20 databases. 
These databases include DNA and protein sequences and protein structure, gene 
expression, genomes, genetic variation, the biomedical literature etc (Wheeler et 
aI., 2005). Entrez takes a link integration approach (see Link Integration on p.23) 
where links between different types of data are established during the process of 
data import from source resources and conversion into ASN.1 format. This 
mechanism is different to that used in SRS which uses indices to support the link 
integration mechanism where each database record in a source database containing 
structured text and field names is parsed. An index is then created and stored for 
each field; these indexes are subsequently used to retrieve appropriate entries 
(Zdobnov et aI., 2002). However, unlike Gene Catalogue where an ontology is used 
to annotate information, both SRS and Entrez are primarily syntax based and do not 
handle differences in terminology of the underlying sources. 
7.5.3 Analysis software 
Scientists both at AstraZeneca and the Sanger Institute utilised various types of 
analysis software. These resources were often used for different tasks such as 
sequence analysis including similarity searching of DNA. In the AstraZeneca case 
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study for example, some data were collected through interviews on how entire 
sequence analysis packages were used such as LaserGene developed by Dnastar 
(DNASTAR, Inc [n.d.]). Evidence from the interview analysis indicated that some 
of the modules of LaserGene used by scientists are Seqman which is a sequence 
assembler and Mapdraw which is a mapping program. LaserGene also contains 
alignment programs such as MegAlign. The MegAlign alignment program is made 
up of multiple sequence alignment tools such as ClustalW and pairwise sequence 
alignment methods including Wilbur-Lipman and Martinez-Needleman-Wunsch. 
These are similar to those multiple alignment methods discussed in Section 3.8.1 on 
p.65. 
ClustalW is based upon the implementation of the progressive alignment strategy 
(see MUltiple sequence alignment on p.50). For example, ClustalW calculates a 
number of pairwise alignment scores from a set of sequences and converts them 
into two distances. ClustalW then makes use of a hierarchical clustering method to 
build a tree that acts as a guide that can be used to favour closely related sequences 
through pre-computed weighting, where sequences are progressively aligned in 
order of decreasing similarity. ClustalW also has a number of heuristics built in for 
performance enhancements. These include the use of local gap penalties, and 
automatic gap penalty adjustment. However the major limitation of ClustalW like 
other progressive approaches is the inability to correct errors later on in the process, 
when remaining sequences are aligned (Heringa 2002). These errors are caused by 
mistakes in the initial alignments and incorrect branching order of the initial guide 
tree. Subsequently, such factors hamper the possibility of finding the global optimal 
solution (Thompson, Higgins & Gibson 1994). 
More specifically the guide tree utilised in Clusta1W is developed using the 
neighbour-joining (NJ) method. In this distance clustering method, two of the most 
closely related sequences are chosen first, and then another branch will be added to 
the tree by including the next most distant tree (Rastogi et aI., 2004, p.1 09). The NJ 
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method is known for its rapidity. Edgar (2004), however in the development of the 
Muscle progressive alignment package decided to use the Unweighted Pair Group 
Method with Arithmetic Mean (UPGMA) method in preference to the NJ methods 
for the development of a guide tree, as this method was found to give results that 
were slightly better (Edgar 2004) (see p.53 for more on Muscle). The main way in 
which the UPGMA method differs from the NJ method is through the calculations 
of average values (Rastogi et aI., 2004, p. 200). 
LaserGene in addition provides the freely available BLAST alignment tool, which 
is the most well known sequence similarity package available to the bioinformatics 
community (Altschul et aI., 1990). Since its introduction a number of BLAST 
related programs for different types of sequence comparison have been introduced. 
The original BLAST is a local alignment tool, based on words, statistics and human 
instincts. For instance BLAST is used to search databases and to look for common 
patterns (Kanehisa & Bork 2003). Comparisons with the human eye are made 
between unknown DNA and protein sequences with hundreds of thousands of 
sequences from humans and other organisms, until a match is found. BLAST 
calculates the statistics of high scoring segment pairs (HSP). These form the basis 
for local alignments that are characteristic of the BLAST output (Attwood & Parry-
Smith 1999, p.127). Care needs to be taken when finding new sequences based on 
homology. For example information deduced, is only as accurate as the original 
information in the databases. In addition, it is only comprehensive as long as the 
database contains all the sequences currently characterised (Apweiler et aI., 2003). 
7.5.3.1 Genetic Data Analysis 
From the Sanger Institute case study some data were collected on the analysis of 
genotyping data. The Illumina genotyping solution used at the Sanger Institute 
made use of the GenCall application that automates the process of clustering and 
grouping individuals based on their genotypes, calling genotypes and giving 
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confidence scores. With this software firstly a clustering algorithm known as 
GenTrain is used to derive a set of locus-specific variables for each SNP and this is 
then used as input for GenCall. A GenCall score is obtained, which is used to filter 
out genotypes that have failed (Fan et aI., 2003). 
Such clustering and classification of genotyping data is analogous to the 
classification of genes into groups as discussed in Section 3.8.2 on p.72. Similar 
clustering algorithms have been applied to genotyping data. For instance, Heil et 
aI., (2002) assessed methods such as k-means clustering, but decided against using 
them due to their inflexibility in genotyping data analysis. For example k-means 
clustering is ineffective in handling the varying number of genotype outcomes and 
would also force data into a fixed number of clusters (say four for example) 
whereas autocalling of genotypes needs to be able to identify scenarios of two 
clusters, three clusters etc. Other machine learning algorithms did not fare much 
better as the training process was confused by the huge differences in dye 
intensities between plates. These authors instead had to design their own algorithm, 
which took account of the relative position of samples in polar coordinates in order 
to make genotyping calls (Heil et aI., 2002). 
Olivier et aI., (2002) are others who also experimented with the use of k-means 
clustering, exposing its limitations for the clustering of genotyping data. These 
authors assessed the performance of k-means clustering with another clustering 
algorithm called CA. k-means clustering was found to have a higher failure rate of 
assigning samples to clusters. Like k-means, The CA algorithm made use of a 
predetermined number of clusters. However, the CA algorithm also made use of 
heuristics to initially define centres of gravity for data points, which were then used 
to reassign cluster membership to these centroids based upon standard deviation 
values of data points around each ofthe centroids. 
209 
Chapter Seven Discussion 
Other interesting work in this area has made use of a model-based clustering 
method for genotyping data analysis in which observations are arranged into 
angles. Such a model is able to handle different variations and can identify outliers. 
However this approach still forces the number of groups to be fixed beforehand like 
k-means clustering. Fujisawa et aI., (2004) addressed this issue by modifying the 
model-based clustering approach using a penalised likelihood. What this does is 
remove the need for prior identification ofthe number of groups. 
7.5.4 Use of LIMS 
A LIMS formed a part of the Pharmacogenomics workflow at the Sanger Institute 
and also in the workflows in place within RDG. The Golden Gate assay in use by 
the genotyping facility at the Sanger Institute is controlled by a LIMS system, 
which is developed by Illumina in collaboration with Wildtype informatics (Fan et 
aI., 2003). Specific information was not obtained about this LIMS but in general 
each sample is given a unique identifier which is then tracked real time. At the 
Sanger Institute another LIMS type system was also in use known as the ExoSeq 
database (implemented in Oracle) developed by informatics experts internally to 
track the peR process and sequencing of exons (see Figure 5.2.1 b on pp.128-131). 
The genotyping samples, used at AstraZeneca are also tracked real time as 
workflows but in contrast to the Sanger Institute, the LIMS used is designed by 
Lab Vantage (Lab Vantage 2004). AstraZeneca had brought in the Lab Vantage 
Sapphire LIMS as their genotyping laboratory information management system to 
track, group and view genetic samples and genotyping data generated through 
Pharmacogenetics projects. The interface of this LIMS has to be customised 
according to the users' requirements and needs. However this is also one of its 
biggest benefits as the functionality of the Sapphire can be used in a number of 
industries and markets (Lab Vantage 2004). The LIMS will become increasingly 
important for activities carried out by scientists in RDG. For example it is possible 
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that it may generate output files of genotyping data in a fonnat that could be 
automatically fed into statistical analysis tools, thus removing the manipulations 
that are carried out on the data pre-analysis at present, making the process faster. 
This would certainly improve efficiency. It seems that the LIMS would also be a 
storage solution for the data generated through whole genome scans, although 
thought would be needed as to how and where to analyse these data. The capacity 
of the LIMS at present may be sufficient, but additional disk space and memory 
may need to be upgraded. 
The commercial Sapphire LIMS by Lab Vantage however lacks some of those 
characteristics of the publicly available MMP-LIMS (Sanchez-Villeda et aI., 2003) 
discussed in section 3.9.2.4 on p.92. For instance the Sapphire LIMS is based on a 
browser-based architecture whereas MMP-LIMS is available both via the web and 
as a client/server system. Having said this, the browser-based architecture of the 
Sapphire LIMS was designed to address the high costs involved in setting up client 
applications. MMP-LIMS also contains a method for validating and verifying 
genotyping scores. The Illumina LIMS in use at the Sanger Institute however does 
provide a GenCall score to each genotype call in order to provide confidence to 
these (Fan et aI., 2003). 
7.6 Contribution to knowledge 
At a broad level the contribution of this study has been to add to limited research 
into infonnation seeking and use in the bioinfonnatics area. More specifically what 
has been lacking are studies into user infonnation needs, infonnation flows, how 
users interact with biomedical infonnation management tools, and what tasks users 
are trying to do making use of infonnation. The following table (see Table 7.6 on 
pp.212-215) will highlight the key contributions from each section ofthe discussion 
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chapter, which will illustrate confinnation of existing knowledge and highlight new 
knowledge fonned. 
Table 7.6 Contributions extracted from the Discussion 
Section/Subsection Title of Contributions 
section/subsection 
7.1 Use of qualitative and Limited number of 
quantitative research qualitative/quantitative 
methods studies in the 
bioinfonnatics domain. 
7.2 Implications of Sanger 
Insitute Case study 
7.2.1 Significance of the The introduction of a 
primer design issue standard for manual 
primer design would 
faciliate the complete 
standardisation of the 
Sanger Institute 
Phannacogenomics 
workflow. 
7.2.2 Significance of the DNA It is possible to standardise 
preparation issue the initial stages of DNA 
preparation including 
quantitation for all 
genotyping platfonns and 
then split into specifics for 
Illumina. 
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Section/Subsection Title of Contributions 
section/subsection 
7.3 Implications of Use ofHenczel's (2001) 
AstraZeneca Case study Information Audit model 
uncovered: 
7.3.1 Use of inappropriate The use of outdated 
resources technologies is prominent 
for data storage and 
processing of lab level 
data. 
7.3.2 Duplication of The use of e-mail for 
information handling important information 
exchange is proving to be 
erronous and unreliable. 
7.3.3 Information Hoarding Scientists were failing to 
put valuable information 
back into the Gene 
Catalogue system to make 
it available to all those 
with access to Gene 
Catalogue. 
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Section/Subsection Title of Contributions 
section/subsection 
7.4.1 Literal Replication Workflows that identify 
genetic variation in DNA 
sequence in a high 
throughput manner, and 
use this information to 
help predict disease are 
similar in pharmaceutical 
labs and publicly funded 
academic labs. 
7.4.2 Theoretical replication Workflows used in 
publicly funded academic 
research labs generate 
data with a greater 
throughput than similar 
workflows in 
pharmaceutical labs. 
Members of a genetics 
department in industry 
involved in more projects 
work at a faster pace than 
a similar department in an 
publicly funded academic 
organisation. 
214 
Chapter Seven Discussion 
Section/Subsection Title of Contributions 
section/subsection 
7.5.1 The use of Human Ensembl is an essential 
Genome resources resource for scientists 
both in academia and 
industry who are 
researching genes of 
medical interest. 
7.5.2.1 Gene Catalogue Publicly available data are 
brought in through an 
internal interface at 
AstraZeneca. 
7.5.3 Analysis software At AstraZeneca there was 
more emphasis on 
commercially available 
analysis tools. 
7.5.3.1 Genetic Data Analysis Genetic data analysis 
techniques are analogous 
to the clustering 
approaches used for 
micro array data analysis. 
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The novelty of the research carried out in this study was the blending of disciplines; 
namely the social sciences and bioinformatics. This involved using case study 
methodology made up of the triangulation of research methods to collect data on 
biomedical information seeking and use, and issues such as those already 
described. Analysis and interpretation of data enabled the differences and 
similarities in scientific workflows used by a Genetics department in a leading 
pharmaceutical company (AstraZeneca in Alderley Park) and a world class publicly 
funded academic biomedical research centre, namely the Sanger Institute in 
Cambridge to be determined. 
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Chapter Eight: Conclusions and recommendations 
This chapter is based on the aims and objectives described in Section 1.5 on p.10 
and discusses whether or not these were achieved. Recommendations for both the 
Sanger Institute and AstraZeneca will be given along with plans for future 
research. 
8.1 Review of the aims and objectives 
Aim one was to critically review the different ways in which the principles and 
concepts of information management are applied to bioinformatics. This aim was 
achieved through the critical literature review in Chapter Two (see p.13). Aspects 
of information management were discussed through topics such as creation of and 
distribution of bioinformatics information, organisation of bioinformatics 
information and the control of its content, information retreival, and analysis and 
storage ofbioinformatics information. 
The second aim was to review causes of information overload experienced by 
scientific researchers and to propose a theoretical/technological solution. This aim 
from a theoretical point of view was met. Chapter Four highlights the problem of 
information overload and discusses current solutions found in the literature (see 
p.103). From a technological point of view, bioinformatics metadata standards were 
envisioned as part of a wider solution to the problem of information overload 
through the standardisation of data collection and representation (see Section 4.8 on 
p.1l9). These issues were explored further and a minimum information guideline 
for the process of primer design was developed. This standard itself can be made 
electronic through its mapping into an XML model (see Section 5.3.2 on p.132). 
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Aim three was to evaluate the use of the semantic web and e-science technologies, 
to improve knowledge repositories, manipulation and dissemination. This aim was 
met through researching into the semantic web field and its application to the 
bioinformatics field. The fruits of this study are the publications found in Appendix 
Aonp.267. 
Objective one was to carry out two case studies to explore the information 
environments in biomedical departments in academia and industry. Processes were 
studied in more detail in a real world setting through the implementation of case 
studies of the Genetics department (RDG) at AstraZeneca in Alderley Park and the 
other in the Pharmacogenomics group at the Sanger Institute. A thorough overview 
was captured of how biomedical departments function in academia and industry, 
and how information is used and distributed between department members both 
electronically and verbally. In the case studies information management strategies 
used in the respective workflows in place at the two organisations were studied. 
This meant that objective two which was to study scientific workflows associated 
with pharmacogenomics was satisfied. Proof of this achievement is evident in 
Chapter Five (see p.120) and Chapter Six (see p.140). Objective three was to study 
the different datasets generated and used in pharmacogenomics and objective four 
was to determine resources used for data storage and processing. These two were 
also satisfied as more specifically details were obtained on the types of data that 
were generated and used, the representation of these, and the databases and LIMS 
in which these data were stored. 
Objective five was to develop a prototype for pharmacogenomics metadata and it 
was hoped that data could be collected from the Sanger Institute to develop a 
metadata standard for gene expression-based pharmacogenomics. However 
implementation of such a standard was not possible as the Sanger Institute used a 
genotyping approach to pharmacogenomics, rather than gene expression. Having 
said this data collected 
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through interviews enabled the design of a minimum infonnation guideline for the 
process of manual primer design which is a key experimental technique used in 
phannacogenomics experiments. This standard is discussed and illustrated in 
Section 5.3.2 on p.13l. 
8.2 Recomendations for Sanger Institute and AstraZeneca 
The recommendations listed below are based upon a synthesis of the points 
discussed in Chapter Five (see p.120) and Chapter Six (see p.140) and Section 7.2 
(see p.181) and Section 7.3 (see p.185). The following are the recommendations for 
the Phannacogenomics group at the Sanger Institute and then for the RDG 
department at AstraZeneca. The recommendations for AstraZeneca highlight 
changes needed at present and in two years time. 
Recommendations for the Pharmacogenomics group at the Sanger 
Institute 
• Introduce a minimum infonnation guideline for the process of manual 
primer design for the exon resequencing project. This would mean that the 
entire Phannacogenomics workflow would be completely standardised. 
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Recommendations for RDG 
EducatiOlI and support 
• Provide training to geneticists with up-to-date knowledge and experience in 
information management solutions, with particular emphasis on database 
technologies and their integration. 
• Provide knowledge to geneticists of high performance computing (e.g. 
GRID's for biosciences and pharmaceutical sciences) along with their 
benefits. 
• Invest in bioinformatics experts for support locally. 
Improvements to current data storage and processing 
• Migration to more updated database management systems that provide 
improved performance and reliability such as MySQL, Oracle, Sybase etc 
for data generated at the laboratory level. 
• Use Access as a front end to another data management platform such as 
MySQL. 
• Make more requests to IS and informatics experts to search for and develop 
new methods of analysis to minimise the need for manual processing and 
cleansing of data to put them into required formats for analysis. 
• cleansing of data to put them into required formats for analysis. 
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• Putting data back into Gene Catalogue by teams working in Genetics in 
Target Discovery and those working on Genetics Supporting Projects that 
support Target Discovery, making it available company wide by the use of 
minimum data content standards such as those developed by the Microarray 
Gene Expression Data Society (MGED) (MGED Society 2005). 
• Develop a single storage and retrieval system specific for RDG with 
integrations to Gene Catalogue, based on the concepts of the semantic web 
(Bemers-Lee et aI., 2001) and standards for data representation and 
exchange such as those developed by MGED and the Human Proteome 
Organisation Protein Standards Initiative (HUPO-PSI) (HUPO Proteomics 
Standards Initiative 2005). 
• Add an audit trail mechanism to Excel spread sheets created and used within 
RDG. This is particularly important for sensitive data being imported from 
clinical trial databases as part of a regulated process. For example 
components such as Information Rights Management found in MS Office 
2003 could be considered (Microsoft Corporation 2006). Alternatively 
applications are available such as Remediation Services for Excel 
spreadsheets from Scientific Software, Inc which could be used (Scientific 
Software, Inc 2006). 
• Research into methods to integrate clinical data into the LIMS. 
• Develop methods to be able to carry out genotype-phenotype analyses using 
the LIMS. 
• Introduction of a more effective database structure to enable meta-analyses 
in Pharmacogenetics studies. 
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• Development of more specific pharmacogenetics resources such as the pilot 
drug transporter system. 
Communication 
• Address communication gap between RDG and CIG. 
8.3 Limitations of study and barriers to progress 
There were limitations within the case studies particularly in terms of external 
validity. For example the results of the Sanger Institute were based on such few 
people, that it was difficult to be confident about the generalisability of the results 
that determined the development of the decision making tree for manual primer 
design, for the exon resequencing project. Having said this it did provide the 
foundations for a larger project in which more data can be collected on how 
scientists carry out primer design and for what types of experiments they were 
needed for. This additional data could possibly be collected from scientists at the 
University of Liverpool, resulting in the expansion of the decision making tree. 
Also the results from the AstraZeneca case study are those specific for the RDG 
department. It would have been interesting however to see how similar or different 
results would have been with another genetics department in a competitior 
pharmaceutical company. 
A further specific limitation of the AstraZeneca case study was in the carrying out 
of the interviews with scientists. The questions asked (see Section 3.3.2.1 on p.90) 
were not piloted beforehand as a consequence of the stringent timeline followed 
when in the organisation. As an indication, the first set of interviews were carried 
out on the same morning that the information context was finalised. In fact the 
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interview questions listed on p.90 evolved from the first set of meetings with senior 
scientists. 
There were also some barriers to progress in the two case studies performed. For 
example in the Sanger Institute case study, an information standard for expression 
profiling pharmacogenomics was planned. However it was found that the Sanger 
Institute carried out pharmacogenomics experiments through a genotyping 
approach. The use of genotyping involves a different workflow to the use of 
expression profiling. This meant that the research had to change focus in terms of 
the type of experiment investigated. A key barrier in the progress of the 
AstraZeneca case study was the lack of access to clinical information stored in their 
databases. This was expected due to the sensitive patient information that these 
resources contained. Nevertheless, being able to study the structure of clinical 
datasets in more detail would have been useful in allowing further study of how 
these datasets are generated and stored, and at which points these data are 
integrated into pharmacogenetics experiments. 
Other general barriers varied in level from research design to barriers in the actual 
selection of the case studies. In the research design for example, it was hoped that 
additional stakeholders would participate in the project so that a more quantitative 
approach could have been taken. Doing this would have allowed more data to be 
collected from a wider sample about requirements for a metadata standard for 
pharmacogenomics, which may have led to the results being more generalisable to 
the wider population. In the end this was not possible and so case study 
methodology had to be used as only four organisations had decided that they would 
possibly participate. The cases were AstraZeneca in Alderley Park and the Sanger 
Insititute. The other two had given tentative permission to organisation access and 
were the Department of Pharmacology and Therapeutics at the University of 
Liverpool and the Queens Medical Centre (see Section 3.2.1.2 on p.85 and 
Appendix B on p.337 on CD-ROM). However these two organisations 
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subsequently chose not to participate in the study. The inclusion of further case 
studies would have been interesting however, as they would have allowed deeper 
exploring ofliteral and theoretical replication issues (see Section 7.4 on p.l93). 
8.4 Plans for future research 
Following the conclusions made above, together with the recommendations to the 
case study sites and limitationslbarriers to progress, the ideas below provide an 
outline to what might be achieved in the near future should research in this area 
continue. 
• Integrate the minimum information guideline for manual primer design into 
an open source initiative such as MIPE (Aerts & VeenendaaI2005). 
• To continue research on the development of a decision making tree for 
manual primer design including data from different laboratories to establish 
any differences in the minimum information required for designing primers 
for peR. This exercise would also determine any different pieces of 
information that need to be captured for primers designed for other 
biological experiments. Any new problems that may occur would be 
established and solutions for these could be stated. 
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• Possible collaboration with the EBI who are actively developing standards 
including a mInImUm information guideline for expression-based 
pharmacogenomics. 
• To study the impact of information overload experienced by biomedical 
scientists more specifically; using case studies or a questionnaire survey, 
and establishing what current methods are being used to reduce information 
overload in intense information environments. 
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Impact of Semantic Web on Bioinformatics 
Hiten Vyas and Ron Summers 
Abstract-The paper will present current research 
work that sees the marriage of internet communication 
technologies that provide semantic links to context and 
the application of large, complex, distributed databases 
to bioinformatics. Crucial to this effort is the 
recognition of novel metadata standards for 
bioinformatics that will allow their seamless 
integration into the semantic web. These standards 
include data exchange and storage as well as 
information representation and visualisation. Using the 
interdisciplinary approaches described will thus 
provide a semantic web solution for the bioinformatics 
discipline. 
Index Terms - Bioinformatics, integration, 
ontologies, semantic web. 
I. INTRODUCTION 
T HE way the intern et has revolutionised the 
publication and dissemination of information is 
extraordinary. However, the way in which humans 
access and retrieve this information is far from ideal. 
The current model supports mostly human browsing 
and searching for textual information. The semantic 
web as proposed by Berners-Lee, Hendler and 
Lassila in [1] aims to develop the current web into 
one in which information and services can be 
manipulated not only by humans, but also by 
intelligent agents (information brokers, search agents 
and information filters). To enable the automated 
processing of web material, where it can be combined 
and understood requires machine-processable 
semantics to be associated with it. This is achieved by 
the use of metadata. The semantic web is not meant 
to replace the existing web; instead it will sit on top 
of it [2]. 
The semantic web acts as infrastructure on which 
applications will extend and develop. Business to 
Business (B2B) e-commerce is one such application. 
However in this paper, we are concerned with 
linkages in the bioinformatics discipline. Many 
definitions of bioinformatics exist that often leads to 
confusion. Here it will be defined as the application 
of information science to obtain, store, organise, 
collect, visualise and analyse molecular biology data 
[3]. 
11. INFORMATION MANAGEMENT CHALLENGES IN 
BIOINFORMA TICS 
A huge amount of bioinformatics information is 
distributed over the internet. Access to these 
distributed data and combining these data from 
multiple sources, while at the same time dealing with 
heterogeneity is very difficult [4]. In addition the 
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biological data are available in different formats. 
These can range from simple words such as gene 
names, to strings for nucleic acid sequences. 
Information can also be found as free text, for 
instance as publications and also as images and 
graphs for pathway networks [5]. The 
incompatibility of data formats and database 
schemas thus adds to the challenges of managing 
this information. 
There are also well documented terminology and 
semantic issues. For example, there is a synonym 
problem in that the same entity, (say a gene for 
example), may have a different name in different 
databases. Likewise a homonym problem exists in 
that different entities can also have the same name. 
In addition, there is often confusion as to the 
definition of the most fundamental biological 
objects, such as gene and protein [6]. For example, 
a term that has multiple meaning is 'protein 
function'. In terms of biochemical function, 'protein 
function' could mean 'enzyme catalysis', or in terms 
of genetic function it could also mean 'transcription 
repressor' [7]. 
The intemet is guided by standards set by the 
World Wide Web. These include standards for data 
exchange, node naming conventions etc that enable 
a certain level of interoperability. Standardisation of 
bioinformatics resources have lagged behind. Lack 
of such standards has meant that research groups 
often have to create their own tools for analysis and 
handling of data. However, standardizing data 
exchange formats would simplify information 
management and analysis tasks. One area in 
bioinformatics that is well standardised is genomics. 
For instance international repositories such as 
GenBank [8], EMBL Nucleotide Sequence Database 
[9] and DNA Databank of Japan (DBBJ) [10] have 
created standards for archiving primary sequence 
data. 
The introduction of high-throughput 
experimentation introduces different challenges. For 
instance, data from transcriptomics studies, 
proteomics studies and pharmacogenomics studies 
produce data that are meaningful only when put into 
context [1 I]. For example, there are many different 
subsets of proteins that are pharmacologically 
relevant, as is also the case for genes. Such studies 
use different data formats, different experimental 
platforms and sample preparation protocols, and 
different normalization algorithms. This makes 
comparing data sets a nontrivial task [12]. The 
combination of information from many experiments 
has the potential to provide much more knowledge 
than a single experiment [13]. However, such tasks 
need the creation of standards for information 
representation capturing all the aspects of an 
experiment from the design of an experiment to 
validation of the results. 
Ill. INTEGRATION AND INTEROPERABILITY 
The integration of information in bioinformatics 
remains difficult for those reasons discussed in the 
previous section. Traditional methods for integration 
have been through federation, one type of which is 
link integration. With this method, the user extracts 
information from one database and moves to other 
databases through hyperIinks [14]. With this kind of 
interoperability, maintaining and updating links can 
prove to be difficult. An example of such integration 
is the powerful and efficient keyword indexing and 
search application: sequence retrieval system (SRS) 
[15]. SRS is based on flat files which is the major 
standard for integration of many databases. The fact 
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that flat file indexing is simple means that new data 
sources can be added to SRS fairly easily. From a 
human computer interaction point of view it has an 
attractive interface that enables researchers to create 
queries straightforwardly. However. SRS is also 
limited in that it is a very basic retrieval system that 
returns entries through trivial aggregation. In 
addition an indexing script has to be provided for 
each database that researchers must create using 
scripting languages such as Perl. Each of these 
indexing scripts has the responsibility for creating 
links to additional databases [16]. [17]. 
Another type of integration is view integration. 
In this approach all the information is kept in 
databases but an environment is created where the 
databases seem as if they are part of one central 
system to form a global schema. This central system 
is a common data model which can be as object-
oriented. relational or complex value. Kleisli is an 
example of a data integration system that is based on 
view integration. allowing numerous data sources to 
be viewed as if they belong in a federated nested 
relational system [18]. Kleisli is a mediator system 
that includes in it a nested relational data model. a 
higher level query language and a query optimiser. It 
functions on top of a large number of wrappers to be 
able to access different sources. Kleisli is extremely 
extensible. In the one instance it is able to support 
different high-level languages by replacing its high-
level query language module. Two of these 
languages are the Collection Programming 
Language that is based upon the comprehension 
syntax. and the nested relationalised version of SQL 
known as sSQL. However these are also the 
disadvantages of Kleisli. CPL and sSQL are high-
level query languages and hide many low level 
details from the user such as communication 
protocols memory management etc. However 
programming queries in CPL or sSQL can be difficult 
for a biologist with minimum computing skills [16]. 
In data warehousing all the information is 
dumped into storage as a global schema and any 
querying is dealt with by the information in the 
warehouse. instead of individual data sources [19]. 
However. this approach requires writing extremely 
difficult web service wrappers that transform 
complicated biological data into a representation that 
the RDBMS can understand [20]. Current Web 
technology is inadequate for effective integration and 
interoperability in an interdisciplinary discipline such 
as bioinformatics. An opportunity to remove these 
problems discussed above is provided by the 
semantic web. Figure 1 outlines a very simple 
semantic web architecture for bioinformatics (please 
note that additional layers can be included). Metadata 
will be crucial for the semantic web ofbioinformatics 
resources [21]. Languages will express this metadata 
and a language layer will be needed to express 
semantic web material such as XML and Resource 
Description Framework (RDF). Resources such as 
shared ontologies and databases will feed the 
language layer and applications such as the 
bioinformatics Grid platforms will exploit the 
semantic web resources. 
IV METADATA 
Metadata is data about data [21]. In 
bioinformatics. standards for metadata will be vital 
for interoperability of biological data held in different 
file formats. databases and repositories. For instance. 
consider a scenario where a bioinformatician needs to 
extract protein data from more than one database and 
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send the results to be matched together by a 
computer. The bioinformatician may use metadata to 
choose which database to use. This metadata could 
describe the quality of the source. Metadata about 
the computer could provide information about its 
availability and metadata about the visualisation 
engine of the client could indicate its suitability for 
display [22]. XML is a technology that allows 
digital sets of biological data to be tagged with 
computer readable metadata. 
V. BIO-XML 
The first step in the direction of a real semantic 
web is to allow the researcher to make hislher own 
tags. XML does this. In XML, tags are used to 
structure textual data in a document. Data in 
bioinformatics is infamously renowned for being 
complex. For instance, for any given record there 
can be many levels of nesting, each level having 
many levels of logical structure. Traditional 
relational storage and integration methods are ill-
equipped to manage effectively such data. XML on 
the other hand mimics the natural hierarchical nature 
of biological molecules and allows for logical 
structuring of knowledge about biological molecules 
[16]. XML is flexible, as it is able to deal with any 
data structure [21] and is a powerful data model that 
provides an effective data exchange format [16]. 
Bioinformatics researchers can use XML to 
integrate metadata and data for use within research 
communities in projects such as BSML. BSML 
(Bioinformatics Sequence Markup Language) is an 
example of an XML based language for 
bioinformatics [23]. BSML attempts to encode three 
types of information known as definitions, research 
and display. Information included in definitions, 
include biological molecules such as DNA and RNA 
and protein structures. In research the information is 
usually about queries, experimental protocols and 
analyses while display is concerned with the 
visualisation of these, information through the use of 
graphical metaphors [23]. 
In BSML the outmost tag is known as the 
<bsml> tag and is used to describe a BSML 
document. Within this tag are found three sub tags 
which correspond to the three major information 
elements represented by BSML which are 
<definitions>, <research> and <display>. Other tags 
can also be used to encode additional biological 
information such as genomes, isoforms and networks 
[23] BSML encodes genomics information at 
multiple levels, from the complete genome down to 
base pairing. For instance a complete hierarchy of 
elements is available for genomes «Cell-line>, 
<Genome>, <Chromosome>, <Cytoband». 
Encoding of isoform includes modelling of 
mutations, SNPs, phenotypes, genotypes and 
pedigrees. The <Case> element can be used to do 
this. The representation of metabolic networks and 
gene regulation networks is carried out making use of 
the graphical elements <Node> and <Arc> [24]. The 
Biological variation markup language (BVML) is 
another data model for the communication of genetic 
variation or polymorphism data [25]. RNAML is 
another initiative especially created for the exchange 
of RNA biology information [26]. 
The functional genomics community has 
introduced some excellent models for information 
storage and exchange. The microarray gene 
expression data society (MGED), have proposed a 
suite of standards including the XML-based 
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microarray gene expression-markup language 
(MAGE-ML) [27]. Complementary to this is the 
microarray gene expression object model (MAGE-
OM). While MAGE-OM provides specification for 
standardised data representation in a database, 
MAGE-ML provides a common data format for data 
exchange between databases [28]. The minimum 
information about a microarray experiment 
(MIAME) [29] is a standard for information 
representation that provides guidelines for 
interpreting microarray data and allows independent 
validation. These three standards and their integrated 
use can elegantly be illustrated by the information 
content of the microarray gene expression database 
ArrayExpress. The three major parts of the database 
which are arrays, experiments and protocols are 
conceptually described using the MAGE-OM data 
model. Data is submitted using the MIAME 
annotation guidelines and the architecture for data 
storing is based upon community use of the MAGE-
ML exchange format [30]. 
It has been suggested that MIAME's 
recommended guidelines are too simplified for 
comprehensive gene annotation. For example the 
suggested annotations for micro array probes include 
attributes such as identity, sequence, the associated 
target sequence and also gene symbol and any 
references to genome databases. Having said this, 
careful and in-depth analysis of gene expression data 
requires access to the functional characteristics of 
target genes for accurate interpretation of analysis of 
results. Another drawback of the MIAME guidelines 
is found in the minimum requirements for sample 
annotations which are insufficient to create the 
context required for analysis of expression profiles. 
Additional information needs to captured, for 
clinical information, morphology and pathology for 
samples [31]. However, the research community has 
welcomed MIAME and major journals such as 
Science and Nature require compliance when a new 
submission is being entered. MIAME requires that 
information be structured through the use of 
controlled vocabularies and ontologies. 
Proteomics is an emerging science and huge 
numbers of datasets are expected to be produced 
using various high-throughput biochemical methods. 
HUPO a similar consortium to MGED, but for 
proteomics and has introduced analogous tools to 
facilitate knowledge discovery in the proteomics field 
[32]. PEDRo (Proteomics Experiment Data 
Repository) [11] has been developed to capture data 
and metadata about laboratory proteomics 
experiments, producing an XML-based PEML 
(proteomics experiment mark-up language) file for 
storage or submission to a repository. PEDRo is able 
to store information about sample origin, mass 
spectrometry data and results of in silico experiments 
[33]. Figure 2 illustrates a multi level description of a 
proteomics experiment. 
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VI. WEB SERVICES 
As the semantic web grows, web services will be 
responsible for more and more infonnation for 
seamless interoperability among online resources. 
The distributed architecture of bioinfonnatics makes 
it ideal for the application of web services. A web 
service uses standard-based components such as 
mutually accepted data fonnats and access methods 
and a directory service that enables scripts to locate 
them [34] For example, imagine a bioinfonnatics 
web services environment where the NCBI, the 
University of California in Santa Cruz (UCSC) and 
the European Bioinfonnatics Institute (EBI) could 
all provide the same sequence-similarity service. 
The same script written for one service could be 
used to work for all three sites, even though the 
service implementation is very different in each case 
[34]. 
An example of an early web service for 
bioinfonnatics is the DAS (Distributed Annotation 
System) [35]. DAS provides a web service for the 
exchanging of genomic annotations. In DAS the user 
asks for a genomic region of interest and does this 
by naming the genome, a landmark on the genome 
(for instance a clone accession number or a genetic 
marker), and a region of the genome related to that 
landmark [36]. Specialised annotation servers then 
return a structured document listing annotations 
across defined areas of the genome. It also provides 
integration but this is limited and does not solve 
semantic discrepancies between resources [35]. DAS 
has other disadvantages like the fact that it is not 
easily extendable. For instance if groups wish to 
create a DAS that functions for protein motifs, 
genetic and physical maps then this would not be a 
simple thing to do [35].. The infonnation about 
annotations presented by DAS is at a minimum. 
Other weaknesses include a difficulty to locate DAS 
servers. A method to register a new server does not 
exist. However, it is its semantic weakness that is the 
main problem [36]. 
The role of XML is paramount to web services. 
Two other components while not obligatory are 
commonly used: SOAP and HTTP. XML can be 
distributed over the Internet by using SOAP (Simple 
Object Access Protocol). SOAP provides 
specification for the encoding of different types of 
data into XML documents and how to exchange these 
documents in a distributed architecture. SOAP uses 
HTTP that carries knowledge of how to transport 
messages that are encoded between Web sites [37]. 
HTTP itself is distributed as a web service through 
application programming interfaces (API). These 
APls are defined using WSDL (Web Service 
Definition Language) [38]. 
Web services standards like those discussed in the 
previous paragraph are incorporated into BioMOBY 
[39] an example of another web services project for 
bioinfonnatics. It provides a simple common fonnat 
that is able to describe in a machine-readable way, a 
broad range of host interfaces. Each host (or service 
provider) is able to register their service types into a 
central registry database known as 'MOBY Central' 
[39]. Application programs then search this registry 
to find web services that could be of use. However a 
limitation of MO BY is that it is unable to describe all 
components of the web services it supports [36]. 
The European Molecular Biology-European 
Bioinfonnatics Institute offers some examples of 
good recent web services. For instance there is the 
XEMBL, a web service that distributes EMBL 
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nucleotide sequence data in five different formats. 
These data can be accessed through a COl-interface 
or in a programmatic fashion through CORBA 
servers [38]. Soaplab is another example [40]. 
Soaplab in-fact is a set of web services. It is often 
referred to as an analysis web service as it provides 
programmatic access to applications found on 
remote sources which are usually analysis tools. It 
uses a universal API to all command-line tools and 
uses detailed metadata stored in XML files to 
describe individual sources. 
In Figure 3 is illustrated an information bus 
which is a system that is able to support 
interoperability of various bioinformatics resources. 
This method involves wrapping various resources 
with web service interfaces. In these interfaces 
information inputs and outputs are transported as 
XML structures. Data that is passed through the 
information bus is represented using standard XML 
formats. These standard formats are enforced by 
publishing the XML schemas being used and 
carrying out validation of messages. The XML 
syntax used for input and output parameters of the 
web services is the same in spite of what the formats 
of the existing resources may be. Visible from the 
architecture is also an XML repository that stores 
documents in a relational database. A web service is 
also used to wrap this repository to allow document 
accesss through metadata and/or language. There are 
also two Universal Discovery, Description, and 
Integration (UDDI) registries. These support sharing 
of and exchange of information between 
bioinformatics resources internally and externally 
[41]. 
VII. ONTOLOGIES AND LIFE SCIENCE 
IDENTIFIERS 
Standards such as SOAP and WSDL and others, 
describe web service content in terms of XML 
syntax. While XML is a good technology for 
providing a solution to the syntax problem observed 
with new exchange formats, it does nothing to solve 
semantic inconsistencies [26]. This is the biggest 
limitation of XML and by itself is not sufficient to 
realize a vision of the semantic web encompassing 
large-scale interoperability. Another level of 
interoperability is needed where programs are able to 
describe their own capabilities and comprehend the 
capabilities of others. Languages other than XML 
will be required to represent such semantic metadata. 
Ontologies can help meet this requirement by 
capturing the main concepts of a domain. Ontologies 
alone do not integrate bioinformatics databases but 
they are excellent facilitators [19]. 
The evaluation of meaning of terms used in data 
and metadata can be done through ontologies, 
through the organisation of terms according to their 
semantic relationship and mapping fragments of 
heterogeneous data into a common framework [42]. 
The most well known ontology in the bioinformatics 
domain is the Gene Ontology (GO) [43] whose main 
purpose is database annotation. It is made up of three 
ontologies: molecular function, biological process 
and cellular component of the gene product. These 
ontologies provide a controlled vocabulary that 
enables interoperability and maintenance of genome 
databases. GO has in fact become a major standard 
used to provide annotations for submissions to a 
minimum of 14 bioinformatics databases [44]. GO 
ontology does however, have some drawbacks. For 
instance it is not clear as to the kinds of reasoning 
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that can be carried out, based upon the hierarchies of 
GO. There are no methods that allow GO to be 
validated and in addition there are not enough rules, 
for determining if a given concept is present in GO 
or not [45]. 
An example of a breakthrough ontological 
integration system is T AMBIS (Transparent Access 
to Multiple Bioinformatics Information System [46]. 
Based upon the TAMBIS ontology (TaO), The 
T AMBIS system manipulates complex concepts 
from the molecular biology and bioinformatics 
domain such as gene or enzyme computationally 
rather then putting the difficulty on the researcher, of 
having to find out themselves. The objectives of 
TaO are different to that of GO. While GO provides 
a controlled vocabulary for databases annotation, 
TaO on the other hand provides an ontology-based 
search. Another difference between the two 
ontologies is that TaO is dynamic and can grow 
without the requirement for new knowledge to be 
conceptualised or encoded. GO on the other hand is 
static and needs developers to work on encoding 
novel conceptualisations to form new concepts [47]. 
Another example of a semantic web application can 
be found in the biomedical informatics domain. 
PharmGKB [48] is a knowledge base for 
pharmacogenetics that contains an ontology made up 
clinical, pharmacological and biological knowledge 
that is interconnected by relationships and organized 
by different levels of abstraction. Experimental data 
and results are represented as instances in the 
knowledge base allowing for more complex data and 
information processing than is possible with generic 
databases [49]. 
exchange. The Resource Description Language 
(RDF) [50] is such a standard. It is an extension of 
XML that can be used to express data and metadata 
about biological information. Its main advantages 
over XML are that it removes the order dependency 
and the constructing of nested structures analogous to 
trees [51]. Metadata in RDF is represented as triples 
which can be used to construct graph-based data 
structures. In these triples are the subject (the 
resource that is being described), the predicate (the 
relationship between the subject and the object), and 
an object (the target value of the relationship) [52]. 
An example of a RDF statement can be found in 
Figure 2 (c). RDF has the ability to represent 
relationships using formal semantics enabling 
inferences to be made. This is important for 
discovering relationships among biological entities in 
an automated fashion. In addition RDF can be used to 
describe resources that exist in other formats and not 
web pages. This point is important when one 
considers that most biological data sets do not reside 
on static web sites [53]. Terms and relations in the 
GO are defined in RDFIXML syntax. 
While on the note of languages for the semantic 
web, it would useful to discuss a little about 
visualisations of ontologies and metadata. 
Visualisation In bioinformatics means the 
aggregation and integration of a variety of data for 
instance protein sequences and literature references 
and expressing relationships between them. 
Visualising such relationships is not easy and 
requires a unified spatial description of the different 
types of data to be visualised, while making use of 
unified retrieval and naming schemes [54]. 
Researchers in [55] in their work expose resources as 
A requirement for the large-scale use of views, which are user interface components that act 
ontologies, are standards for their description and as substitutes for resources. Describing views in RDF 
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enables views to be characterised according to the 
RDF classes it supports (for example gene sequence 
and protein 3D structure) and the manner in which it 
displays the resource (for example a full screen or as 
an applet). A view is then chosen that includes all 
the relevant characteristics when a specific way to 
display the information, such as a summary is 
required [56]. 
Shared ontologies can at least provide reliability 
that a term used in one database in an integrated 
environment corresponds to a matching term in 
another database. However they do not proved any 
guides about how biological objects should be 
named. Globally unique identifiers are needed. To 
address problems of disparate identifiers the Life 
Sciences Identifier naming standard proposed by the 
Interoperable Informatics Infrastructure Consortium 
(BC) has been used [57]. The LSID scheme can be 
used to assign biological data with unique LSIDs. 
LSIDs are known as a uniform resource name 
(URN) that is made up of the internet domain name 
of the resource and a database-dependent identifier. 
A valid example of an LSID would be 
urn:lsid:ebi.ac.uk:SWISSPROT.accession:P34355:3. 
The 'urn:' at the beginning is used to distinguish 
from a Universal Resource Location (URL). 'lsid' in 
the next field of course identifies the urn as a life 
science identifier. The next field is the domain name 
of the organisation, which in this case is the 
European Bioinforrnatics Institute. The authoritative 
source controls the object in the next field which is 
the SWISS-PROT database. The following field is 
an arbitrary identifier that is unique to the SWISS-
PROT. Here it is the accession number for an entry 
which in SWISS-PROT is an enzyme acyl-
coenzyme A oxidase. The last field which is a '3' is 
used to denote a unique LSID for every successive 
version of the specific entry [58]. LSID is compatible 
with a number of bioinformatics infrastructure 
projects such as DAS, BioMOBY, myGrid, MAGE-
ML and GO [59]. 
VIII. SYNERGY BETWEEN SEMANTIC WEB 
AND GRID 
The name 'Grid' refers to the distributed 
computing infrastructure for sophisticated science 
and engineering. Imagine an electricity power grid, 
but one that is made up of computing and data 
resources available seamlessly and transparently over 
the internet. The bioinformatics knowledge grid is 
where biological data and knowledge resources are 
seamlessly connected together. An example of such 
an e-science project that explores semantic web ideas 
is the Discovery Net system. It allows service 
developers to integrate tools based on already 
existing and emerging Grid standards like web 
services. It is a middleware technology that supports 
analysis of high-throughput data using workflow and 
pipeline methodologies. Data flow processes and 
pipelines are developed to express data 
transformations from one form into another through 
making use of varying services. Services catered for 
in Discovery Net include database access, data 
clustering, similarity and homology searching and 
notification [60]. 
mYGrid is another e-science project created for 
scientists working in a distributed environment. The 
primary focus of mYGrid is on data-intensive 
bioinformatics project that that aims to develop like 
Discovery Net open source high-level middleware, 
for the supporting of personalised in silico biology 
experiments on the Grid [61]. It is another example of 
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the application of semantic web concepts to 
bioinfonnatics and hence provides a good 
opportunity to discuss such concepts in a real 
bioinfonnatics set up. This section will discuss 
major semantic web concepts such as workflow 
management, service discovery, semantic integration 
and data provenance, giving practical examples of 
them, by referring to their incorporation in the 
mYGrid architecture. 
A. Workjlows 
When carrying out in silico experiments, 
bioinfonnaticians often use combinations of local 
applications and remote services. These experiments 
are made up of computer-based infonnation 
repositories and analysis tools. W orkflow techniques 
are an important component of bioinfonnatics in 
silica experimentation [62]. Workflow organises 
interoperability, distributed data, processing tasks, 
and are important for allowing the explicit 
representation of the experimental process that a 
bioinfonnatician uses [41]. InteIligen is an example 
of a workflow system that discovers protein-protein 
interactions [63]. 
It is vital to be able to capture in silico 
experiments as a reusable process that can be 
defined, published and executed repeatedly. In 
bioinfonnatics, processes are reusable at many 
levels. For instance, at the basic level a process may 
capture how to use a CGI-interface of a remote 
application [64]. This could include for example 
providing data for input, execution of the task and 
then retrieval of results for a protein sequence 
similarity search. Basic processes like this can be 
combined so that a set of applications can perfonn a 
higher-level function. An example would be 
combining the protein similarity searching with a 
pattern database to identify the family to which the 
protein belongs [65]. 
In mYGrid, in silico experiments are regarded as 
distributed queries and workflows [61]. mYGrid aids 
scientists in the creation of workflows at different 
levels of abstraction. After a workflow has been 
constructed it is run using the workflow enactment 
engine. This software device is able to send queries to 
services that already exist or can activate tools and 
interact with them [66]. mYGrid developers initially 
adopted the Web Service Flow Language (WSFL) to 
specify the types of the services and the order in 
which they are run. However, mYGrid requirements 
for supporting workflow provenance, authoring and 
versioning are not catered for by existing standards 
such as WSFL and others. Not being able to specify 
processes or resources at a semantic level meant that 
developers of mYGrid created their own conceptual 
workflow language known as XScufl. The FreeFluo 
workflow enactment tool [67] in mYGrid is able to 
support both WSFL and XScufl. FreeFluo is 
workflow orchestration tool implemented in Java. At 
its core is a orchestration framework that is not 
reliant on any workflow language. By decoupling 
itself from workflow specifications, information of 
service invocations and data models, the workflow 
enactment engine is able to orchestrate workflows in 
a generic fashion [62]. 
B. Service discovery and semantic integration 
The description of a service is vital for the for 
automated discovery and search functions, and for 
selection, matching, interoperation, invocation and 
the monitoring of execution [68]. Service discovery is 
a process where the researcher or an intelligent agent 
presents the system with a query and returned back is 
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a list off services available that match that query. 
Such resource discovery and selection is very 
important for the bioinformatics domain, where 
bioinformaticians must know the most applicable 
services so that their results are valid within the 
wider community [64]. The Universal Description, 
Discovery, and Integration specification (UDDI), 
another XML based standard can be used to provide 
a registry of web services but this does not represent 
service capabilities [69]. 
In [70], Rocco and Critchlow in their approach 
to discovery and classification of bioinformatics 
services use a service class description that groups 
web services according to the functionality they 
provide. Such a framework encapsulates services 
aIlowing the researcher to reason about a class of 
services, and not have to worry about complicated 
details of each member. Although this work defines 
the functionality of a coIlection of interfaces, it is 
still limited as XML syntax that describes the 
service classes lack explicit semantics. While mYGrid 
supports UDDI, it also aIlows for additional 
metadata due to a flexible RDF storage component. 
More precise searching is enabled due to semantic 
descriptions in RDF as triples and DAML+OIL 
attached to registry entries. DAML+OIL is an 
ontology language that builds upon existing 
standards such as XML and RDF. RDF is used to 
describe metadata about the operational factors of 
the services such as, availability of the service, 
location cost, quality etc (Goble et aI., 2003). In 
mYGrid the DAML-S service profile ontology is 
extended using DAML+OIL descriptions to describe 
the functionality of services and workflows in terms 
of inputs, outputs and function of the registry entries 
[71]. 
The discovery component of my Grid is based upon 
a set of questions which are put into categories 
according to the information that must be searched. 
An additional category of questions involve finding 
services that will carry out a specific bioinformatics 
task such as similarity searching. A question could be 
what services perform alignment and similarity 
actions? Other questions could involve wanting to 
find a service that wiII accept a particular kind of 
data. For instance, one may want to know what 
services accept a gene sequence as input. A 
successful answer to such a query would need 
domain information that described the semantic 
relationships between the various biological data 
types. Ontologies again, are used to do this [72]. 
C. Data provenance 
Data provenance is a type of metadata [73] that 
has various important uses in bioinformatics. Data 
provenance can be used to record the history of data, 
including where it came from, and all the 
manipulations it has undergone since it was created. 
Data provenance is extremely important to a 
distributed discipline like bioinformatics where data 
has been coIlected by various academic and 
commercial organisations using many different 
methods, and is then corrected and transformed and 
passed through many databases containing redundant 
curations [41]. Often these databases are complex and 
researchers are not sure about which resources are 
available. There is a lack of trust about the quality 
and reliability of these sources that is a barrier to the 
efficient access to sources. Provenance can be used 
to provide this much needed trust. A way in which 
provenance can be expressed is though annotating 
data. mYGrid, does this in an automated fashion, 
making use of ontologies to annotate provenance 
documents. 
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In mYGrid, when a workflow is executed 
provenance logs are produced in an XML fonnat, 
which are stored in the mYGrid repository. By 
annotating these provenance logs with concepts 
form the mYGrid ontology, hypertext documents of 
provenance can be created dynamically [67]. Within 
mYGrid, there are two main types of provenance. 
One type is the derivation path that records the 
process by which results are produced from input 
data. This could be a workflow, or a database query 
or a program with all its parameters. An example of 
derivation path in the bioinfonnatics domain could 
be a change in worktlow where a BLAST search is 
substituted for a PSI-BLAST one. The other type of 
provenance is annotations that objects or collections 
of objects have attached to them. Basic annotations 
can include when and where an object was created, 
the author who created it and its fonnat. There can 
also be scientific annotations that describe objects 
and their related concepts. An example would be 
describing a nucleotide sequence in a fonnat such as 
FASTA or ASNJ in tenns of its function [74]. The 
benefit of such annotations about scientific entities, 
are that they add context to raw data transfonning it 
into infonnation that is vital for interpretability 
Additional provenance data and metadata about the 
nucleotide sequence could be notes about where it 
came from, the source organism etc [73]. 
IX. CONCLUSIONS 
Bioinfonnatics is overwhelmed with challenging 
problems of an infonnation nature. Hundreds of 
resources are distributed over the internet. Much 
bioinfonnatics data resides in different data formats, 
that makes storage and retrieval tasks difficult. 
Databases exist that do not share consistent 
tenninology. Such problems make the integration of 
resources difficult and the current approaches are far 
from ideal. The semantic web, the name given to the 
next generation of the current web, offers solutions to 
these types of problems, where the current web will 
be transfonned into one that IS machine 
understandable. Imperative to the semantic web will 
be metadata. The use of XML to express metadata is 
the first step. Many bio-XML initiatives are in 
existence that, address storage and accessibility. This 
technology is vital for creation of web services for 
bioinfonnatics resources. 
However, for a true semantic web of 
bioinfonnatics resources XML will not be enough. 
Technologies that provide context and meaning will 
be needed. Ontology languages such as RDF and 
more expressive ones such as DAML+OIL will 
provide such semantics. These should be 
incorporated with standards such LSID to help the 
bioinfonnatics communities on agreeing how to name 
biological objects. mYGrid, is an e-science project that 
aims to develop open source high-level middleware 
for the supporting of personalised in silico biology 
experiments on the Grid. It is a real example of the 
application of semantic web concepts such as 
worktlow management, service discovery and data 
provenance to the bioinfonnatics discipline. 
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Figure 1. A simplified architecture of a semantic web for bioinformatics 
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<rdf:RDF xmlns:rdf=''http://www.w3.org/1999/02/22-rdf-syntax-ns#'' 
xmlns:promis=''http://ils.unc.edu/promis/terms/''> 
Have 
Parameters 
J Have 
<promis:sampleProcess rdf:about=''http://ils.unc.edu/promis/examples/ex#l/''> 
<promis:sampleProcessType> separation </promis:sampleProcessType> 
<promis:sampleProcessTool> Two-dimensional gels </promis:sampleProcessTool> 
<promis:sampleProcessToolProtocol> http://ils.unc.edu/promis/protocols#101 
</promis:sampleProcessToolProtocol> 
</promis:physicalProcess> 
</rdf:RDF 
Figure 2. Multi-level description ofa typical proteomics experiment: (a) Partial entity-relationship diagram. (b) 
Examples of entities with their metadata attributes. (c) An example ofRDFIXML document type definition from the 
Proteomics Metadata Interchange Schema (PROMIS) project. 
(after MacMullen, 2003) 
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Bringing Semantics to Pharmacogenomics 
Hiten Vyas and Ron Summers 
Department of Information Science 
Loughborough University UK 
Abstract-Effective knowledge management of the 
pharmacogenomics discipline presents many challenges when 
compared to other 'omic' studies such as genomics and 
proteomics. For instance, there are different approaches to 
pharmacogenomics and different high-throughput methods 
are used that produce data that are highly variable. 
Conversely what makes pharmacogenomics unique is the 
need for effective management and integration of phenotypic 
data (that is molecular, cellular and clinical data) along with 
genotypic data. This paper will explore data, information and 
knowledge management issues associated with 
pharmacogenomics. The identified issues, such as 
interoperability of data sources, will be facilitated by the use 
of GRID and e-science technologies. Emphasis will be placed 
on the use of semantic methods and a novel metadata 
standard for pharmacogenomics will be proposed. 
I. INTRODUCTION 
Phannacogenomics can be defined as the total 
complement of genes that may detennine drug response 
with the aim of finding novel targets for drug design. It 
can be considered a broader concept than 
phannacogenetics, which is the study of genetics to 
detennine drug response (often associated with drug 
metabolism) [1]. Although the tenns are used 
interchangeably, the focus of both fields is different with 
phannacogenomics focusing on differences between 
several drogs with regard to expressed or non expressed 
genes and their association with phenotype, while 
phannacogenetics emphasises on differences among 
individual people with regard to clinical responses to 
drugs [2]. In this paper however, the tenns are considered 
equivalent. 
From a phannacogenomics point of view, the 
deciphering of the human genome and the knowledge that 
there are about 30,000 genes has greatly boosted drug 
discovery research. For instance the possibility of 
identifying novel genes that may be important in the 
mechanistic processes of disease and thus may be potential 
targets for therapeutic intervention has been greatly 
increased [3]. The ultimate goal of phannacogenomics is 
the prescribing of individualised medicine having at hand 
the knowledge of an individual's genetic profile and the 
genetic basis of the disease resulting in the reduction of 
adverse effects and increased efficacy of the treatment [4]. 
Parallel with such new opportunities, the challenge of 
managing effectively the data being produced from 
phannacogenomics experiments increases. The need for 
biomedical infonnatics defined as the application of 
infonnation science and technologies for the management 
of biomedical data will be vital to provide resources for 
storage and analysis of phannacogenomics data. The data 
produced through phannacogenomics using high-
throughput technology are highly variable, which increase 
in infonnation content and complexity in the context of 
drugs. Associated with the field are genetic data and there 
is a need to associate these with genomic, cellular, 
molecular and clinical phenotypic data (see Fig. I). These 
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data are stored in public and proprietary repositories that 11. APPROACHES AND TECHNOLOGIES 
are distributed and are often associated with heterogeneity A major research area when identifying the genetic 
in their information structures and content. This makes the variations among individuals that play a role in drug 
integration, exchange and storage of data difficult, response is the analysis of SNPs. A SNP is a substitution 
hampering the progress of studying pharmacology at a of one base pair at a given position in the genome. These 
systems level. substitutions can be found at non-functional sites and have 
Clinical outcome I 
III 
Ph.1rm.1codynamics and drug response I 9; 
0 
c I 'l) .r:: Pharmaco kinetics fl. 
Molecular and cellular functional :J.Ssays I 
Genotype 
Figure I A model showing the variability ofpharmacogenomics data and 
the linkage of genotype to phenotype which itself can be split further into 
other subcategories. Source: [5). 
The structure of this paper is as follows. The next 
section will highlight the importance of Single Nucleotide 
Polymorphism (SNP). research to pharmacogenomics and 
discuss typical approaches and high-throughput techniques 
used. A short review of SNP information resources will 
then be given. The need for transition from such 
repositories into semantic web interoperability 
architectures will then be discussed in relation to 
knowledge bases and the placing of these onto GRIDS. A 
novel metadata standard for pharmacogenomics will be 
proposed in the following section, and challenges with 
information representation and similar work carried out in 
other biological research areas will be explained. The 
paper will finish with conclusions. 
influence on gene regulation and expression. However, 
me SNPs occur at protein coding regions and can alter 
ene function, can contribute to disease, increase 
sceptibility to disease and affect drug response [6]. For 
ample Glutathione S-transferase (GST) MI and Tl are 
olymorphic enzymes and deficiency in these has shown 
have an increased risk of developing head and neck 
ncer [7]. The importance of cataloguing all the SNPs in 
e genome has been recognised internationally through 
the SNP consortium [8]. 
so 
g 
su 
ex 
p 
to 
j 
Inherited differences in drug responses in 
pharmacogenomics can be studied by two main methods 
known as phenotype-to-genotype correlations and 
genotype-to-phenotype correlations [9]. The former 
approach usually involves starting with clinical 
observations that show interindividual differences in drug 
response. Population studies are then carried out of the 
drug disposition and response phenotype. The genetic 
defect responsible for the observed phenotype is then 
searched for through biochemical and molecular methods 
to identify gene products that play a part in the variation 
[10]. In contrast, the genotype-phenotype approach 
involves using high-throughput methods and DNA 
databases to firstly identify gene polymorphisms such as 
SNPs. This is then followed by a search for associations 
with phenotypes such as changes in expression of RNA 
and/or changes in protein concentrations [11]. 
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Recent evaluations have resulted in conclusions that sequence that surrounds the polymorphism. In addition 
haplotypes (specific polymorphisms on a chromosome that experimental methods used and a reference to a 
are inherited together as blocks) could express better companion STS or GenBank accession number are 
association with phenotype rather than single or included. Integration in dbSNP is both internal and 
monogenic genes [12]. This has resulted in much interest external. 
into utilising methods that enable whole genome analysis 
for polymorphisms. Microarray technology is being used Internal integration with other NCBI sources such as 
for SNP genotyping; enabling simultaneous assessment of GenBank [17], dbSTS [18] and LocusLink [19] requires a 
the thousands of polymorphisms in patients. Chip 
technology can also be used for expression profiling where 
expression profiles at the genomic level can be compared 
for a target tissue after the addition of a drug. Such a 
number of computations making use of BLAST and 
Electronic-PCR (E-PCR) similarity analysis; the results of 
these being annotated onto the NCBI resources. If two 
submissions to dbSNP happen to be the same, then these 
technique has been used in pharmacogenomic studies of are clustered into a single reference SNP record (rs ID). 
respiratory diseases, where the regulation of genes in an 
inflamed airway has been studied by comparison of tissue 
from both affected and unaffected individuals [3]. 
Ill. SNP INFORMATION RESOURCES 
Recent surveys of public SNP databases have reported a 
lack of well characterised polymorphisms across different 
ethnic populations. Such knowledge of the frequency 
differences between these groups is vital for a 
comprehensive coverage of polymorphisms that are 
clinically relevant [13], [14]. The main public repositories 
storing SNPs are dbSNP [15] and HGVbase [16]. 
Reference records are also created for submissions that are 
found to be unique and these will be used as a non-
redundant set of markers for mapping variations to other 
NCBI databases (known as ss records). As dbSNP is 
integrated through accession links with GenBank, 
Locuslink and STS, accession numbers from these 
databases can be used as indexes to search dbSNP. dbSNP 
itself can be accessed through Entrez meaning it can 
manipulate the LinkOut integration mechanism for 
interoperation with external resources such as the SNP 
Consortium data repository [20] and HGVbase [16]. 
Another major variation database is HGVbase (Human 
db SNP was created in collaboration between the Genome Variation database) whose primary purpose is to 
National Human Genome Research Institute (NHGRI) place human genome sequence variation data into the 
along with the NCBI and can be considered the variation public domain. Originally released as HGBASE [21], 
complement to Genbank. The majority of nucleotide improvements in the HGVbase include the ability to 
sequence variations in dbSNP are classified as single handle phenotypic descriptions in relation to human 
nucleotide polymorphisms, but included also are lesser polymorphism and the inclusion of a retrieval system 
variations such as small insertion/deletion polymorphisms, called HGVSearch that can be accessed using web 
microsatellite repeats and named variants. The types of interfaces and command-line tools. HGVSearch has a 
information required when submitting to dbSNP include flexible search mechanism and its modes of action include 
the observed alleles at a specific locus and the flanking being able to make keyword and chromosomal positional 
291 
searches. Submissions are received regardless of 
functional relevance and the system design of HGVbase is 
based upon a relational database back-end [16]. 
SNPer is a recent on line application for SNP research 
[22]. SNPer is a much more complete and up to date tool 
when compared with other public efforts, providing a 
database containing SNP data and a package of user-
friendly tools for querying and visualisation. The main 
data source is dbSNP and others include LocusLink [19] 
and the Gene Ontology (GO) database [23]. Queries can 
be made to SNP er by specifying rs or ss identifiers. More 
standardised querying is also made possible through 
specifying interesting genes through GO classes allowing 
SNPs that may be linked to a biological process to be 
studied. 
While the disadvantages of link integration can be 
associated with dbSNP such as the existence of naming 
genetic sequences, cellular and molecular phenotype and 
clinical phenotype data. The diverse concepts that 
represent these data and the numerous relationships 
between them are modelled using the PhannGKB 
ontology giving rise to the PharmGKB data model. 
An XML schema is used in PhannGKB as a mediator to 
map the structure and content of data coming into the 
knowledge base to the PhannGKB ontology. The XML 
schema is designed such that users submitting their data 
can map their internal data schemas into an XML 
document [27]. This is the main method for infonnation 
integration with other external submitting centres. 
PhannGKB is also interoperable with dbSNP. Users can 
submit SNP data to PhannGKB and if a particular SNP is 
not contained in dbSNP, PharmGKB can automatically 
submit a SNP to it [28]. PharmGKB also has associated 
with it a SNP surveillance system as it is vital that 
researchers have knowledge of new SNPs as and when 
clashes, confusion in meaning oftenns and the validity of they are discovered so that duplicated work can be 
links [24], data exchange in HGVBase and SNPer with avoided. 
other databases such as dbSNP is carried out using XML, 
giving rise to the potential of variation data sharing 
through web services. 
IV. SEMANTIC WEB APPLICATIONS 
Semantic web research provides a means for the 
development of metadata standards which can be used as a 
basis for the creation of both infonnation resources and 
distributed computing infrastructures for the biomedical 
community [25]. The groundbreaking semantic web 
system for phannacogenomics is the 
PhannacogeneticslPhannacogenomics Knowledge Base 
(PhannGKB) [26]. PhannGKB is a storage and retrieval 
system implemented in Protege which is a frame based 
knowledge management system. PhannGKB contains 
The dbSNP surveillance system is a tool that allows the 
automated and personalised management of SNP 
infonnation. There are two types of data flows in the 
dbSNP surveillance system. The first is the data collection 
from PhannGKB, dbSNP, LocusLink, and GenBank into a 
data repository. A warehouse approach is used to 
integrate these resources and the data down loaded from 
them include for instance gene names and symbols and 
sequence accessions (for every gene from PhannGKB) 
from LocusLink [19]. Also involved in this step is the 
downloading of SNPs (from db SNP) that are associated 
with RefSeq sequences [\9] and coding sequence positions 
from GenBank. The second data flow involves the 
processing of these raw data with alignment of each SNP 
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record to each RefSeq sequence enabling functional 
classification. Each user is able to have their own V. E-SCIENCE PLATFORMS FOR 
personalised gene list and is able to add additional genes PHARMACOGENOMICS 
of interest. At the end of every data flow cycle, the system Due to the complexity of information, and resources 
establishes any novel SNP discoveries made on the genes that are needed for pharmacogenomics research, efforts 
of interest for each user and personalised e-mails are sent need to be made to expand integration systems such as 
out [29]. PharmGKB and incorporate these with clinical databases, 
genetic variation repositories and interrogation tools into 
Another project for the sister field of wider integration architectures resulting in 'Pharma' web 
pharmacogenomics 
Chemical Effects 
namely toxicogenomics 
III Biological Systems 
IS the services and GRIDs. A prior presumption with web 
(CEBS) services is that they are available and stateless. In contrast, 
Knowledge Base. What is interesting about this GRID services are presumed to be transient and dynamic, 
knowledge base is the introduction of systems thinking or meaning that services can be turned on and off. In addition 
"systems toxicology" enabling the evaluation of biological GRID services are distributed globally and do not have a 
systems at the toxicogenomic level. Integrated in it are centralised control. GRID applications can be made up of 
global gene expression data, protein expression metabolite hundreds of GRID services which are often long-lived 
profiles and information about effects that are brought [34]. 
about through chemicals and stressors in multiple species; 
cross-species homology between these allowing 
information on functional pathways and networks to be 
discovered [30]. 
A recent application also in this area is the 
toxicoinformatics integrated system (TIS) (or ArrayTrack) 
in which three components are linked together [31]. These 
are MicroarrayDB that captures toxicogenomic 
information associated with microarray experiments, 
TOOL which provides a suite of analysis algorithms for 
microarray data visualisation, gene discovery, class 
prediction etc and LIB which is made up of three local 
mirrored databases which are the product of the 
downloading of the major public databanks such as 
GenBank [17], Swiss-prot [32] and KEGG [33]. These 
databases are known as GeneLib, Protein Lib and 
PathwayLib, with GO terminology being used to 
functionally assign the contents ofthese. 
Lessons can be taken from the main bio-GRIDs in 
development that include the Open Bioinformatics GRID 
(OBIGRID), Discovery Net and myGRID. OBIGRID has 
been developed in collaboration between the Japan 
Committee on High-Performance Computing for 
Bioinformatics and Initiative for Parallel Bioinformatics 
Processing (IPAB). OBIGRID is not particularly focused 
on performance, but on network transparency. Included in 
OBIGRID is an open bioinformatics environment, 
genomic XML databases and bioinformatics script 
programming libraries such as BioPerl and BioJava [35]. 
The requirement for computing power for sequence 
searching and biological simulations has meant that 
OBIBlast, a BLAST search system [36] and OBIY agns a 
simulation system [37] have been included in the 
OBIGRID platform. 
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Another more generic GRID system that has been applied 
to bioinformatics is Discovery Net [38]. Discovery Net is 
based upon a services approach which distinguishes 
knowledge discovery tools into two categories that are 
known as computation services and data services. The 
primary difference between the two is that computation 
services aIlow the implementation of distributed and 
paraIlel data mining processes, while data services attach 
metadata to heterogeneous and distributed sources [39]. 
The selecting of components and services and connecting 
them into a process is standardised through the use of an 
XML-based language known as the Discovery Process 
Markup Language (DPML). These processes are then 
reusable and can be implemented as new services [38]. 
facilitate information integration, sharing, seeking and 
ultimately the discovery of new knowledge In 
pharmacogenomics. This particular study involves 
working closely with pharmacogenomics researchers to 
develop an experimental and protocol annotation standard 
based on the concept of attaching metadata to 
experimental data and information being submitted to a 
repository. Such standards are increasingly becoming 
important during validation steps in scientific experiments 
aIlowing experiments to be assessed externaIly and for the 
reproduction of experiments and results, and also for the 
development of new information resources. Plans for the 
future include the development of a data exchange format 
using a semantic web technology such as XML or RDF to 
provide a common data exchange format that can be used 
Metadata and ontologies are essential, for the flexible for pharmacogenomics data import/export. This would 
creation of GRID services, transforming them into then facilitate the creation of a new pharmacogenomics 
Semantic GRIDS. MyGRID can be considered a semantic repository that is integrated with other biomedical 
GRID and its emphasis is on databases integration and resources. The next important step would be to place these 
workflow (similarly to Discovery Net) but also the repositories into a GRID-enabled semantic service. 
inclusion of provenance data and personalisation [40]. 
Driving such advanced functionality are a suite of 
ontologies expressed in DAML+OIL which provide the 
A participant case study of pharmacogenomics research 
at the Sanger Institute UK wiIl be carried out. An 
means for defining a global schema for the description of additional case study may also be carried out at 
services and the inclusion of concepts that can be queried, AstraZeneca, Macclesfield UK. Data coIlected wiIl help 
returning services matching the query. In addition establish the information produced during scientific 
ontology in myGRID can be used for the annotation of workflows, what information is recorded, and how, and 
data and results produced through in silica biology where. This will then direct work on the proposed 
experiments [41]. standard. The reusability and extensibility of existing 
VI. A METADATA STANDARD FOR 
PHARMACOGENOMICS 
There is an urgent requirement for standards to be 
created for pharmacogenomics knowledge representation. 
A metadata standard for pharmacogenomics would 
metadata standards (see Part B of this section) wiIl be 
studied. When developing this initial framework the 
PharmGKB XML Schema will be referred to, to aid in the 
development of metadata entities and attributes. In 
addition the feasibility of using terms from the PharmGKB 
ontology (and other bio and clinical ontologies) as a 
controIled vocabulary of terms in the proposed 
294 
experimental and protocol annotation standard will be 
established. Before other related work is discussed it is 
important to highlight some of the challenges associated 
with this work. 
A. Challenges with Information Representation 
Pharmacogenomics requires a genotype-phenotype 
connection. While the problem of representing genotype 
particularly in the form of SNPs is a fairly well addressed 
Maize Genetics and Genomics Database (MaizeGDB) 
[44]. These repositories although useful, suffer from the 
common problems associated with flat files such as 
primitive querying and difficulty with integrating with 
more structured information resources. In recent times 
ontologies are being used to represent phenotypic data. An 
early example of ontology knowledge representation can 
be found in FlyBase [45]. FlyBase organises genetic and 
genomic data on D. Melanogaster and related species and 
(as has been illustrated by Section Ill), the standardised uses the GO terms to index both gene records and 
representation of phenotype information is much more phenotypic data using the 'Phenotypic class' and 
difficult. Phenotypic information is often not easily 'Anatomy' class. Phenotypic data in FlyBase can be 
computed as genomic data which can be transformed into queried using the Allele Search form, and the' Anatomy & 
bits. Phenotype can be defined at multiple levels of Images' section can be used to find information 
complexity, encompassing, molecular, cellular, organ, and specifically relating to anatomy. In the Mouse Genome 
clinical studies (see Fig. 1). This results in the number of Database (MGD) much emphasis has been placed on 
parameters for these being huge, which are specific to 
genes and diseases under investigation. These issues raise 
difficulties for consistent sharing and integration of data 
across laboratories and organisations. Clinical data needs 
to include not only clinical trial data, but also patient 
records which itself introduces more challenges that 
remain unresolved. Often patient records are not available 
developing a high-level phenotype vocabulary of terms to 
classify phenotype data [46]. The terms in the vocabulary 
can be used to search, classify, compare and analyse these 
data. Ontology efforts in this case have primarily 
concentrated on developmental and adult anatomy of the 
mouse [47]. 
electronically and are found in qualitative form. It is B. Related Standards Based Work 
important to ensure the maintenance of patient The Microarray Gene Expression Data (MGED) society 
confidentiality at all times. There are also issues of has developed the Minimum Information About a 
medical terminologies being different among different Microarray Experiment (MIAME) specification [48]. This 
specialises. Such data are often accompanied with is an experimental and protocol annotation standard that 
inconsistent metadata descriptors [42]. These types of provides researchers in functional genomics with a 
problems illustrate the importance (but difficulties) of methodology by which to submit their micro array 
defining standardised metadata descriptors for phenotype. 
So far phenotype has been represented in spreadsheet 
format and flat files respectively. Examples of databases 
containing phenotype as flat files for other organisms 
include the Rat Genome Database (RGD) [43] and the 
experiments. Researchers when following the MIAME 
guidelines must provide description for experimental 
design, array design, samples, hybridisations, and 
measurement data and specifications of data processing 
(see Fig. 2). 
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Figure 2. A model illustrating a microarray experiment through six 
components. 
Source: [48]. 
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Most recently MIAME has been adapted and extended The MGED society has developed a standard data 
for toxicogenomics and environmental genomics resulting exchange format for microarray data called Microarray 
in MIAMEffox [49] and MIAMElEnv [50]. These two Gene Expression Markup Language (MAGE-ML), which 
standards both recognise the limitations of the original is based upon an object model called MAGE-OM [51]. 
MIAME standard with respect to toxicogenomics and This object model provides a solid platform upon which 
environmental genomics experiments. For example in the other micro array repositories can be built. A weakness of 
experimental design section, acute, pre-chronic or chronic MAGE-ML from a technology point of view is that it is 
treatment experiments are included in MIAMEfTox and represented using a Document Type Definition (DTD). 
geographical location comparison experiments are From a practical point of view the format is highly 
included in MIAMElEnv. MIAMEfTox is particularly extensible, but suffers with disadvantages associated with 
interesting as it captures clinical information associated DTD such as a non-XML structure and lack of data types 
with toxicological assessments with descriptors for clinical [52]. 
observations, gross necropsy examination, histopathology 
evaluation and clinical pathology. ArrayExpress is a database that stores microarray gene 
expression data in a structured way at the EBI, accepting 
data that is MIAME compliant and submitted using 
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MAGE-ML [53]. The fact that Nature and Science require 
data to be MIAME compliant is evidence that the 
scientific community is taking seriously the importance of 
such standard methodologies. In addition there is the 
MGED ontology effort that is developing an ontology to 
experimental methods and can be used as standalone or 
incorporated into a wider schema such as PEDRo [58]. 
As focus moves to providing automated repositories and 
analysis systems for the emerging field of systems 
provide standardised terminology for the annotation of biology, new research is moving towards the development 
microarray experiments [54]. 
The Proteomics Standards Initiative (PSI) is a similar 
consortium that aims to develop standards for proteomics 
data representation to facilitate the comparison, exchange 
and validation of proteomics experimental data and 
metadata. An example of a global standard for proteomics 
is the Proteomics Experiment Data Repository (PEDRo) 
[55]. PEDRo is created according to the MGED guidelines 
and has a similar focus to the microarray model, capturing 
data (and associated metadata) produced in the steps of a 
proteomics experiment from hypothesis generation to peak 
identification [56]. The UML class diagram upon which it 
is based can be considered to be complex, however it 
forms the basis by which proteomics repositories can be 
developed and a data entry tool known as PEDRoDC is 
able to generate a Protein Expression Markup Language 
(PEML) file. 
PEDRo is very much mass spectrometry based and is 
able to capture data produced from for instance, matrix-
assisted laser desorptioniionisation (MALDI) mass 
spectrometry and multi-dimensional chromatography fed 
into a tandem mass spectrometer [57]. Another exchange 
format for a related area is the Annotated Gel Markup 
Language which is centred on the identification of proteins 
through 20 gel electrophoresis combined with mass 
spectrometry. It is a common standard developed for the 
storage and dissemination of data produced through these 
of standard components for the representation and 
integration of different biological data sets. Recently the 
SysBio-OM (an object model) has been developed as a 
means to integrate microarray, proteomics and 
metabolomics data in the CEBS system. The concept 
behind this model is the study of transcriptomics, 
proteomics and metabolomics experiments into a 
generalised workflow allowing the processing of 
biological samples, experimental protocols and 
experimental metadata. SysBio-OM is based upon the 
MAGE-OM model and has integrated with this, 
information representation elements from PEDRo and 
from protein interactions and metabolomics experiments, 
illustrating the re-usable properties of such standards. 
Such a hybrid architecture is able to generate output files 
in MAGE-ML and PEML data formats, while the use of 
ontologies will improve the usability of data produced 
through different omic studies and will allow users to 
easily use other information resources [59]. 
VII. CONCLUSIONS 
Pharmacogenomics is a field that brings more 
challenges for effective management along with the hope 
of personalised medicine. Associated with the field are 
genotypic data and phenotypic data that vary in the context 
of drugs. Phenotype can be defined at multiple levels of 
information content and complexity. Overall there is a lack 
of repositories for pharmacogenomics but it is vital to 
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develop these as the field progresses. Standards for data 
representation, storage and exchange will be needed for 
the development of pharmacogenomics information 
resources enabling them to be integrated into advanced 
computing environments such as web services and GRIDs. 
[10] 
[11] 
A novel metadata experimental and protocol annotation 
standard for pharmacogenomics has been proposed. It is [12] 
hoped that such a framework will promote information 2003. 
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Effective infonnation management of the phannacogenomics discipline presents many unique 
challenges. Genetic and genomic data generated via high-throughput methods need to be integrated 
with phenotypic data which are defined at multi scale levels, ranging from the molecular level to the 
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Introduction 
The drug discovery and development process 
has much to gain through genetics and 
genomics research. During discovery, novel 
gene(s) involved in the mechanistic processes 
of disease can be identified which can 
become potential targets for therapeutic 
intervention. In development, clinical trial 
parameters are correlated with genetics 
datasets to detennine inter-individual 
differences in drug response. This knowledge 
sometimes tenned personalized medicine can 
then be applied to reduce adverse events and 
increase efficacy of treatment [1]. The need to 
integrate effectively these different data sets 
poses unique challenges for infonnatics 
specialists as they aim to capture infonnation 
in infrastructures that are standardized. Data 
are stored in both proprietary and public 
infonnation sources which are distributed 
throughout research institutes and 
phannaceutical companies around the world. 
Heterogeneity is present in the fonnats in 
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which data are found, hampering efficiency 
and ease at which manipulations and analyses 
can be carried out. In addition, the data 
content within information sources exhibit 
semantic variations which make the 
consistent integration and exchange of data 
more difficult. The semantic web transforms 
current web technologies into a machine-
understandable form that allows automated 
polling of information requested VIa 
intelligent software agents [2]. This advance 
is suggested as an opportunity to address 
issues of integration and interoperability 
associated with the management of disparate 
bioinformatics information resources. 
The structure of this paper comprises two 
main parts: information management and 
semantic web applications. Issues related to 
information management cover genetic 
information resources via Single Nucleotide 
Polymorphisms (SNPs) and challenges that 
follow the need for integration of 
geographically dispersed bioinformatics 
information resources. The second part of the 
paper explores the use of semantic web 
technologies and their application to 
bioinformatics. 
SNP Information Resources 
Data on SNPs are perhaps the most important 
resource for pharmacogenomic scientists who 
are studying the contribution of genetics and 
genomics to disease and drug response. There 
are both public and private efforts at the 
development of a complete map of validated 
SNPs in the human genome, generated 
through sequencing reactions and assayed in 
genotyping studies. The SNP consortium 
(TSC) has contributed millions of SNPs [3] to 
the public databases (e.g. dbSNP) with 
parallel private efforts undertaken by, for 
example, Celera Genomics™. Most of the 
SNPs from funded projects are archived in 
numerous publicly accessible databases; some 
of these will now be discussed. 
The TSC data are available to the research 
community via the TSC Data Coordinating 
Center (DCC) web site [4]. Data submitted 
include that relating to the process of SNP 
discovery, including flanking sequences and 
sequence traces utilized in drug discovery. 
The focus of the TSC-DCC website is also on 
the inclusion of data that describe allele 
frequencies in populations from genotyping 
studies. Querying for SNPs is carried out on 
the TSC-DCC website, users being able to 
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utilize identifiers from the dbSNP database or 
perform a search via genomic location. In 
addition, the names of genes and their 
descriptions can be retrieved through a gene 
keyword search. Linkage maps are also 
available for browsing, using a comparative 
map viewer. In fact, TSC consortium database 
implementation comprises two sections: one 
which is a main Orac1e™ database containing 
all SNP data from TSC and the other which is 
a MySQL database back-end that contains 
SNPs publicly available [4]. 
dbSNP was created in collaboration between 
the (US) National Center for Biotechnology 
Information (NCBI) and the (US) National 
Human Genome Research Institute (NHGRI), 
and is the largest public repository of SNP 
data in the world [5]. Sources of data in 
dbSNP come from individual laboratories, 
collaborative genetic variation discovery 
projects, large scale sequencing centers and 
industry sources. Although the majority of 
nucleotide sequence variations in dbSNP are 
classified as SNPs, also included are lesser 
variations such as small insertion/deletion 
polymorphisms, micro satellite repeats, and 
named variants. Two important identifiers are 
used for submission of data and their 
subsequent querying. These are unique 
submission identifiers (ss identifiers or 
reference SNP IDs (rs identifiers). ss 
identifiers are used to describe each separate 
submission of a SNP, while rs identifiers are 
used to describe a set of independent 
submissions of that same SNP [5]. 
Internal integration with other NCBr sources 
such as GenBank [6], dbSTS [101] and 
LocusLink [7] requires a number of 
computations making use of BLAST and 
Electronic-PCR (E-PCR) similarity analyses, 
the results of these being annotated onto the 
NCBI resources. dbSNP itself can be 
accessed through Entrez [8], making use of 
the LinkOut integration mechanism for 
interoperation with external resources such as 
the TSC data repository [4] and HGVbase 
(Human Genome Variation database) [9]. The 
quality of data in dbSNP is questionable. A 
recent survey showed that the majority of 
SNPs in dbSNP are unvalidated and 
unclassified [10]. Another report suggested 
that 6-12% of SNPs in the public and Celera 
Genomics™ databases are unvalidated [11]. 
The primary purpose of HGVbase is to place 
high quality human genome sequence 
variation data into the public domain [9]. 
Strict data quality criteria are used to 
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maximize the possibility of SNPs being truly 
polymorphic. Data for RGVbase are acquired 
from public databases and the literature. It is 
a unique database as it handles phenotypic 
descriptions in relation to human 
polymorphisms. Low quality sequences such 
as repetitive elements are screened, giving 
scientists the option to remove them from 
genotyping studies. Queries can be made 
using a retrieval system called RGVSearch 
which is accessed using web interface and 
command-line tools. RGVSearch has a 
flexible search mechanism, its modes of 
action include being able to make keyword 
and chromosomal positional searches. The 
system design is based upon a relational 
database back-end. The developers of 
HGVbase have recognized the importance of 
standard transmission formats for genetic 
variation data with the primary data export 
format being Extensible Markup Language 
(XML) [102]. 
There are also resources designed specifically 
to integrate genetic data from multiple 
sources. For example, there is the SNPper 
application for SNP research [12]. A mySQL 
relational database contains SNP data and a 
set of user-friendly tools for querying and 
visualization. The main data source is dbSNP, 
others include LocusLink [7], the Gene 
Ontology (GO) database [13] and SWISS-
PROT [14]. Queries can be made to SNPper 
by specifying dbSNP ss or rs identifiers. 
More standardized searches are possible 
through specifying genes of interest through 
GO classes allowing SNPs that may be linked 
to a biological process to be studied. In 
addition SNPper allows the export of data in 
multiple formats including XML and tab-
delimited text files, while SNP information 
can be retrieved in XML format. This gives 
rise to the potential of variation data sharing 
through web services which allow distributed 
applications to communicate with each other 
over the Internet using standard web 
protocols. More generic is the ROWDY 
integration system for human genome 
information [15]. Based upon object oriented 
concepts, ROWDY stores information about 
relationships between Biological Objects 
(BO) and Database Objects (DBO) extracted 
from databases that include dbSNP, JSNP 
repository of Japanese SNP data [16] and 
Online Mendelian Inheritance III Man 
knowledge base (OMIM) [17]. ROWDY can 
be searched using a web interface through 
keyword or cytogenetic location. In addition 
gene maps are available for individual 
chromosomes. 
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[Table 1 here] 
Issues with current resources 
While the SNP resources discussed in the 
previous section are invaluable, initially they 
were not designed to address issues of an 
informatics nature such as the implementation 
of independent, heterogeneous repositories 
with limited interoperability, proprietary user 
interfaces, and different data formats [18]. 
The methods which have been used for 
integration, although effective, have 
limitations. For example, the LinkOut 
integration used in dbSNP involves the use of 
hypertext links and is intuitive to use but 
susceptible to many problems such as naming 
clashes, confusion in meaning of terms and 
the validity of links [19]. Warehousing is a 
common method used to collect together data 
from multiple sources into a local repository, 
in which subsequent queries are also carried 
out. The information architectures of many 
genetic resources such HGVbase and SNPper 
are based on such an approach which provide 
great ability for the manipUlation and 
annotation of data. Warehousing, however, 
can prove to be costly in terms of maintaining 
system designs and keeping data up to date 
[20]. The other major Issue is of a less 
technical nature, and is the lack of consistent 
structures for biomedical data representations 
[21]. The representation of phenotypes is 
particularly difficult. 
Challenges in representing Phenotypes 
Phenotypic data are difficult to manage as 
they have been captured in non-standard ways 
and stored in databases in an ad hoc fashion 
[21]. Unique challenges which highlight the 
importance of standardization of phenotypic 
metadata include [22]: 
• 
• 
• 
Phenotype being poorly defined and 
captured at multiple levels of 
biomedical significance, 
Single causative genes do not 
necessarily result in a phenotype, 
Phenotypic data are not static and are 
dependent 
understanding, 
on biomedical 
• There are potentially hundreds of 
parameters for phenotypic data which 
are often disease specific, 
• Phenotypic data are represented III 
different formats ranging from free 
text to clinical vocabularies. 
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It is important to address the issues discussed 
thus far with the tools and techniques of the 
semantic web and e-Science applications such 
as GRID computing. The development of 
resources using such technologies provides 
solutions for the management of biomedical 
infonnation that becomes increasing complex 
in tenns of their content and complexity. 
Semantic Web 
Data annotation is an important task in 
bioinfonnatics. Bioinfonnatics database 
developers can make use of terminologies to 
annotate individual pieces of data. Annotation 
of data involves adding descriptive 
infonnation to experimental data. The 
primary result of such activity is the creation 
of data objects that can be linked intelligently 
to data that are related in other databases. 
The most widely used data annotation model 
in the biomedical sciences is that of the self-
describing data collection where metadata is 
used to tag all of the data fields [23]. 
Metadata is data or information that is used to 
annotate other data or information, and is a 
fundamental component of the semantic web. 
For instance, current web material for human 
use is not suitable for software agents to 
understand and act upon. However, attaching 
metadata would have the opposite effect, 
allowing software agents to utilize what 
previously they would have ignored. 
Scientific data and metadata can be described 
using languages such as XML and Resource 
Description Framework (RDF) [103]. In 
addition, ontologies can be used to provide 
controlled tenns to describe concepts and 
their relationships used within semantic web 
applications such as web services and GRIDs. 
The following sub-sections will give 
examples of the utilization of these 
components in other related studies. 
BIO-XML 
In recent times many markup languages based 
on XML technology have been created as 
formats for the representation and exchange 
of biological objects. Well known examples 
are the Microarray Gene Expression Markup 
Language (MAGE-ML) [24] for representing 
microarray data developed by the Microarray 
Gene Expression Data Society (MGED) 
[104]. This exchange format provides the 
transmission protocol needed to submit data 
annotated according to the Minimum 
Infonnation About a Microarray Experiment 
(MIAME) guidelines [25]. MGED along with 
other interested parties are developing a 
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mInImUm infonnation set of guidelines for 
expression based phannacogenomics. Such 
data content standards will increasingly 
become important for data capture from other 
high-throughout technologies such as 
genotyping platfonns. 
The Proteomics Standards Initiative was 
created by the Human Proteome Organization 
(HUPO PSI) [105] to develop community 
wide standards for proteomics data and 
metadata storage and exchange. An example 
of a global standard for proteomics is the 
Proteomics Experiment Data Repository 
(PEDRo) [26]. PEDRo is created according to 
the MGED guidelines and has a similar focus 
to the micro array model, capturing 
information produced in the steps of a 
proteomics experiment from hypothesis 
generation to peak identification. Another 
exchange fonnat for a related area is the 
Annotated Gel Markup Language which is 
centered upon the identification of proteins 
through 2D gel electrophoresis combined 
with mass spectrometry. Designed for the 
storage and dissemination of data produced 
through these experimental methods, it can be 
used as standalone or incorporated into a 
wider schema such as PEDRo [27]. 
From controlled vocabularies to ontologies 
While XML provides a solution to the 
syntactic problem, it does nothing to address 
semantic inconsistencies; this being its 
biggest limitation for the realization of a 
semantic web providing large-scale 
interoperabiIity. Ontologies provide the 
additional level of interoperabiIity. The term 
ontology is often used to refer to the semantic 
understanding or capturing the knowledge 
shared by communities belonging to specific 
domains [28]. 
Integration aided through the use of 
ontologies seems a promising solution 
considering the many infonnation 
representation challenges that exist in 
bioinfonnatics. There are well documented 
tenninology and semantic issues in the 
bioinfonnatics field. For example, there is a 
synonym problem in that the same entity, (say 
a gene for example), may have a different 
name in different databases. Likewise a 
homonym problem exists in that different 
entities can also have the same name. In 
addition, there is often confusion as to the 
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definition of the most fundamental biological 
objects, such as gene and protein [29]. For 
example, a term that has multiple meanings is 
'protein function'. In terms of biochemical 
function, 'protein function' could mean 
'enzyme catalysis', or in terms of genetic 
function it could also mean 'transcription 
repressor' [30]. 
The Gene Ontology (GO) was developed to 
provide a controlled vocabulary of terms for 
the annotation of concepts in bioinformatics 
resources [31]. GO is used to annotate gene 
products according to three separate 
hierarchies known as molecular function, 
biological process and cellular location. The 
terms in GO are represented in RDF and are 
arranged as nodes in a directed acyclic graph. 
RDF is an XML-based language used to 
encode information in semantic web 
resources [103]. A natural language term, its 
definition and a seven digit numeric identifier 
are used to represent each node in the GO 
structure, while edges are is-a or part-of 
relationships [32]. 
Despite, its name, GO is not considered a 
fully fledged ontology. For example, it lacks 
both additional ontological characteristics 
such as relationships between the molecular 
function, biological process and cellular 
location controlled vocabularies; and axioms 
that can be used to constrain values of 
concepts and instances. The existence of such 
components would enable the capturing of 
further biological facts in the ontology. The 
hand crafted nature of natural language 
ontologies also means that they are difficult to 
maintain and are prone to errors [33]. 
Clearer semantics can be captured usmg a 
frame-based conceptual representation which 
is similar to taking an object view of the 
world. An example of a frame-based ontology 
is EcoCyc, used for describing database 
schema of the EcoCyc database of metabolic 
pathways and signal transduction pathways of 
Escherichia Coli [34]. However frame-based 
ontologies are essentially hand-crafted and 
inconsistencies in classification schemes can 
be problem [33]. The Transparent Access to 
Multiple Bioinformatics Resources 
(TAMBIS) system provides maximum 
transparency when accessing bioinformatics 
resources, relieving researchers of the 
difficulties of knowing what applications to 
use, their locations, etc [35]. Within the 
system, the TAMBIS ontology (TaO) is used 
for querying resources. TaO is based upon the 
more expressive Description Logic (DL) 
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fonnalism. Such a conceptualization is 
complex and is based upon an object-oriented 
approach where the structure of the domain 
being modeled is described in tenns of classes 
and properties. Class definitions and 
descriptions are provided through the use of 
assertions or axioms. In addition, DL supports 
logical reasoning that can be used to 
automatically create classification schemes 
[35]. 
The PhannGKB ontology is frame-based and 
used to define the knowledge base schema of 
the Phannacogenetics Knowledge Base 
(PhannGKB). PhannGKB is a semantic web, 
storage and retrieval system and acts as a 
central repository for data collected by 
laboratories of the Phannacogenetic Research 
Network, providing tools for submission, 
editing and processing of data [36]. An 
advantage of PhannGKB is that IS 
interoperable with dbSNP. Users can submit 
SNP data to PhannGKB and if a particular 
SNP is not contained in dbSNP, PharmGKB 
automatically submits a SNP to it [37]. The 
PhannGKB ontology comprises genetic data 
and cellular and clinical phenotypes, and the 
relationships between these concepts [38]. 
Added as instances of tenns in this ontology 
are experimental data from genotyping 
studies in which genetic data are correlated 
with phenotypic responses to drugs. 
Web services 
Web service technology forms one 
component of the semantic web, and is 
predicated upon the use of XML. The 
semantic web is required to poll web services 
automatically for the purposes of comparison, 
creation and orchestration [39]. 
Web services are implemented using five 
mam components. The XML-based Web 
Services Flow language (WSFL) is used for 
making descriptions of web service 
compositions. UDDI (Universal Description, 
Discovery and Integration) is an XML-based 
registry that web services can use to register 
themselves on the Internet. The Web Services 
Description Language (WSDL) is used to 
describe web services, and communication 
among web services is carried out using the 
Simple Object Access Protocol (SOAP) [39]. 
Web services are becoming increasingly 
important in the biomedical sciences as they 
provide an opportunity to integrate distributed 
resources as scientific workflows. The first 
web services project in the bioinfonnatics 
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field was the Distributed Annotation System 
(DAS) for exchanging genomic annotations 
[40]. A limitation of DAS is its lack of 
extensibility and its inability to function for 
other biological data sets such as protein 
motifs and genetic and physical maps [19]. 
BioMOBY IS another example which 
provides a simple common format that is able 
to describe a broad range of host interfaces in 
a machine-readable form [41]. These initial 
web services are important and others need to 
be developed for proteomics, metabolomics 
and pharmacogenomics. 
The XML-based descriptions of web services 
can be enriched further by adding the 
semantic characteristics of services and data. 
These descriptions will provide the tools 
needed for automatic validation of sequences 
of data and operations, and the automated 
composition and discovery of workflows, 
their interoperation, monitoring and recovery 
[42]. For example, the DAML-Service 
(DAML-S) is a collection of ontologies that 
enables the creation of web servIce 
terminology through objects and their 
relations. Recently, this language has been 
used to describe the properties and 
capabilities of web services in the myGRID 
project [43] which is discussed in more detail 
in the next section. It is based upon DARPA 
Agent Markup Language + Ontology 
Inference Layer (DAML+OIL), a language 
that combines features of both DL and frame-
based systems [44]. 
GRID Computing 
GRID computing IS the name given to 
advanced environments in which resources 
over the Internet are connected seamlessly, 
autonomously and transparently. Most e-
Science GRID projects for the biomedical 
sciences execute in silica experiments as 
workflows through network connecting 
software i.e. middleware platforms (using 
XML). It is possible to place web services 
into GRIDs to develop GRID-enable web 
services [39] 
The Globus Toolkit is a community-wide 
open source set of tools and services for the 
development of GRID applications. Some of 
the issues addressed by the toolkit are 
security, information discovery and 
management and communication. The Open 
Grid Services Architecture (OGSA) is an 
evolution of the Globus Toolkit. OGSA 
provides an environment where previously 
inflexible functions such as the invoking of 
remote web services can be re-implemented 
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In other application programs. This 
functionality allows the integration and 
interoperability of GRID services that parallel 
similar functions in the provision of web 
servIces. Further, OGSA extends a service-
oriented approach where a Grid service 
makes use of existing web service standards 
such as WSDL to develop standard interfaces. 
The application of appropriate standards can 
address issues that include among others, the 
creating, naming and discovery of GRID 
services, and their lifetime management [45]. 
GeneGRID has been developed as a GRID 
solution for the management and mining of 
the wealth of genomic data to facilitate target 
identification for protein and antibody 
discovery. GeneGRID extends OGSA 
through three main components which 
themselves are made up of further web 
services [46]. The three components are the 
GeneGRID Data Manager (GDM) that is 
responsible for access and integration of 
datasets; the GeneGRID Application Manager 
(GAM) which integrates bioinformatics 
applications; and, the GeneGRID Workflow 
and Process Manager (GWPM) for the 
creation and manipulation of workflows. The 
scheduling and allocation of resources needed 
to complete these workflows also takes place 
via the GWPM [46]. 
The e-Protein project aims to deliver a GRID 
infrastructure of distributed resources and 
specialized analysis software for protein 
structure annotation; such analyses require 
enormous computing power [47]. The three 
main sites involved in the project are the 
European Bioinformatics Institute at 
Cambridge, UK, Imperial College, and 
University College, both based in London, 
UK. At each of these sites a local DAS 
interface to the database provides access 
allowing each organisation to contribute 
towards proteome annotation [47]. The GRID 
middleware used to enable sharing of high-
performance computing resources is the 
Imperial College e-Science Networked 
Infrastructure (ICENI) [48]. ICENI enables 
scientists to compose workflows through 
drag-and-drop components in a graphical 
environment. These are then mapped onto the 
available resources through scheduling 
functionality. Within ICENI, XML Schema is 
used to provide rich metadata about resource 
capability, availability of GRID services and 
behavior of applications. XML Schema 
enables the contents of XML-based 
311 
documents to be constrained according to a 
structure and a particular vocabulary [39]. 
Interestingly, when examined more closely, 
the relationship between the GRID and the 
semantic web is complementary. Both require 
the need for machine-understandable 
metadata to support information discovery, 
integration and aggregation. In addition, both 
function in an environment that is distributed, 
global and susceptible to frequent change 
[49]. So the incorporation of metadata and 
ontologies in the GRID will transform them 
into semantic GRIDs. myGRID is such as 
example, and its emphasis is not only on 
database integration and optimizing 
workflow, but also on the inclusion of 
provenance data which is a type of metadata 
that can be used to audit various tasks [50]. In 
myGRID its use includes allowing scientists 
to record information about their experiments 
in an electronic lab book, and also for keeping 
track of workflow execution such as start and 
end times to ensure traceability of in silica 
experiments. 
Also available in myGRID are 
personalization functions in which users can 
have their own personal views over data and 
services offered depending on the tasks they 
are performing. Semantic web technologies 
utilized in myGRID include RDF to describe 
resources; Life Science Identifiers (LSIDs) 
[51] which are a type of Universal Resource 
Name (URN) to identify the bioinformatics 
resources and ontologies expressed III 
DAML+OIL to provide a common semantic 
view of the data. The myGRID ontology is 
also used for the annotation of data and their 
interpretation produced via in silica 
experiments [50]. 
Highlights 
• There is an increasing need for better 
informatics methods to integrate 
genotype data with phenotype data. 
• Current integration systems are 
inadequate. 
• Standardized methods are needed to 
represent phenotypes. 
• Application of semantic web 
technologies such as XML for data 
exchange standards and ontologies 
for data representation standards. 
• Use of semantic web applications to 
integrate disparate 
pharmacogenomics resources. 
Expert Opinion 
In pharmacogenomics, as knowledge of the 
impact of genetic variation on disease and 
drug response is further understood, so there 
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will a need for the development of specific 
resources to effectively store and analyze data 
generated. While the problem of genotype has 
been addressed through the development of 
many SNP databases, effective methods for 
the integration of genotype and phenotype 
remain elusive, with the exception of 
PharmGKB. Existing genetics resources do 
not store phenotype data in the most suitable 
form. Other issues with existing informatics 
resources are the lack homogeneity and lack 
of use of appropriate information standards. 
Database standards for storage and exchange 
of data address these issues and their 
development can be facilitated through the 
use of semantic web technologies. The 
integration of resources can be provided by 
advanced applications including web services 
technologies. A further development that 
takes these ideas forward is the roll out of 
web services to GRID applications. 
Outlook 
Although some bioinformaticists have been 
pessimistic about the semantic web, its future 
seems promising. XML and web services are 
considered mainstream technologies, while 
others such as RDF and DAML+OIL are now 
gaining acceptance in terms of delivering 
resource content. This change will ensure that 
appropriate autonomous tools are available 
for accessing and retrieving data and 
knowledge as the scale on which 
pharmacogenomics experiments are carried 
out increases. Over the next 5-10 years 
genetic data are likely to increase in 
magnitude, particularly if the cost of 
genotyping goes down. Personalized genome 
scans are likely to be carried out in 
abundance, which will generate enormous 
amounts of data which will need to be 
correlated with disease and drug response 
phenotypes. The semantic web will be a 
critical technology for the development of 
suitable infrastructures for data storage, 
retrieval and integration. 
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Table 1. A non-exhaustive list of SNP resources 
Database Type of variation Web site 
dbSNP SNPs, short insertion http://www.ncbi.nlm.nih.gov/SNP/index.html 
and deletion 
. polymorphisms 
HGVbase Human gene and http://hgvbase.cgb.ki.se/ 
genome variation, 
human phenotypic 
variation 
JSNP SNPs in the Japanese http://snp.ims.u-tokyo.ac.jp/ 
population 
OMIM Genes and genetic http://www3.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM 
disorders 
FESD Functional elements http://combio.kribb.re.krIFESD/ 
in human genes 
ALFRED Allele frequencies of http://alfred.med.yale.edulalfredlindex.asp 
polymorphisms 
PharmGKB Variation data that http://www.pharmgkb.org/ 
affect drug response 
GeneSNPs Variation data that http://www.genome.utah.edulgenesnps/ 
affect susceptibility to 
environmental 
exposure 
Glovar SNPs in the context http://www.glovar.org/ 
of the genome 
Human SNP SNPs identified at the http://www.broad.mit.edu/snplhumanlindex.html 
database Whitehead 
InstitutelMIT Center 
for Genome Research 
HOWDY Variety of genome http://www-alis.tokyo.jst.go.jpIHOWDY/ 
data including SNPs 
The SNP SNPs, allele http://snp.cshI.org/ 
Consortium frequencies and 
genotypes 
SNPper SNP data integrated http://snpper.chip.org/ 
from various 
resources 
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Abstract 
Interoperating Bioinformatics Resources 
Biten Vyas and Ron Summers 
Bioinfonnatics is a science that is used to manage biological data from multiple levels of 
complexity. There is a need to integrate these data sets in order to produce new 
biological knowledge. This increases the need for interoperable resources that store, 
integrate and provide easy access to these data sets. However in bioinfonnatics, these 
resources are highly distributed and problems of syntactic and semantic heterogeneity 
flourish. This paper highlights some of these problems with examples and suggests the 
use of solutions taken from the concepts of semantic web and Grid computing research. 
Introduction 
Interoperability and compatibility of resources remains one of the biggest challenges for 
bioinfonnatics, which is defined as the application of infonnation science, and 
technologies for the management of biological data (Denn and MacMullen, 2002). 
Primarily introduced to store and make sense of data produced from the Genome project 
studies; now post-genome biology requires bioinfonnatics to manipulate and ultimately 
discover new biological knowledge at several levels of increasing complexity: genomics-
transcriptomics-proteomics-metabolomics etc, the need to integrate these different 
biological data sets and study biology more holistically (through systems biology) 
increases. Such integration would improve both functional annotation and aid in the 
development of new biological hypotheses (Ge et al., 2003). This increases the need for 
suitable repositories that store and integrate these different datasets and analysis tools for 
their interrogation. Effective integration and interoperability of bioinfonnatics resources 
is not a new issue, but one that up until now infonnation scientists have not been 
involved in. Information specialists have been dealing with such matters for years 
applying their expertise to information and communication technologies. However, it is 
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time now for these professionals to work along side wet bench biologists and apply their 
skills to biological data. 
This short paper is structured as follows. Then following section will outline the 
uniqueness of biological infonnation management, placing particular emphasis on 
resource structure and content problems (syntactic and semantic heterogeneity). The use 
of semantic web technologies and concepts will then be introduced, giving examples of 
how these are being used in bioinfonnatics. The paper will then focus on infrastructures 
that incorporate semantic web technologies, namely web services and Grids and 
explanations will be given as to how these address infonnatics challenges in post-
genome biology. The paper will finish with conclusions. 
Interoperability problems 
Bioinfonnatics resources are unique in that solutions found for example in the business 
domain cannot be easily applied. In reality biological data is produced through different 
high-throughput methods, which means that they are highly variable. A typical 
bioinfonnatics query involves multiple databases and analysis tools. These data sources 
contain different biological data that are stored in different data fonnats. For examples 
gene names can be found as words, DNA sequences as sequence strings. In addition 
other infonnation can be found as images or graphs as is the case with biological 
networks (Ben-Miled et aI., 2003). These incompatible fonnats and the schemas in 
which they reside raise serious difficulties for interoperability and integration of 
bioinfonnatics resources, as software often requires specific input and output fonnats for 
seamless connectivity. Some of the well-known integration architectures in 
bioinfonnatics have concentrated on mediator/wrapper concept used for federated 
integration of data sources. Examples of these include K2IKleisli (Davidson et aI., 2001) 
and DiscoveryLink (Haas et aI., 2001). While these have addressed syntactic issues, 
semantic problems on the other hand were ignored. 
Semantic heterogeneity also needs to be addressed in addition to structural differences. 
There is still argument over what constitutes fundamental biological entities such as 
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genes and proteins, with bioinformatics databases containing synonyms and homonyms. 
Often, biologists have to use their own knowledge of bioinformatics resources and be 
able to distinguish between biological concepts with inconsistent meanings. Such 
ambiguity in terms, terminology and ontologies adds much difficulty to integrating data 
from different resources (Vershelde et aI., 2003). To address these issues and other 
information related problems in bioinformatics requires the next generation of database 
integration architectures to be based upon technologies and concepts used for the 
semantic web. 
Semantic web technologies 
The semantic web can be defined as an extension to the current web in which 
information is given well defined meaning allowing not only humans, but also 
computers to manipulate it (Berners-Lee et aI., 2001). To make the semantic web a 
reality, standards need to be established that enable machine-understandable information 
to be exchanged. Present efforts are focused on developing languages and technologies 
for the standardised modelling and implementation of metadata and ontologies. These 
languages include XML and XML Schema, RDF schema, DAML+OIL and OWL. The 
use of XML and XML Schema for data exchange in bioinformatics can be illustrated by 
the many XML-based markup languages created for exchanging data for particular 
research areas. These include the Microarray Gene Expression Markup Language for 
microarray research (Spellman et aI., 2002) and the Annotated Gel Markup Language 
(AGML) for transmission of data generated by 2D gel electrophoresis (2DE) combined 
with mass spectrometry (MS) (Stanislaus et aI., 2004). 
While XML and XML(s) address well the issue of differing data formats, these 
technologies do not provide means for expressing the meaning of data being exchange. 
Resource Description Framework (Lassila and Swick, 1999) is a semantic web 
technology that provides a data model that is suitable for bioinformatics integration 
tasks, and also provides the foundation for ontologies. Ontologies enable community 
defined and sharing of various biological domain vocabularies and rules or assertions 
that allowing the processing of biological data and metadata (Tangmunarunkit et aI., 
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2003). Ontologies are needed to organise tenns used in heterogeneous data sources 
according to their semantic relationships so that heterogeneous data fragments can be 
mapped into a consistent frame of reference (Buttler et aI., 2002). In contrast to schema 
languages such as XML Schema, ontologies make use of knowledge representation 
primitives that include classes and instances of those classes, a set of properties that are 
associated with a class and relationships between classes. Additional knowledge can be 
captured by axioms (Stevens et aI., 2003a). 
The most recognisable bio-ontology is the Gene Ontology (GO). GO has been 
implemented as a controlled vocabulary introduced to address tenninology 
inconsistencies and the lack of linkages between tenns in disparate knowledge bases 
(The Gene Ontology Consortium, 2000). Other examples of bio-ontologies include 
EcoCyc used for describing database schema in the EcoCyc database (Karp, 2000). The 
other main use of ontologies is for resource integration and this can be exemplified by a 
number of recent ontology-based bioinfonnatics integration systems such as TAMBIS 
(Goble et aI., 2001), and SEMEDA (Kohler et aI., 2003). These ontologies differ in their 
expressiveness such as RDF used to describe the Gene Ontology and Description Logic 
used to describe TAMBIS. 
Web services applied to bioinformatics 
Web services, a technology is related to the semantic web as it is based upon XML 
allowing distributed applications to communicate with each over the Internet using 
standard web protocols. In addition semantic web technologies will be needed to· 
discover web services and they will also be needed to enable automation of advanced 
web services applications such as comparison, creation and orchestration of web services 
(Daconta et aI., 2003). The main advantages of web services are that they can be rapidly 
deployed and add value to existing applications. Web services are implemented using 
five main standards. The XML-based language Web Services Flow language (WSFL) is 
used for making descriptions of web services compositions. UDDI (Universal 
Description, Discovery and Integration) is an XML-based registry which services can 
use to register themselves on the internet. The Web Services Description Language 
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(WSDL) is used to describe services and communication among services is carried out 
using Simple Object Access Protocol (SOAP) (Bernardi et aI., 2004). 
Web services are becoming increasingly important to the life sciences as they provide an 
opportunity to interoperate distributed resources as scientific workflows. The first web 
servIces project in bioinformatics was the Distributed Annotation System (DAS) 
(Dowell et aI., 2001) for exchanging genomic annotations. DAS provides a good 
infrastructure upon which other biological data such as genetic variation data could also 
be shared. BioMOBY (Wilkinson and Links, 2002) is another example which provides a 
simple common format that is able to describe in a machine-readable way, a broad range 
of host interfaces. These web services are important and others need to be developed and 
used ones created and used for proteomics, metabolomics and pharmacogenomics 
studies. 
The XML based descriptions of web services can be enriched further with descriptions 
of the semantic characteristics of services and data. The effect of this will be the creation 
of semantic services that provide the tools needed for automatic validation of sequences 
made up of data and operations and the automated composition and discovery of 
workflows, interoperation, execution monitoring and recovery (Mcllraith and Martin, 
2003). DAML-S is an ontology based upon DAML+OIL that addresses these issues 
allowing the properties and capabilities of web services to be described in a machine-
understandable way (Wroe et aI., 2003). This strategy was used recently to describe web 
services in the myGrid project which is discussed in more detail below. 
Grid Services and e-science 
It is possible to place web services into the Grid to develop grid-enable web services 
(Daconata et aI., 2003). The Grid is the name given to an advanced computing 
environment where resources over the internet are connected seamlessly, autonomously 
and transparently. It is important to implement data warehouse and federated systems 
onto Grids, while also adapting data mining algorithms and biological knowledge 
discovery tools to them. Interestingly the relationship between the Grid and the semantic 
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web is complementary. Both require the need for machine-understandable metadata to 
support information discovery, integration and aggregation that is automated. In addition 
both function in an environment that is distributed, global and susceptible to frequent 
change (Goble and De Roure, 2002). So the incorporation of metadata and ontologies in 
the Grid will transform them into semantic Grids. 
myGrid - a case study 
An example of an e-science project is the myGrid application which is metadata based 
middleware for data intensive bioinformatics (Stevens et aI., 2003b). It demonstrates 
how Semantic web concepts and Grid concepts combine to form a bioinformatics 
semantic grid that provides advanced functionality needed in an e-science environment 
such as the provision of provenance data, semantic discovery, semantic integration, 
notification services and personalisation. myGrid is based upon a service-based 
approach. These services can be decomposed into four categories: (1) tools that make up 
the experiments, (2) services for forming and executing experiments, (3) semantic 
services and (4) services for supporting e-science. These four services are exploited by 
an additional layer of applications and application services (Goble et aI., 2003a) (See 
Figure 1). 
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Examples of services for tools that make up experiments include external databases, 
analysis and simulation tools. These are are glued together into web services such as 
Soap lab which is an analysis web service in which the complete EMBOSS suite is 
included (Senger et aI., 2003). Other specialised functions such as text mining programs 
are also provided. Services for forming experiments consist of workflows, distributed 
query processing and a personalised repository called myGrid Information Repository 
(mIR). After a workflow has been discovered or created, enactment is carried using the 
FreeFluo workflow enactment engine and the XScufl workflow language (Addis et aI., 
2003). As for distributed query processing, there is the service based distributed query 
processor OGSA-DQP which allows queries to be made using a declarative language to 
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data resources on the Grid (Alpdemir et aI., 2003). mIR provides personalised 
information relevant to a researcher carrying out an in silica experiment. Provenance 
records of experimental data, together with specifications of workflows can be stored in 
mIR (Goble et aI., 2003b). 
Semantic service discovery and metadata management is carried out using an extension 
of service registries (used in web services) known as views which allows users to 
aggregate information from distributed registries based on personalised profiles while 
RDF has been included to extend UDDI, enabling the attachment of metadata to services 
(Miles et aI., 2003). Services are also provided for automated annotation using 
annotation tools such as COHSE (Conceptual Open Hypermedia Services Environment) 
(Zhao et aI., 2003). DAML+OIL is used extensively in myGrid for the creation of 
semantic descriptions and also for an ontology service. This provides a reference point 
for concepts used in myGrid and to support automated reasoning over concept 
relationships. 
In addition myGrid offers servIces for supporting the process of e-science through 
notification services. There can be times when workflows may take days or even weeks 
for execution to complete and users need to be aware of when a workflow finishes. The 
myGrid notification service provides functionality for asynchronous transmission of 
notifications (in the form of metadata) between services (Krishna et aI., 2003). An 
example of an application that is able to make use of the services discussed above is 
Talisman. It is a default function of Talisman to interact with mIR to enable the storage 
of provenance data and intermediate results of experiments to allow users to go back and 
track all the information they may require from a previously carried out in silica 
experiment (Oinn, 2003). 
Conclusions 
This paper provides a brief review of the types of challenges faced by post-genome 
bioinformatics. Data is flooding in through multiple high-throughput methods. There is a 
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need for standardised repositories and analysis tools to transform this data into 
information and then knowledge. It is important that the next generation of 
bioinformatics system architectures are semantically integrated and are incorporated into 
wider interoperability architectures such as web services and semantic Grids so that 
bioinformaticians are provided for example with methods for semantic resource 
discovery, provenance data and notification and personalisation services for a more 
complete e-science environment. 
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